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ABSTRACT 
Metrifonate is a second generation cholinesterase inhibitor (ChEI) and was used in this 
study as a reference compound to evaluate behavioural tasks and models that could be 
employed to test future putative cognition enhancers in the treatment of Alzheimer's 
Disease, a neurodegenerative disorder which is characterised by a decline in memory and 
other cognitive abilities. 
" The biochemical activity of metrifonate was assessed, specifically in relation to 
the development of tolerance after repeated exposure to the compound. With 
administration of central or peripherally acting cholinergic compounds to animals 
pre-treated with metrifonate it was found that the development of tolerance is a 
centrally acting phenomenon and specifically related to the cholinesterase 
molecule. Further study on the gene expression of acetylcholinesterase and 
butyryicholinesterase showed that there is a two fold up regulation of the gene 
increasing the amount the these two proteins. This up regulation of ChE 
expression could be responsible for the decrease in adverse side effects observed 
over time. 
" Metrifonate was observed after either chronic or acute administration in the 
passive avoidance task that is commonly used as a fast screening tool. Acute 
metrifonate had no effect on the performance deficits in the retention session. 
The chronic study demonstrated that the reference compound effectively 
inhibited the scopolamine-induced deficit. 
" Sub-chronic metrifonate was tested in neurologically normal rats in the standard 
Morris water escape task and failed to improve spatial memory. Metrifonate had 
no ameliorating effects on water maze navigation in mice with scopolamine- 
induced amnesia, though metrifonate improve spatial performance of rats with 
bilateral lesions of the entorhinal cortex (EC) suggesting that under conditions of 
pathological impairment of brain structures such as entorhinal cortex lesion, 
rather than pharmacological intervention such as scopolamine, future ChE-Is 
might produce beneficial effects on learning and memory. 
" The Peak interval procedure was used to assess the effects of the ChEI's on time 
estimation. A single administration Metrifonate (60 mg/kg) shifted the peak time 
to the right, indicating an impairment in time estimation, whereas sub-chronic 
administration of metrifonate had no effect on time estimation. 
" Sub chronic metrifonate treatment (60 mg/kg) increased the escape latency to 
reach the platform. However there was no difference in choice accuracy. No 
specific conclusion could be drawn as to the effectiveness of this task in 
assessing future cognition enhancers 
Although animal models used in this thesis, particularly EC lesions, rats show, mnemonic 
deficits similar to those seen in AD, the relationship is less than perfect. From this study it 
is recommended that the efficacy of a test compound should be determined in a series of 
tests that cover a variety of cognitive processes. Employing animal models that integrate 
lesions, transgenics and/or pharmacological manipulation could increase the validity of 
animal models of behavioural dysfunctions and therefore the evaluation of future 
cognition enhancers could become more effective. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Alzheimer S7 Disease 
The term cognition refers to all processes by which sensory inputs from an 
environmental stimulus are perceived; how association between stimuli are 
compared, stored, and then used to modify behaviour on the basis of past 
experiences. Learning efficiency depends upon factors such as motivation, attention, 
opportunity for rehearsal and prior experience (D'Mello et al 1996). 
Conditions that disrupt cognitive function are devastating. For example Parkinson's 
disease, Huntingdon's Chorea and Schizophrenia are often accompanied by cognitive 
deficits. Normal aging is associated with a decline in functions such as sensory and 
motor performance and at times this decline is accompanied by declining cognitive 
function. Dementia is a group of conditions that is characterised by a gradual 
deterioration of intellectual abilities to the point that social and occupational functions 
are impaired. Alzheimer's disease (AD) is the form of dementia that is produced by 
disease directly attacking the brain. This is a progressive clinical state characterised 
by deterioration in intellect, memory, judgment and abstract thinking (American 
Psychiatric Association: DSM IV, 1994). Patients afflicted with cognitive disorders feel 
they no longer have a good quality of life and eventually may require full time care 
for they are unable to function independently. AD effects about five percent of the 
population older than 60 years of age (Coyle et al, 1983; Katzman, 1986) and in the 
United States can account for around 100,000 deaths per year (Robertson, 1990). As 
the average life span increases, with a greater percentage of an aging population in 
industrialised western countries, it is expected that a dramatic increase of AD will 
follow in the near future (Brody, 1990). The prevalence of AD doubles rapidly every 
4.2 years (Molnar et al, 1997). 
AD is occasionally inherited within families in which case it is called familial AD, and 
this usually has an early onset between the ages of 35 and 55. It can be 
distinguished from nonfamilial or sporadic AD, which generally has a later onset 




The syndrome typically begins with the onset of amnesia (a selective impairment in 
memory) and subsequently includes elements of aphasia (impairments in naming 
and the use of vague and empty speech), apraxia (impairments in the performance 
of routine tasks like cooking and dressing) and agnosia (inability to recognise objects 
and familiar faces). A problem with executive function includes impairments in 
judgement, reasoning and the ability to plan, execute, monitor and revise certain 
activities. In advanced stages of the illness, individuals are severely confused, 
bedridden, incontinent and unable to feed themselves. The duration of the illness is 
highly variable, though it commonly lasts 8-10 years. 
In addition to their cognitive impairments most patients develop other behavioural 
disturbances. These include suspiciousness, paranoia, delusions, hallucination, 
wandering and pacing verbal and physical aggression, apathy and social withdrawal, 
repetitive behaviours and depression. 
Hasegawa and Aoba (1994) proposed 3 stages of increasing intellectual impairment 
in AD. 
0 Stage 1: - the amnesia stage. This corresponds to the early clinical symptoms of 
AD, which are typically manifested as short-term memory deficits. They may last 
2-4 years before progressing to the next stage. 
" Stage 2: - the confusional stage. This involves a continuing decline in cognitive 
functioning, which also might include severe mental confusion, personality 
changes and behaviour disturbances such as extreme aggressiveness or 
wandering and sometimes psychotic episodes. 
9 Stage 3: - the dementia stage. This involves complete dementia in which the 
patient is withdrawn, unresponsive, incontinent and unable to care for him or 
herself. Ultimately the patient is likely to die from a secondary illness or problem 
such as bronchopneumonia, urinary infection or aspiration. 
Neuropathology 
Alzheimer's disease is characterised by several distinct neuropathological features: 
neuritic (senile) plaques and neurofibrillary tangles and loss of neurons and synapses 
(Terry et al, 1994; Hof et al, 1994). 
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Senile plaques are spherical, multicellular lesions that are usually found in moderate 
or large numbers in limbic structures (Dickson, 1997). They contain cellular deposits 
of ß-amyloid protein (Aß), a peptide made up of a varying number of amino acids 
(42-43; Zubenko, 1997). It is synthesised from a larger protein called the ß-amyloid 
precursor protein (APP). APP has shown to be coded by a single gene (Goldgaber, 
1987). 
Neurofibrillary tangles are intraneuronal cytoplasmic lesions consisting of non- 
membrane bound bundles of paired or helically wound filaments (PHF; Goedert eta/, 
1996). The tangles generally occur in large numbers in the entorhinal cortex, 
hippocampus, amygdala, frontal, temporal, and parietal lobes. The subunit protein of 
the PHF is the microtubule-associated protein, Tau (Selkoe, 1991). It is found to be 
hyperphosphorylated and highly insoluble and promotes dissociation of the protein 
from microtubules and self-aggregation into the PHFs in the neurofibrillary tangles 
(Selkoe, 1999). 
The major histopathological features of AD probably contribute to cognitive decline, 
neuritic plaques appear to form in the early stages of AD (Morris et al, 1996) 
however, they are not correlated to the severity of cognitive impairment (Bierer et al, 
1995). In contrast, neurofibrillary tangles appear to develop in conjunction with the 
progression of the illness (Gomez-Lima at al, 1997). Loss of synapses and neurons is 
very strongly correlated with the severity of cognitive decline (Gomez-Lima at al, 
1997). 
A massive decrease of basal forebrain cholinergic neurones (particularly in the 
nucleus basalis of Meynert, NBM; Bowen et a/ 1976; Whitehouse et al, 1982) is 
paralleled by large reductions in cholinergic markers such as Choline 
acetyltransferase (ChAT, Perry et al, 1978; Reisine et al, 1978), reduced level of 
acetylcholine (Ach, Bowen et al, 1988) and reduced muscarinic and nicotinic receptor 
binding (Mash et al, 1985; Whithouse et al, 1987, Giacobini, 1989). These markers of 
cholinergic denervation are highly correlated with the degree of dementia and 
neuropathological changes in AD (Perry et al, 1978; Bierer et al, 1995). The 
presumed causal relationship between the pronounced decline in cholinergic activity 
and cognitive dysfunction led Bartus and co-workers to introduce their 'cholinergic 
hypothesis of geriatric memory dysfunction' (Bartus et al, 1982). 
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There are indications that other neurotransmitter systems may also be compromised 
in AD. Noradrenergic deficits have been found in the cortex and in the hypothalamus 
(Rossor and Iversen, 1986). In the cortex there is some loss of both presynaptic 5- 
HT concentrations and uptake sites and post-synaptic 5-HT, and 5- HT2 receptors 
(Court and Perry, 1991). It has also been reported that there is a significant loss of 
cortical somatostatin neurones and receptors in AD (Geula and Mesulam, 1994; 
Rossor and Iversen, 1986). Cholinergic fibres innervate cortical somatostatin neurons 
and stimulate somatostatin release. Therefore it might be possible that somatostatin 
neurons may be damaged due to the loss in cholinergic innervation. 
Genetics 
There are four well-confirmed genes in which mutations or polymorphisms occur that 
can result in AD. The first AD causing gene to be identified was that encoding the 
precursor Aß, the ß-amyloid precursor protein (APP) that is located on chromosome 
21 (St George-Hyslop et a/, 1987). Mutations of the APP gene can cause familial 
forms of AD. APP in cell membranes is processed by proteolytic breakdown that gives 
rise to various fragments of the molecule. The initial cleavage of APP is accomplished 
by a protease, a- secretase (review; Checler, 1995). The site of action of this 
protease is within the Aß domain of APP. This results in the release of soluble APP. 
Another less frequent proteolytic pathway involves the recently identified ß-secretase 
(Vassar eta/, 1999; Hussain eta/, 1999) and the still unidentified y-secretase. In the 
hypothesised processing pathway necessary for amyloid deposition, a protease 
cleaves APP. Subsequent action of y-secretase liberates the fibrillogenic and 
potentially neurotoxic Aß42.43 peptide, which is found in AD senile plaques. 
The AD1 locus on chromosome 19 was discovered to be associated with differential 
risk for late-onset familial and sporadic AD (van Broekhaven, 1995). The critical gene 
within this locus was discovered to be apolipoprotein E (apoE; Corder et al, 1993). 
There are three major alleles of the apoE gene, designated apoE2, apoE3 and apoE4 
and each individual possesses two of the alleles of the apoE gene. It has been shown 
that the apoE4 heightens the risk for late-onset AD; whereas apoE2 exerts somewhat 
of a protective effect i. e. the individual is likely to develop the disease later in life. 
There is evidence for a role of apoE in amyloid deposition and Aß fibril formation 
(Namba etal, 1991; Kida etal, 1994). 
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Sherrington and colleagues (1995) identified a gene within the AD3 locus on 
chromosome 14, which, when mutated, appears to be linked to early onset familial 
AD with the age of onset being between 35 and 55 years. The gene was initially 
termed S182 and was subsequently given the name preseni/in-1 (PS-1). The function 
of the PS-1 protein is unknown, however putative functions for PS1 include roles in 
the regulation of signal transduction during development, in apoptosis and possibly 
in cellular calcium ion homeostasis (Fraser et a/, 2000). A novel locus for a similar 
gene on chromosome 1 has been named presenilin-2(13S-2; Levy-Lahad etal, 1995). 
The PS-2 protein shows significant sequence homology to PS-1, and when mutated 
is also thought to be linked to AD, though the age of onset of the disease in patients 
carrying PS-2 ranges from 40 and 85 years. Both proteins reside within the 
endoplasmic reticulum, Golgi and nuclear envelope. Given the strong similarities in 
structure and amino acid sequence, it is likely that PS-1 and PS-2 have similar or 
overlapping activities (Fraser eta/, 2000). 
In summary, early onset forms of familial AD show patterns of simple autosomally 
dominant inheritance that have been linked to mutations in three different genes; 
APP, PS-1 and PS-2. These mutations are thought to directly (APP) or indirectly (PS- 
1 and PS-2) affect APP processing, Aß deposition and amyloid plaque formation. 
Variation in the apoE4 gene has been shown to influence the risk for and severity of, 
late-onset familial and sporadic AD (for a recent review see: Van Gassen and Van 
Broeckhoven 2000). For a general view on age of onset, the chromosome and gene 
involved and the genetic effect, see table 2. 
Table 2: Genetic factors in Alzheimer's disease. Summarised are the age of onset, the chromosome and 
gene involved and the genetic effect in Alzheimer's disease. 
Type Chromosome 
Early- Onset, Familial 21 
Early- Onset, Familial 14 
Early- Onset, Familial 1 
Late - Onset, Familial 19 
and sporadic 
u. _ý, _. ., 
Gene Genetic Effect 
APP Direct Linkage 
PS-1 Direct Linkage 
PS-2 Direct Linkage 
APOE Risk Factor 
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1.2 The cholinergic system 
Acetylcholine. Synthesis 
Acetylcholine (Ach) was first synthesised in 1837 though its biological importance 
was not discovered until much later. It was not until 1921 that Loewi, a German 
pharmacologist, established the role of acetylcholine as a neurotransmitter in the 
heart of a frog. Stimulation of the Vagus nerve induced a drop in heartbeat. 
Simultaneously, the heart was perfused with physiological solution, which 
subsequently led through a second denervated heart. He observed that the 
stimulation induced drop in heartbeat also occurred in the recipient heart. Loewi 
called the substance " Vagusstoff". He did not realise that this was actually Ach. In 
1914, Dale noted that applying Ach to the nerves mimicked the effects of stimulating 
the parasympathetic fibres. 
Many subsequent experiments revealed similarities between Ach and Vagusstoff, 
however they were not accepted as being identical, because Ach had not been 
shown to be a constituent of the body. Ach was subsequently isolated from spleen 
extracts and the parallel actions of Ach and Vagusstoff finally led to acceptance that 
they were the same substance (review; Karczmar, 1993). Later it was shown that 
Ach was also the neurotransmitter of a number of secretory glands and of both 
smooth and striated muscle (Dale, et a/, 1936). Acetylcholine (Ach) is a small 
molecule with a simple structure. It has a positively charged nitrogen atom with four 
attached methyl groups. Thus Ach is classified as a quaternary amine 
Acetylcholine is synthesised in a single reaction from the precursors acetyl coenzyme 
A (acetyl CoA) and cho/ine. The reaction is reversible, although the equilibrium is 
strongly shifted in favour of acetylcholine. The synthesis is catalysed by the enzyme 
cho/ine acetyltransferase (ChAT). The by-product generated by the reaction is free 
coenzyme A (Feldman eta/, 1997). 
ChAT is found primarily in isolated nerve terminal preparations (synaptosomes) and 
also is thought to exist freely in the nerve terminal cytoplasm. CoA is found within 
mitochondria and contains the purine nucleotide adenine, the vitamin pantothenic 
acid and other chemical groups. The acetyl group forms an attachment with the 
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suifhydryl group at the bottom of the hydrocarbon chain to form acetyl CoA. This is 
synthesised mainly by the pyruvate dehydrogenase complex, located in the 
mitochondrial matrix of nearly all cells. Choline is commonly found in foods such as 
vegetables, egg yolk, kidneys, liver, seeds and legumes. It is also produced in the 
liver. Choline enters the blood stream and is carried across the blood-brain barrier by 
a specific carrier system located in the membrane of capillary endothelial cells 
(Partridge, 1984). 
The rate limiting process in acetylcholine synthesis appears to be choline transport, 
the activity of which is regulated according to the rate of acetylcholine release, which 
is stored in synaptic vesicles. Release occurs by exocytosis in response to calcium 
entry resulting from depolarisation of the nerve terminal following the arrival of an 
action potential. Acetylcholine then diffuses across the synaptic cleft to act upon 
acetylcholine receptors (Feldman etat,, 1997). 
Early studies (Dale, 1914) showed that peripherally administered acetylcholine 
effects were mimicked by muscarine, an alkaloid found in a mushroom (Amanita 
muscaria), whereas other effects were mimicked by nicotine, an alkaloid from a 
tobacco plant (Nicot/ana tabacum). These findings led to the classification of 
acetylcholine receptors into nicotinic and muscarinic subtypes. Nicotinic actions are 
always excitatory and occur very rapidly. The receptors belong to the superfamily of 
ligand gated ion channels. The muscarinic actions can either be excitatory or 
inhibitory. They have a longer latency of onset. Muscarinic receptors belong to the 
superfamily of G protein coupled receptors. Multiple subtypes have been discovered 
for both the nicotinic and muscarinic receptors. In the periphery nicotinic receptors 
mediate ganglionic and skeletal muscle responses, and muscarinic receptors mediate 
cardiac and smooth muscle responses. These receptor types are also found in the 
central nervous system of which the majority of the responses are reported to be 
muscarinic and their activation is associated with a variety of actions (Feldman eta/, 
1997). For example, muscarinic receptors appear to mediate the main behavioural 





The principal mechanism for terminating the synaptic action of acetylcholine involves 
the hydrolytic breakdown of acetylcholine. Enzymes responsible for catalysing this 
reaction are generally known as cholinesterases because they cleave the ester 
linkage between the choline and acetate moieties of the acetylcholine molecule. 
There are two distinct types of cholinesterases: acety/cho/inesterase (AChE) and 
butyrylcholinesterase (BuChE). The two enzymes are encoded by separate genes and 
differ in their substrate specificity and tissue distribution. 
AChE is a glycoprotein made up of one or more subunits. The various forms of AChE 
can be subdivided into heteromeric and homomeric families as well as into globular 
and asymmetric forms. This diversity is produced by alternative mRNA splicing. 
Asymmetric forms of AChE are so named because they possess a tail made up of 
three collagen filaments wound in a helical arrangement. This form is found mainly at 
the neuromuscular junction, where it is secreted by muscle and nerve cells. The 
enzyme molecules then become attached to the extracellular matrix by their 
collagenous tails (Review; Massoulie, eta! 1993) 
The globular forms are more complex due to their heterogeneity. For example G1 and 
G2 each have two variants, a hydrophilic form found in the cytoplasm and a 
glycophospholipid-linked form that is anchored to the cell membrane. G4 also exists 
in two forms, a homomeric hydrophilic form and a heteromeric form with a lipid 
membrane anchor (Taylor and Radic, 1994). It is likely that in the brain, 
acetylcholine released into the synaptic cleft is degraded mainly by the membrane 
bound forms of G1, G2 and G4. 
Tablel: The various molecular species of Acetylcholinesterase (A: asymmetric, G: globular) 
HETEROMERIC HOMOMERIC 
Lipid Linked (G4) 
Asymmetric (A12) 
G1 (Exon 4) 
G1 
G2 
G2 - glycophospholipid linked (G1,2) 
G4 - hydrophilic (G1,2,4) 
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The active domain of AChE comprises two subsites critical for its functioning. One of 
these sites is termed the anionic subsite, which has an important role in binding 
part of the substrate to the enzyme molecule. The other region is the active site, 
termed the esteratic site, which possesses a serine residue that is responsible for 
the hydrolytic action. Following binding of acetylcholine to the active site of AChE 
the ester bond of the acetylcholine molecule is broken and choline is released into 
the surrounding medium, where it is taken up by the presynaptic nerve terminal. 
The acetate group then becomes bound to the serine residue resulting in an 
acetylated enzyme. A molecule of water then rapidly reacts with this unstable 
intermediate to liberate the acetate group and regenerate the active enzyme 
(Feldman eta/,, 1997). 
Distribution 
The location of cholinergic cell groups and pathways in the brain has been 
accomplished using markers associated with cholinergic neurones, the most 
important of which uses staining procedures for ChAT which can be labelled by 
inmmunofluorescence. Acetylcholine itself cannot be made visible by histochemical 
techniques. The localisation of acetylcholinesterase, which can be readily stained, is 
sometimes used to indicate the presence of acetylcholine. However, its distribution 
is widespread and not specific to cholinergic pathways. The distribution of central 
cholinergic pathways has been illustrated in figure 1. 
Cholinergic neurones that play an important role in the functioning of the 
extrapyramidal motor system can be found in parts of the striatal complex, 
including the caudate putamen, nucleus accumbens and the olfactory tubercule. 
They serve as interneurones and can receive glutamatergic afferents from the 
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Figure 2: Distribution of cholinergic cell groups and projections in the rat brain (Woolfe, 1991). 
The basal forebrain contains a major cholinergic projection system. The main rostral 
cholinergic cell groups of the basal forebrain are located in the medial septal nucleus 
and the vertical limb nucleus of the diagonal band of Broca. These send projections 
to the hippocampus and the limbic system. The caudal portion of this system is 
represented by cells in the nucleus basalis, the substantia innominata and the 
nucleus ansa reticularis. These neurones innervate all parts of the neocortex. The 
basal forebrain cholinergic neurones appear to play an important role in memory and 
other cognitive functions (Feldman eta/, 1997; for full review: Woolfe, 1991). 
The hippocampus is a brain structure, known for its role in cognitive functions such 
as memory, learning and spatial orientation (O'Keefe et a/, 1978; Olton et a/, 1976, 
Eichenbaum, 1992). A neurotransmitter system vital to the physiological functioning 
of the hippocampus is the cholinergic projection of the medial septum-diagonal band 
complex. The view that the septohippocampal cholinergic system is involved in 
regulating memory is supported by findings that memory performance is correlated 
with cholinergic activity in the hippocampus, as measured by ChAT activity, Ach level 
and high affinity choline uptake (Decker, 1991). 
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Learning and memory 
The first experimental studies, in which the role of cholinergic synapses in the 
storage and retrieval of new information were evaluated, were performed by Deutsch 
(1971). Since then there has been a vast amount of research providing support for 
the cholinergic hypothesis of learning and memory. The effects of cholinergic 
antagonists and cholinomimetics have been used to study the involvement of the 
cholinergic system on learning and memory performance. 
Much evidence supporting the cholinergic hypothesis is provided by reproduction of 
the age and dementia related impairments by drug treatment or lesioning of specific 
brain regions in animals (Fibiger, 1991; Andrews, 1994; Gallagher and Colombo, 
1995). 
Cholinergic dysfunctions induced either by lesions of cholinergic nuclei or by 
transections of major cholinergic pathways, have been shown to induce specific 
disturbances in memory and learning performance. Deficits in learning and memory 
can be achieved with cholinergic lesions of the hippocampus (Hagan, eta/, 1987; van 
der Staay et a/, 1989). This can also be achieved by transections of the fimbria 
fornix, lesions of the vertical limb of the diagonal band of Broca or the medial septum 
(Mesulam eta/, 1983). Lesions of the nucleus basalis magnocellularis (nbm) lead to a 
decrease in cortical ChAT and a decline in performance in learning and memory tasks 
(Smith, 1988). 
Blockade of muscarinic receptors by atropine or scopolamine has been shown to 
interfere with the acquisition and maintenance of many different kinds of learning 
tasks (Fibiger, 1991; Hagen and Morris, 1987; Spencer and Lal, 1983). Scopolamine 
induced memory impairments have gained widespread acceptance as a model of 
dementia (Broks et al, 1988). In animal studies, for example scopolamine disturbs 
spatial orientation in water and radial maze tasks (Blokiand et al, 1992). In addition, 
acetylcholinesterase inhibitors, such as physostigmine, which enhance the availability 
of Ach in the synaptic cleft, were able to reverse the scopolamine-induced deficit, 
indicating that the cognitive deficit is cholinergic in nature. 
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1.3 Cognition enhancers 
A cognition enhancer is a compound that improves cognitive function, such as 
learning, consolidation and/or retrieval (Wenk and Olton, 1989), i. e. that increases 
information processing capacity. A cognition enhancer should not have other classical 
psychopharmacological activity (Gamzu, 1989), with little or no side effects (Porchel, 
1988) and have a very low toxicity. It should also readily cross the blood brain 
barrier. 
Maitre and Pepeu (1989) have stated that the goal of a cognition enhancer is "not to 
improve the facilities of learning and memory but rather to And remedies for their 
impairment in the aged and, as a corollary to that, the means of retarding the 
deteriation of these faculties" 
Since there is at present no cure for AD, current treatments are palliative in nature. 
Most treatment strategies have been based on the cholinergic hypothesis of cognitive 
dysfunction in AD (Bartus et a/, 1982). To counteract the cholinergic decline in the 
central nervous system three possible strategies have been described (Drachman et 
al, 1982) 
0 Initially, it has been proposed that large supplements of the Ach precursor 
choline or of lecithin (phosphatidylcholine) might be able to increase the 
availability of Ach in the brain. However this therapeutic approach was 
unsuccessful. A severe limitation to this strategy was that only 1% of plasma 
choline is incorporated into Ach, the remainder enters alternative metabolic 
pathways (McGeer, 1984; Mohs and Davies, 1985). 
" Agonists that can be directly administered to stimulate post-synaptic cholinergic 
receptors, such as nicotine and arecoline (Flood and Cherkin, 1988). These have 
disadvantages due to their short duration of action narrow therapeutic window 
and the lack of selectivity. 
" Cholinesterase inhibitors, which inhibit the enzyme responsible for the cleavage 
of acetylcholine are a second possible treatment in Alzheimer's disease. By 
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preventing the breakdown of acetylcholine in the synaptic cleft, it thus prolongs 
the action of this neurotransmitter. 
Tacrine (Cognex), [tetrahydroaminoacridine (THA)] is a potent, centrally acting first 
generation cholinesterase inhibitor which acts reversibly (Dawson, 1990) and non- 
competitively (Patockat, 1976). This compound has been shown to improve 
cognitive performance in Alzheimer patients (Summers et a/, 1989; Gamzu, 1990) 
and also in animal studies. In animal studies tacrine has shown no effects in young 
intact rats in the spatial reference memory version (stable platform position) of the 
Morris water escape task or spatial working memory version (reversal of escape 
platform). However it has been shown to alleviate the cognitive deficits produced by 
medial septal lesions and age related impairments using the reference memory 
paradigm (Riekkinen et at, 1991) and also to alleviate scopolamine-induced amnesia 
in the rat (Jackson, 1996). 
In addition to the cholinesterase inhibitory action and its effects on nicotinic and 
muscarinic acetylcholine receptors, tacrine possess a very complex pharmacology 
and has been reported to affect other neurotransmitter systems including 
noradrenaline, dopamine, glutamate and 5-hydroxytryptamine (Freeman and 
Dawson, 1991). Tacrine induces a high incidence of peripheral cholinergic toxicity 
and has low oral bioavailability. Overall, with the compound's lack of specificity, 
transience of effects and concerns over the risk/benefit ratio indicated that more 
specific compounds were required. 
Metrifonate: Background Information 
Metrifonate (0,0-dimethyl- (1-hydroxy-2,2,2-trichloroethyl)-phosphonate) is an 
organophosphorus compound and is a member of the class of second-generation 
cholinesterase inhibitors (Giacobini, 1991). These are characterised by high 
penetration through the blood brain barrier, long lasting and selective inhibition of 
cholinesterase with few cholinergic side effects. In a study with Alzheimer disease 
patients, metrifonate was found to be effective in treating decline (Becker et a/, 
1990). The compound was taken through into Phase III clinical trials as an 




elderly and demented patients are augmented by batteries of computerised tests 
(Robbins et al, 1989). The Cambridge Automated Neuropsychological Test Battery 
(CANTAB) was developed to adapt paradigms for testing animal models of dementia 
in order to relate the findings to human patients. The tests of pattern and spatial 
serial recognition memory and delayed matching to sample process analogues are 
included. 
Metrifonate is not a cholinesterase inhibitor by itself. In aqueous alkaline solutions it 
is spontaneously dehydrochlorinated non-enzymatically to the organophosphate ester 
dichlorvos (2,2-dichlorovinyl dimethyl phosphate). It is thought that metrifonate acts 
as a prodrug via non-enzymatic release of dichlorvos, which covalently 
phosphorylates the acetylcholinesterase (Hinz et a/, 1996). In human blood in vitro, 
the half-life of metrifonate is about 60 minutes compared to 10 minutes for 
dichlorvos (Villen et al., 1990). Therefore, it is not possible to accumulate dichlorvos 
after in vivo administration of the parent drug, metrifonate. Due to this slow release 
formulation, metrifonate has fewer side effects than many other cholinesterase 
inhibitors. Dichlorvos is 100 times more potent than metrifonate (Hinz, etal, 1996). 
In a number of studies metrifonate has been shown to improve the cognitive 
performance of animals in various behavioural models. Using the passive avoidance 
paradigm with rats, metrifonate was found to alleviate scopolamine- induced or basal 
forebrain lesion induced deficits in rats (Itoh, et a/, 1997). Riekkinen et a/ (1996) 
described a beneficial effect of metrifonate on passive avoidance performance 
deficits induced by scopolamine or by medial septal lesions. Metrifonate facilitated 
passive avoidance retention in 23-month-old and 27-month-old rats (Riekkinen, eta/, 
1996). The effects of metrifonate on cognitive performance have also been 
investigated in the Morris water escape task, in which the rats are trained to locate 
an invisible submerged platform in a water pool. The compound facilitated 
acquisition of the task by young (van der Staay eta/, 1996b), elderly [19- month old 
(Blokland et a/, 1995)] and aged (23- and 25, but not 27-month old) rats (Riekkinen 
et all 1996; van der Staay et a/, 1996b). Metrifonate treated rats needed less ti me 




Cognitive performance after sub chronic administration of metrifonate has also been 
investigated in aged rabbits (33- to 34- months old) in a classically conditioned eye- 
blink task. Ageing rabbits and humans show an impaired performance in this task 
(Disterhoft et a/, 1999). The animals were pre-treated for 1 week with Metrifonate 
at one daily dose. The animals were then trained on classical eye-blink conditioning, 
with drug administration continuing. Associative learning was improved by 
metrifonate compared with the aged control group (Kronforst-Collins et at, 1997). 
Side effects and Administration schedules 
Side effects, induced by metrifonate treatment are mild in comparison to those of 
other cholinesterase inhibitors (Hallak and Giacobini, 1989), follow maximum 
cholinesterase inhibition and disappear shortly after administration (Dubois and 
Cotter, 1955). The acute toxicity of metrifonate in animals, expressed in terms of 
lethality, is quite low compared to many organophosphorous compounds (for a 
review see Holmstedt et al, 1978). The oral LD50 values vary from species to 
species. In rats the value ranges from 400-700mg/kg (Jones et al, 1968). Acute 
high doses of metrifonate induce adverse symptoms such as salivation, tremor and 
diarrhoea, which are typical for cholinergic drugs (DuBois and cotter, 1955; Edson 
and Noakes, 1960) 
After acute administration of metrifonate to rats (80 mg/kg im; 125 mg/kg p. o), 
ChE activity in brain and blood recovers within 24 hours (DuBois and cotter, 1955; 
Hallak and Giacobini, 1989). Repeated administration of metrifonate leads to a long 
lasting inhibition of blood ChE (DuBois and cotter, 1955). Neurotoxicological studies 
showed that after 13 weeks of metrifonate treatment (Chan and Peters), no 
toxicological damage were observed on rat brain, spinal cord, sciatic nerve and 
other organs at doses of up to 5000ppm metrifonate. 
In this dissertation the term "subchronic" is used for repeated drug administration, 
lasting up io 4 weeks. The term "chronic"is used for drug treatment lasting longer 
than one nth. 
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1.4 Animal studies of behavioural dysfunction 
The search for valid animal models capable of mimicking human pathophysiology 
and which enable us to detect and optimise therapeutically interesting drugs is 
essential in pharmacology. Despite some controversy about the validity of 
extrapolating data from animal models to human physiology their use is necessary 
before carrying out clinical trials in humans. However, no single animal model of 
Alzheimer's disease, which combines all the relevant pathophysiological and 
behavioural aspects of the disease, is known. Most models attempt to reproduce 
certain features of the disease, for example; behavioural deficits, histological 
stigmata or metabolic disturbances. 
The most relevant information can be derived from the study of humans, however 
the neurobiological variables associated with behavioural dysfunctions cannot be 
sufficiently controlled in experimental and clinical studies with human subjects. 
Therefore animal models are used to answer questions about behavioural 
dysfunctions and their underlying neural substrates. Animal models have been 
defined as follows: " An animal model in the behavioural neurosciences is a living 
organism used to study brain-behaviour relationships under controlled conditions, 
with the final goal of gaining insight into these relationships in humans and/or (a) 
species other than the one(s) studied, or in the same species under conditions 
different from those in which the study was performed" (van der Staay, 1998). 
Validity 
Criteria have been proposed for the validity of animal models of behavioural 
dysfunctions, such as those seen in dementia. Validity is a central concept in science 
and it centres on the question as to how close is the model to reality and how 
relevant results are for to humans. 
Animal models should possess face validity, predictive validity and construct validity 
(D'Mello & Steckler, 1996). These different forms of validity help us to identify 
weaknesses or defects in a particular model. 
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" Face validity evaluates the degree of similarity between measures in the animal 
model and their correspondence in humans. i. e. an animal model should meet 
the requirement that it resembles the condition to be modelled with respect to its 
aetiology symptomology, underlying processes and treatment (McKinney & 
Bunney, 1969). 
" Predictive validity indicates how well the animal data predicts behaviour in the 
situation it is supposed to model. i. e. if it allows extrapolation of the effect of a 
particular experimental manipulation in one species to other species, including 
humans. 
0 Construct validity refers to the theoretical clarification of what a test measures, 
establishing relationships that are based on definition of a trait, such as 
intelligence or emotional reactivity. 
In general, face validity is the naive level, i. e. the test appears valid because of a 
perceived resemblance between the model and the situation or process to be 
modelled. Predictive validity is the empirical level, i. e. data shows that the outcome 
of the model has some predictive value and construct validity is the theoretical level. 
Type of drug screening models 
Models have provided information about potential biochemical and structural changes 
that might underlie associative learning. Animal models that reproduce brain damage 
that impacts upon cognitive function have indicated the relative importance of 
various brain structures for aspects of cognitive functioning. These models, primarily 
developed for basic research purposes, can be used to identify cognitive enhancers, 
i. e. drugs for the treatment of cognitive deficits associated with AD. 
Normal subjects 
Normal subjects are used most widely to assess the effects of putative cognition- 
enhancing compounds. Though they may not fulfil any criteria concerning the 
neuropathology or the occurrence of behavioural dysfunctions and consequently, in a 
strict sense cannot be considered an animal model, there is an underlying 
assumption that compounds that improve performance in normal animals would also 




The use of aged animals represents a naturally occurring impairment model. The 
model is based on the similarity between behavioural symptoms in old rats and in 
patients suffering from AD, such as sensorimotor dysfunctions (Markowka et al, 
1990), decreased social activity (Spuijt, 1991) and cognitive impairments. The 
advantages of this model are that small rodents have a relatively short life span of 2- 
3 years, their environment can be controlled and they show age- related impairments 
(Elias, 1976). However, these models do not mimic the specific neuropathological 
changes underlying AD. 
Genetic Lines 
If a selected population is inbred for several generations, a genetic line of biologically 
uniform animals is obtained. For example, genetic lines can be developed which have 
deficits in cognitive functioning. Closely related to the model of the aged animal is a 
mouse model genetically selected to show characteristics of accelerated ageing. The 
senescent accelerated prone mouse shows an earlier than 
normal onset of age- related deterioration in learning and memory (Miyamoto et a/, 
1986). 
Selective impairment- Pharmacological Manipulations 
Several lines of evidence support the notion that a loss of cholinergic function 
contributes to the cognitive deficits seen in AD (Bierer et al, 1995). Therefore 
pharmacological disruption of cholinergic function has been an approach in modelling 
cognitive deficits in AD. Scopolamine, a muscarinic acetylcholine receptor antagonist 
is used to produce cognitive deficits originally described as resembling those 
normally occurring in aged subjects (Drachman, 1977). It is perhaps the most widely 
used model of memory impairment of AD. The impairment induced by scopolamine is 
pervasive and can be indexed by performance on such tasks as object discrimination 
learning (Ridely et al, 1984), radial maze performance (Okaichi et al, 1989), and 
acquisition and retention in the Morris water maze (Dunnett et al, 1991) and can 
impair passive avoidance (Matsuoka et al, 1992). Scopolamine is also thought to 
disrupt attentional functions. Several studies have provided experimental evidence 
that scopolamine affects the allocation of attentional processes rather than impairs 
memory per se in humans (Dunne 1986; Warburton et al, 1992) 
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Although the disruptive effects of scopolamine, on a variety of cognitive tests, are 
robust and reproducible it has a few problems and may not be ideal to model the 
mnemonic deficits in early stages of AD. The effects of scopolamine are reversible 
whereas AD is a progressive, irreversible disease. Scopolamine reduces cholinergic 
activity post-synaptically, whereas reduced muscarinic neurotransmission in AD is 
mainly pre-synaptic. The nature of the disruptive effects is often only partially known 
and test compounds aimed at reversing the deficit could change the metabolism or 
tissue disposition of the cholinergic antagonist (Decker, 1995). 
CNS Specific Lesions 
Lesion models have been extensively used to test compounds for cognition 
enhancement, in an attempt to mimic the neuroanatomical, histological and 
neurochemical correlates, which are observed in post mortem samples of AD affected 
brain. Lesions focus primarily on the cholinergic innervation areas of the basal 
forebrain and on higher regions such as the cortex and hippocampus, which show 
pronounced deterioration in AD (Bierer etal, 1995). 
Transgenic Mode/5 
Transgenic approaches allow the development of animal models of human disease. 
Whenever a disease is shown to be caused or influenced by specific, identified 
human genes, introduction or modification of those genes in animals can mimic the 
geneticity of the human pathology. As discussed previously, genes that are involved 
in AD have been identified. Mutations in the genes presenilin-1 (PS-1) and presenilin- 
2 (PS-2), and, additionally mutations in the human amyloid precursor protein (APP) 
gene, cause changes in the processing of APP, leading to amyloid formation in the 
brain (Nitsch, 1996). 
The key pathological changes of AD that transgenic rodents would express is the 
senile plaques and neurofibrillary tangles which could be produced by introducing 
human transgenes carrying one or more disease causing gene mutations (Loring et 
a/, 1996). Two genetically engineered AD models are based on transgenic mice 
expressing familial AD mutations or fragments of normal APP: the Minnesota mouse 
(Hsiao et a/, 1997) and the Exemplar/Athena mouse (Games et a/, 1995). The APP 
mutations they express cause an early onset of familial AD in humans, possibly as a 
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result of the increased production of total ß-amyloid and ß-amyloid1_42. Both models 
are characterised by the accumulation and deposition of amyloid. 
Selection of Animal Species. 
The use of non-human primates in science does not seem to be wholly necessary in 
this field. Non-human primates do not offer many advantages compared to other 
animals. They are difficult to handle, and cannot be obtained in sufficient number. 
More important, it is impossible to obtain genetic homogeneity and they are 
impractical for conducting longitudinal studies. Moreover, their close evolutionary 
relationship to humans does guarantee neither similar pharmacodynamic and 
pharmacokinetic responses, nor behavioural homologies (D'Mello & Steckler, 1996). 
Small animals such as rodents and pigeons are preferentially used. They are easy to 
handle, have a relative short life span and can be studied in controlled conditions. 
Rodents are particularly well suited for cognition and ageing research, which is 
comparable to that of humans (Steckler & Muir, 1996). In addition, dissociation 
between chronological and biological ageing occurs in rodents (Collier & Coleman, 
1991). 
Animal studies can thus be of great help in determining the relative contribution of 
various factors regarding ageing in learning and memory, which will indirectly foster 
dementia/cognitive research. Some rat or mouse strains are more suited to certain 
tests than others. Differences between strains must first be identified to be able to 
evaluate their influence on cognitive performance and drug effects. Strains may react 
differently in behavioural tasks and, as a result, performance may be confounded by 
different factors e. g. changes in attention compared to changes in motivation. 
Furthermore, small differences in feeding behaviour and food requirement of 
different strains can have fundamental effects on performance. In addition, strains 
certainly differ in their pharmacodynamic and pharmacokinetic characteristics, which 
in turn may affect drug evaluation. Strain, but also age and gender are important 




Man's utilization of animals for any purpose is a privilege that carries with it a series 
of responsibilities. In the case of research animals, these fall into three broad 
categories: 1) technical, 2) ethical, and 3) legal. The technical include factors such as 
selecting the proper animal, providing the proper environment and care, and 
designing experiments to use as few animals as possible while maintaining scientific 
validity. Ethical considerations stem from an inherent respect and reverence for life 
which anyone utilization animals should have. This carries with it a responsibility to 
assure proper care and humane treatment. Some legal requirements have resulted 
from the ethical considerations. While these vary considerably, nearly all countries 
have some laws related to this subject. 
Selection of the task 
The first requirement of any test of animal cognition is that it really measures 
cognition, which is defined as the 'faculty of knowing, perceiving, (and) conceiving as 
opposed to emotion and volition', rather than a non-cognitive process, for example 
sensory, motoric and non-specific arousal processes. The tasks should be chosen for 
their specificity and selectivity toward the behavioural phenomena observed in the 
disease. Short-term memory and spatio-temporal abilities seem to be first affected in 
AD (Adams, 1997). Tests have therefore been developed that focus on these 
processes in which animals have to develop and learn new strategies, to memorise 
and retrieve cues in order to solve the task successfully. 
Pre-clinical evaluation of drugs affecting memory in animals involves observing their 
behaviour in experiments consisting of a presentation of information (the training 
stage) followed by a delay and the opportunity for performance (the test stage). 
Higher cognitive processes can be evaluated by providing situations in which 
reorganisation of the information presented is necessary before the appropriate 
response is made. A task selected for drug evaluation should be rep/icab/e by an 
independent group of researchers; as stated by van der Staay (1998) "results are 
preliminary as long as they have not been corroborated, and preferably by 
investigators other than those who originally performed the investigation". The 
cognitive measures are specifically affected by selected drugs in a sensitive manner 
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and should be a part of a batteryof cognitive tasks. It is also necessary to remember 
that factors such as housing conditions, biological rhythm, stress and route of drug 
administration can affect test data significantly as can strain, age and gender 
(Andrews, 1996) 
One way to improve cognitive research is to refine existing animal models and to 
create new ones. An animal model should initially be derived from a theory, which 
will then be confronted. If the theory is correct, the model already possesses 
construct validity and then needs to be transformed to fulfil further criteria. At this 
point, predictive and face validity should be increased. Face validity may be absent 
or only partially present because of species-specific particularities. Once a cognitive 
enhancer is identified, particularities of the drug can be investigated to develop quick 
tests. 
1.5. " Tests to assess behaviour in animals with Cholinesterase 
Inhibition 
In this thesis a number of behavioural tests are used to determine the effects of 
cholinesterase inhibitors at the cognitive level. 
Passive Avoidance Task 
The passive avoidance task is based on an instinctual effect in which, when you hurt 
yourself unexpectedly, e. g. have a mild electric shock you will avoid or refrain the 
action that caused you the discomfort. Although avoidance tasks are seldom, if ever 
used with patients they are widely used in animal research and because they are 
tests of learning and memory, results are often used to model Alzheimer's disease. 
The test is considered as a useful early screening test to identify putative cognition- 
enhancing compounds in rodents and has been extensively used in the majority of 
drug screening programs (Iversen, 1997) mainly due to being fast and cheap. Many 
patents are based on positive effects of a compound in this task. Compounds are 
usually tested in scopolamine- treated rats. 
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Standard Morris water escape task 
The standard Morris water maze (MWM) was developed by Morris (1984) as a device 
to investigate spatial learning and memory. Age related deficits in spatial maze 
learning are evident in both place and route learning in a number of mammalian 
species (Barnes, 1979; Ingram, 1988; Mclay et al, 1999). In this task, a rat is trained 
to localise a submerged platform and measures predominantly spatial reference 
memory (Mundy eta/, 1990). Reference memory holds trial- independent information 
(Barnes, 1990). 
Many studies have examined the role of specific brain regions that could be involved 
in Morris water maze learning. The involvement of brain regions in spatial navigation 
is complex and may comprise numerous regions (Cain et al, 1996). It has been well 
established that the hippocampal formation is essential for spatial learning (O'Keefe 
and Nadel, 1978; Barnes, 1988). Lesion studies have shown that damage to the 
hippocampus and virtually all its associated structures (fornix, septum, entorhinal 
cortex, subiculum, post subiculum) induces severe and permanent deficits in a wide 
variety of spatial abilities (Rasmussen et al, 1989). Other regions include the striatum 
(where bilateral lesions have shown to affect Morris water maze performance; 
Whishaw et al, 1987), the basal forebrain (Brandeis et al, 1989), cerebellum 
(Lalonde, 1994; Leggio et al, 1999) and the neocortex (Brandeis, 1989). 
The Morris water task has been used in studies on the involvement of neurochemical 
systems in place learning and memory and the effects of neuropharmacological 
manipulation on spatial functions (Brandeis, 1989; McNamara et al, 1993). 
McNamara and Skelton (1993) reviewed the involvement of different 
neurotransmitter and modulator systems in spatial learning, and suggested that only 
the cholinergic, glutaminergic and some peptidergic systems may really be involved 
in learning, whereas GABA, opioids or biogenic amines are either detrimental or 
unrelated. 
There have been a few studies that have examined age-related vulnerability in route 
learning or topographical memory in humans. Elderly individuals have deficits in 
navigation and develop behavioural patterns to avoid unfamiliar routes and places 
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(Burns, 1999). Impairments in navigation are often apparent in the early stages of 
dementia (Klein et al, 1999; Passini et al, 1995). 
The two choice water escape task 
In a variation of the standard Morris maze task, as discussed above, the subjects are 
given trials which consisted of two runs: an information run and a test run which is 
separated by a retention interval. The information run consists of a forced choice trial 
during which subjects are forced to the correct choice section by closing of the 
incorrect sections. The test run consists of a free choice trial, during which the doors 
to all choice sections are open. 
The two choice water escape task is a water version of a delayed matching to 
position or sample task that can be either visual or spatial and can be performed in 
either operant conditioning chambers or mazes. Although there are various various 
they generally involve the presentation of a conditional (sample, choice) stimulus 
followed by a delay and then two or more discriminative (comparison) stimuli. Only 
one of the comparison stimuli designates a correct choice and is given a reinforcer on 
any given trial. Patients with early stages of AD show increased impairment, relative 
to controls on visual delayed matching to position task (Money et al, 1992; Sahakian 
et al, 1988). 
The task has many advantages of the Morris water maze, in that it involves no food 
or water deprivation which could interact with pharmacological or neural 
manipulations and ultimately alter behaviour that indirectly influence cognitive 
performance scores. It appears to be less aversive than shock motivated tasks. The 
task provides a choice measure of performance as well as a latency measure. Choice 
is a better measure of cognitive processes than is response latency because choice is 
influenced less by variables that alter motor ability and activity levels. The task has 
proven to be sensitive to age (Means and Kennard, 1991), to oestrogen therapy in 
ovariectomised female rats (O'Neal et a/, 1990) gender (Means and Dent, 1991) and 




Timing behaviour is thought to be a cognitive function of the brain in terms of a 
subjects' ability to control the way in which stimulus information is integrated over 
time. Neuropharmacological studies have shown some of the neural and behavioural 
mechanisms involved in timing and time perception. The 'internal' clock is used for 
measuring the speed or durations in which information is integrated and this appears 
to be linked to dopamine function in the basal ganglia and the memory storage 
process used for the representation of the duration's of prior events appears to be 
linked to acetylcholine function in the frontal cortex. These two systems appear to be 
linked by frontal striatal loops (Meck, 1996). Past studies have shown that distortions 
in perceptions of time accompany a number of different neurological disorders 
(Fraisse, 1984; Goody, 1969; Malapani et al, 1993; Meck, 1983; Nichelli et at, 1993) 
Degenerative diseases of the basal ganglia can cause subjects to underestimate time 
in the short range (O'Boyle et al, 1996; Freeman et al, 1996) while causing them to 
overestimate time in the longer time ranges from minutes to second ranges. Studies 
have shown that patients with AD have defective accuracy and precision in time 
estimation (Carrasco et al, 2000; Nichelli et al, 1993). 
In this study the peak interval procedure is used which is an operant conditioning 
schedule in which a lever is presented and the animal is free to respond at any time, 
but only the first response after a fixed duration (e. g. 20 seconds) is reinforced. In 
the peak interval (PI) procedure some trials are identical to the FI procedure where 
others consist of the lever presented for a time that goes beyond the fixed duration 
(e. g. 50 seconds), and no reinforcement is given. 
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1.6; Aims of Study 
Alzheimer's disease is accompanied by pronounced neurodegenerative changes in 
the brain (Braak and Braak, 1991). These changes are likely to lead to impairments 
in cognitive performance, such as attention, learning, and memory, depending on the 
quality and extent of the damage. Pharmacological therapy might ameliorate 
cognitive functioning in affected patients. One such therapy is metrifonate, a second 
generation cholinesterase inhibitor (Giacobini, 1991) that has been show to be 
effective in patients with mild to moderate AD (Gelina et a/, 2000) and in various 
behavioural tasks (Riekkinen, et a/, 1996; van der Staay eta/, 1996b; Schmidt eta/, 
1997; Itoh, eta/, 1997; Disterhoft et al, 1999). 
Firstly the aim of this thesis was to look further in to the biochemistry of the 
reference compound, metrifonate. Specifically to look at the process of how the 
compound induces tolerance to cholinergic side effects after subchronic 
administration. 
The main aim of this study was to confirm the behavioural effects of metrifonate, 
serving as reference cognition enhancers in known behavioural models in the rat to 
determine that the results are reproducible across laboratories and 
animals/experiments and then to determine these effects in a second species i. e. the 
mouse. It was also planned to assess new methods, using metrifonate, in order to 
evaluate their potential for investigating future cognitive enhancers. Finally, the 
effectiveness of metrifonate to be used as a reference compound for future studies is 
to be discussed 
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Adaptation to Prolonged Administration of Metrifonate: Effects 
on the Periphery and CNS 
Abstract 
Metrifonate, a long lasting and well-tolerated cholinesterase inhibitor was 
administered once daily for up to twelve weeks at oral doses of 0,10,30,50,100 
and 150 mg/kg. During the sub chronic treatment period, experiments were 
performed to determine behavioural and neurochemical changes. Cholinesterase 
activity was determined in both central and peripheral tissues. It was found that 50 
mg/kg Metrifonate caused a 30 % reduction in the cholinesterase activity in the 
brain. After 12 weeks of treatment erythrocyte cholinesterase inhibition compared to 
the shorter period of treatment period of 6 weeks mediated the same level of about 
60%. The reduction in cholinesterase activity was not reflected in peripheral tissues 
suggesting that inhibition of peripheral cholinesterase in the blood does not 
necessarily lead to peripheral inhibition and thus to peripheral side effects. 
In determining the development of behavioural tolerance centrally and peripherally 
cholinergic compounds (bethanechol, neostigmine, nicotine, oxotremorine and 
donepezil) were administered to metrifonate pre-treated rats. No changes were 
seen with the peripherally acting muscarinc agonist, bethanechol or the 
cholinesterase inhibitor, neostigmine in adverse events or body temperature. In 
response to the centrally acting muscarinc agonist oxotremorine, a subsensitivity 
was observed in only one of the side effects i. e. clonic seizures whereas nicotine did 
not induce any changes. These two compounds also produced no changes in 
sensitivity in body temperature. Donepezil, a centrally acting cholinesterase inhibitor 
produced a supersensitivity in both adverse effects and to body temperature. We 
conclude that the development of tolerance is a centrally mediated phenomenon 





The cholinergic hypothesis of memory dysfunction in ageing people and Alzheimer's 
patients (Bartus et a/, 1982; Coyle et a/., 1993) led to the development of 
compounds designed to increase the deficient acetylcholine levels in the brains of 
these patients. These compounds, known as second generation cholinesterase 
inhibitors are long lasting, safe and well tolerated. They aim to restore levels of 
endogenous acetylcholine in the synaptic cleft by preventing its enzymatic 
breakdown by acetylcholinesterase. 
Metrifonate, an organophosphorous compound acts as a pro-drug for an active 
metabolite (Hinz et a/, 1996a). The slow release of the active metabolite from the 
parent drug ensures a smooth onset of cholinesterase inhibition. In a wide range of 
models of learning and memory, metrifonate has shown cognition enhancing activity 
(Schmidt et at, 1997) and data from clinical studies confirmed that this is also true 
for Alzheimer patients (Becker, 1990, Cummings et al, 1998) 
Cholinesterase inhibitor treatment produces an accumulation of acetylcholine at the 
muscarinic and nicotinic cholinergic receptors. In high doses, this produces classical 
cholinergic side effects such as salivation, diarrhoea, tremor etc. However, multiple 
doses of some cholinesterase inhibitors induce the development of tolerance, which 
is shown by a marked recovery from the signs of toxicity associated with cholinergic 
overstimulation (Chippendale et a/, 1972; Overstreet et a/, 1974; Costa et a/, 1982; 
Russel eta/, 1986). 
Behavioural tolerance is supposedly due to the activation of secondary processes 
which compensate for the increase in ACh resulting from cholinesterase inhibition. 
Theories of tolerance development include compensatory synthesis of enzymes that 
metabolise or bind organophosphates (OPs) thus resulting in increased degradation 
or scavenging of incoming OPs. The accumulation of acetylcholine might lead to a 
reduced release of acetylcholine by a pre-synaptic feedback. Accumulation of 
acetylcholine may cause desensitisation and a rise in the threshold of the post- 
synaptic membrane (van Dongen et al, 1989) or receptor down regulation. The 
resulting subsensitivity is not restricted to the occurrence of cholinergic side effects, 
tt rr y also affect the functionality of 
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central cholinergic pathways including those involved in attentional or cognitive 
processes (e. g. Bushnall et a/, 1991; Mcdonald et al., 1988; Stamper et a/., 1988; 
Wolthuis et al, 1990). In the case of metrifonate one behavioural aspect of 
cholinergic activation, i. e. adverse reaction to cholinergic overstimulation appears to 
become hyposensitive, whereas beneficial effects on cognitive improvement are 
spared or unaffected. Alternatively, it has been suggested that metrifonate acts via 
a second, unknown mechanism of action (van der Staay, 1996; Itoh eta1,1997), 
which is not prone to desensitisation of procognitive effects. However, the 
exclusively cholinergic nature of metrifonate (Blokland eta/, 1995; Hinz eta/, 1996) 
as well as the failure of metrifonate or its active metabolite to interact with more 
than 60 molecular receptor targets in an in-vitro receptor screening (Hinz et a/ 
1996) suggests a differential adaption of central vs peripheral responses to 
cholinergic stimulation. 
The aim of this study was to determine if there is a differential adaptation of central 
versus peripheral responses to cholinergic stimulation. The first experiment was 
designed to determine whether cholinesterase inhibition is limited to central areas 
or if it is also a peripherally mediated phenomenon. To do this cholinesterase 
activity is studied in the brain and also peripheral tissues, which mediate cholinergic 
side effects such as salivation and diarrhoea. 
In the second experiment we determined whether development of tolerance 
originates centrally or peripherally. This is achieved by observing behavioural side 
effects after introducing challenge doses of centrally or peripherally acting 
cholinergic compounds. The final study looked specifically at a selectively central 
phenomenon, that of body temperature which is regulated by ACh muscarinic 
receptors in the hypothalamus (Ghanta et al, 1996). Challenge doses of specific 
centrally mediated cholinergic compounds are administered to animals that have 
received sub-chronic metrifonate treatment and changes in body temperature are 
observed. 
Bethanechol, a muscarinic agonist and neostigmine, a cholinesterase inhibitor was 
chosen because of their inability to cross the blood-brain barrier. Doses were chosen 
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that does not have greater toxic effects than metrifonate. Nicotine, oxotremorine, 
and donepezil, were chosen for their predominant central actions. 
2.1: Comparison of Cholinesterase activity between the CNS and 
periphery in rats with sub-chronic metrifonate 
Procedure 
Animals: Thirty male HsdCpb: WU (Harlan Wistar) rats (supplied by Harlan- 
Winkelmann, Borchen, Germany) were used. They were approximately 10 weeks old 
at the beginning of the experiment. Their weights ranged from 220-250 grams. The 
rats were housed in pairs in standard MakrolonTm Type III cages in which food and 
water was continuously available, with a 12: 12 hour light/ dark cycle, lights on at 
07.00 am. 
Treatment and processing of samples: The animals were treated daily with 10 (N = 
7), 30 (N = 8) or 50 (N = 8) mg/kg of metrifonate (p. o) in an application volume of 
5 ml/kg for up to 12 weeks. Control animals received vehicle only (sodium citrate 
buffer, pH 5.5, N=7). After 6 weeks of treatment 0.5ml of blood was collected from 
the tail vein. Eighteen hours after the final application the animals were killed by 
decapitation. Whole forebrains, salivary glands, heart, striated muscle (0.5g) from 
the hind leg and ileum (0.4g) were dissected over ice and homogenised in 3 
volumes (w/v) of 0.9% NaCl solution. Trunk blood was collected in tubes of 0.5 ml 
of 0.3M EDTA, pH 7.4. The blood was then diluted (2: 1) with Triton-100 followed 
by careful sonification. 
Enzyme assay were performed on ice. 50µI of the protein solution were mixed with 
10µI of 30mM aqueous solution of acetylcholine iodide containing 100,000 dpm [3H] 
acetylcholine iodide (New England Nuclear, Boston). After 3 min of incubation, the 
reaction was stopped by adding 100µI of an ice-cold solution containing iM- 
chioroacetic acid, 0.5M NaOH, and 2M NaCl. Finally, 4 ml of a polar scintillation 
cocktail (Quickscintz 501) were added to extract and quantify the formed [3H] 
acetate by ß- scintillation counting. 
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Analysis: The inhibition of cholinesterase activity across the selected dose range was 
analysed by ANOVA, with the factor Dose, complemented by post-hoc Fischer LSD 
comparisons. In order to analyse whether the effect on erythrocytes of chronic 
metrifonate changed across the 12 weeks of treatment an ANOVA with factors Dose 
and sample time point (6 vs 12 weeks) with repeated measures on the last factor 
was performed 
Results 
Cholinesterase activity in erythrocytes- (See figure 1, upper left panel) 
Averaged over all groups the cholinesterase activity in the erythrocytes after 6 
weeks was reduced by metrifonate treatment (F3,25 = 5.12, p<0.05). Metrifonate 
treatment continued to affect cholinesterase activity in the blood after 12 weeks 
(F3125 = 5.21, p<0.05). Post hoc comparisons revealed that at both 6 and 12 weeks 
the 50 mg/kg dose of metrifonate differed from vehicle, producing a 40 % reduction 
in cholinesterase activity. Metrifonate treatment had an effect when the average 
across the 6th and 12th week samples was considered (GENERAL MEAN: F3,25 = 
6.33, p<0.05). However, no further decrease in cholinesterase activity was 
observed between the two sample collection points (F1,25 = 1.35, n. s). 
Cholinesterase activity in the brain (See figure 1, upper middle panel) 
Metrifonate treatment caused a 30 % reduction in the cholinesterase activity in the 
brain (F3125 = 4.75, p<0.01) after 12 weeks of administration. Post hoc comparisons 
revealed that the ChE activity of the group treated with 50 mg/kg metrifonate 
differed from that of the vehicle treated group. 
Cholinesterase activity in the heart (See figure 1, lower middle panel) 
Averaged over all groups the cholinesterase activity in the erythrocytes in the heart 
weeks was reduced by metrifonate treatment (F3,25 = 2.77 p<0.05), however post 
hoc analysis revealed that no dose differed from vehicle treated groups and that the 




Cholinesterase activity in skeletal muscle (figure 1, upper right panel), salivary 
glands (figure 1, lower left panel), and smooth muscle (figure 1, lower right panel) 
Metrifonate had no effects on the cholinesterase activity in skeletal muscle (F3,25 = 
0.56, n. s. ), the salivary glands (F3,28 = 0.55, n. s. ), or smooth muscle (F3,25 = 0.81, 
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Figure 1. Effects of sub-chronic Metrifonate on cholinesterase activity in tissues in the periphery and 
the CNS. Data is depicted as percentage, ± SEM. N =7-8. 
2.2: Study of the adverse event response to cholinergic compounds in rats 
with sub-chronic metrifonate 
Procedure 
Animals: Forty male HsdCpb: WU (Harlan Wistar) (supplied by Harlan- Winklemann, 
Borchen, Germany) were used. They were approximately 10 weeks old at the 
beginning of the experiment. Their weights ranged from 220-250 grams. The rats 
were housed in pairs in standard MakrolonTM Type III cages in which food and water 




Drug Administration: Rats (N=10) were pre-treated orally once daily with 50,100, 
or 150 mg/kg Metrifonate in an application volume of 5 ml/kg for 7 weeks in order 
to induce steady state cholinesterase inhibition. Controls received the vehicle 
(sodium citrate buffer, pH 5.5) under identical conditions (see Appendix 2 for 
adverse event profile for sub-chronic metrifonate treatment). 
Eight weeks after the start of the experiment, challenge doses of either centrally 
acting or peripherally acting cholinergic compounds were administered to each of 
the metrifonate treated groups and to the control group. The centrally acting 
compounds used were: nicotine, 0.7 mg/kg, oxotremorine, 0.3 mg/kg and 
donepezil, 3 mg/kg. Peripherally acting compounds used were: neostigmine 0.2 
mg/kg and bethanechol 30mg/kg. All compounds were administered in an 
application volume of 2 ml/kg, i. p. simultaneously with metrifonate or vehicle. A 
week was introduced between each challenge dose to ensure drug washout. 
Methods: Immediately after administration the animals were put singly into small 
MakrolonTM Type II observation cages. Their behaviour/adverse symptoms such as 
ptosis (drooping eyelid), salivation, sedation, diarrhea, arched back (kyphosis), 
exopthalmus (eye swelling), piloerection, Straub tail, tremor, clonic seizure, limb 
abduction, vocalisation were observed by a skilled observer every 15 min for 3 
hours after administration (adverse effects observed between 0-15 minutes were 
also noted). The occurrence of abnormal behaviours was scored quantitatively. The 
animals receiving the challenge drug only served as controls for the effects of the 
challenge drug itself. An untreated group was not included, as previous experiments 
in our lab had consistently shown that vehicle treatment did not induce any 
observable effects. 
Statistycal analysis: The effects of the compounds were analysed on the sum of 
individual side effects over a nine-point observation period by ANOVA, with the 
factor Dose, complemented by post-hoc Fischer LSD comparisons. 
Results 
Sub-chronic metrifonate with Oxotremorine 
Adverse effects were observed in all animals 3 minutes after administration of 
oxotremorine alone or oxotremorine with Metrifonate 50,100 or 150 mg/kg (see fig 
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2 and table 1). Particularly evident signs were: prone position and abnormal 
respiration (gasping). Other symptoms observed included tremors and clonic 
seizures and salivation. Only clonic seizures were differentially affected by the 
treatment (F3135 = 4.33, p<0.01). Post hoc comparisons revealed that these seizures 
occurred in the group treated with oxotremorine alone, and in no other group. All 
other symptoms did not differ between treatment groups (Prone position: F3135 = 
0.18, n. s.; Abnormal respiration: F3,35 = 0.18, n. s; Head tremors: F3,35 = 0.09, n. s; 
Salivation: F3,35 = 0.67, n. s). The abnormal effects peaked around 5 minutes after 
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Figure 2: Effects of a challenge dose of oxotremorine 0.3 mg/kg in young adult rats subchronically 
treated with metrifonate 50,100 or 150 mg/kg. The percentage of animals showing the symptoms was 
determined over an observation period of 90 minutes. 
Oxotremorine 0 3mg/kg 50 mg/kg 100 mg/kg 150 mg/kg 
Salivation 4 1 1 3 
Head Tremors 17 14 12 12 
Prone position 30 30 25 21 
Clonic seizures 14 0 0 0 
Abnormal respiration 30 30 25 30 
Table 1: Effects of a challenge dose of oxotremorine, 0.3 mg/kg (i. p) in young adult rats sub- 
chronically treated with metrifonate 50,100 and 150 mg/kg. Entries represent the sums of observed 
symptoms during 9 observation points of 10 rats per group. All groups N= 10. 
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Sub-chronic metrifonate with nicotine 
Adverse symptoms were observed in all animals 2 minutes after administration of 
nicotine alone or nicotine in combination with Metrifonate 50,100 or 150 mg/kg 
(see fig 3 and table 2). No differences were observed between treatment groups 
averaged over all 9 observation points (See table 2). Symptoms included 
tachycardia (F3,35= 0.01, n. s), ptosis (F3,35= 0.94, n. s), Clonic seizures (F3339= 0.47, 
n. s), nausea (F3135= 0.09, n. s), prone position (F3,35= 0.11, n. s) and nose bleeding 
(F3,35= 0.35, n. s). The abnormal effects peaked about 2 and 15 minutes after 
administration of the challenge drug. They were transient and disappeared about 75 















Nicotine 0.7 mg/kg 










025 15 30 45 60 75 90 105 025 15 30 45 60 75 90 105 
Min After Administration 
Figure 3: Effects of a challenge dose of nicotine 0.7 mg/kg in young adult rats subchronically treated 
with metrifonate 50,100 or 150 mg/kg. Percentage of animals showing the symptoms over an 
observation period of 105 minutes is depicted. 
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Nicotine 0.7 mgft__ 50 mg/kg 100 mg kß 150 mg/kg 
Tachycardia 9 10 11 12 
Ptosis 12 19 23 23 
Clonic Seizures 15 16 18 17 
Nausea 8 10 13 12 
Prone position 12 14 16 11 
Nose Bleeding 0 4 5 4 
Table 2: Effects of a challenge dose of 0.7 mg/kg nicotine (i. p) in young adult rats subchronically 
treated with metrifonate 50,100 or 150 mg/kg. Entries represent the sums of observed symptoms 
during 9 observation points of 10 rats. All groups N= 10. 
Sub-chronic metrifonate with Donepezil. 
Adverse symptoms were observed in all animals 3 minutes after administration of 
donepezil or donepezil with Metrifonate 50,100 or 150 mg/kg, particularly with the 
symptoms of Repetitive chewing and Hypoactivity (See fig 4 and table . 3). Repetitive 
chewing (F3,35 = 0.07, n. s) and Hypoactivity (F3,35 = 1.64, n. s) were not differentially 
affected by the treatment over the 8 time points. However post hoc analysis 
revealed that the animals treated with 100 and 150 mg/kg metrifonate and 
donepezil showed more hypoactivity than the animals treated with donepezil alone. 
Head tremors were observed in the group treated with donepezil and Metrifonate 
100 mg/kg (F3,35 = 2.33, p<0.01). The abnormal effects peaked around 15 minutes 
after administration. They were transient and disappeared about 75 min after drug 
administration. 
Doneezil 3 mkg 
_50 
mý/kam 100 mg/kg 150 mg/kg_ 
Repetitive chewing 13 14 13 16 
Hypoactivity 19 18 28 21 
Tremors 0040 
Table 3: Effects of a challenge does of donepezil 3 mg/kg in young adult rats subchronically treated 
with metrifonate 50,100 or 150 mg/kg. Entries represent the sums of observed symptoms during 9 
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Figure 4: Effects of a challenge dose of 3 mg/kg donepezil in young adult rats subchronically treated 
with metrifonate 50,100 or 150 mg/kg. Percentage of animals showing the symptoms over a period of 
90 minutes. 
Sub-chronic metrifonate with Bethanechol (See) 
All animals exhibited adverse symptoms after administration of Bethanechol alone or 
in conjunction with Metrifonate 50,100 or 150 mg/kg, particularly with the 
symptoms of Salivation and Exopthalmus (bleeding and swelling of the eye. (See 
figure 5 and table 4). Other symptoms observed were Kyphosis (hunched back) and 
Nose bleeding. Abnormal respiration was observed in 90-100% of all rats. This 
symptom occurred only at the 15 minute time point. No differences were observed 
between the bethanechol treated group and the groups treated with a combination 
of metrifonate and bethanechol. The abnormal effects peaked between 2 and 30 
minutes after administration were transient by disappearing about 75 min after 
administration. 
Bethanechol Metrifonate Metrifonate VMetrifonate 
30 mg/kg 59 ! pgjN 
_ 
100 mgkq 150 mg/kg 
Exoptha lm us 26 27 27 23 
Salivation 35 27 24 28 
Kyphosis 20 17 18 18 
Prone position 19 14 11 19 
Nose Bleeding 5 3 2 3 
Abnormal respiration 10 9 9 9 
Table 4: Effects of a challenge dose of 30 mg/kg bethanechol, in young adult rats subchronically 
treated with metrifonate 50,100 and 150 mg/kg. Entries represent the sums of observed symptoms 
during 8 observation points of 10 rats. All groups N= 10. 
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Figure 5: Effects of a challenge dose of bethanechol, 30 mg/kg in young adult rats subchronically 
treated with metrifonate 50,100 or 150 mg/kg. Percentage of animals showing the symptoms over a 
period of 90 minutes. 
Sub-chronic metrifonate with neostigmine 
All animals exhibited adverse symptoms after administration of Neostigmine alone 
or in conjunction with Metrifonate 50,100 or 150 mg/kg. 60-100% of rats showed 
symptoms, which included Ptosis, Prone position, Clonic seizures and slight tremor 
(See figure 6 and table 5). The 100 mg/kg metrifonate appeared to have a greater 
incidence of side effects over the 8 time point period compared to that of 
neostigmine, however further statistical analysis revealed no difference between 
treatment groups (Ptosis: F3,35 = 0.05, n. s; Prone Position: F3,35 = 0.20, n. s; Clonic 
seizures: F3,35 = 0.09, n. s; Tremor: F3135 = 0.33, n. s). The abnormal effects peaked 
between 5 and 45 minutes after administration. They were transient and 
disappeared about 60 min after administration. 
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-ý Neostigmine, 0.2 mg/kg --D- Neostigmine 0.2 mg/kg and Metrifonate 100 mg 
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Figure 6: Effects of a challenge dose of 0.2 mg/kg neostigmine, in young adult rats subchronically 
treated with metrifonate 50,100 or 150 mg/kg. The percentage of animals showing the symptoms 
over a period of 75 minutes is depicted. 
Neostigmine, Metrifonate Metrifonate Metrifonate 
---- ------- ---~ýý 
0.2 /kam 
ýýý --- -- - --- 
50 mg 100 mg/kg 150 g/kg 
Ptosis 13 14 13 16 
Prone position 19 18 28 21 
Clonic seizures 13 13 19 14 
Tremors 26 23 38 29 
Table 5: Effects of a challenge does of 0.2 mg/kg neostigmine, (i. p) in young adult rats subchronically 
treated with metrifonate 50,100 and 150 mg/kg. Entries represent the sums of observed symptoms 
during 8 observation points of 10 rats. All groups N= 10. 
2.3: Hypothermic response to cholinergic compounds in rats with sub- 
chronic metrifonate 
This experiment investigated whether challenge doses of 0.7mg/kg nicotine, 0.3 
mg/kg oxotremorine or 3 mg/kg donepezil affected the body temperature of rats 
treated daily for 12 weeks with metrifonate 50,100 or 150 mg/kg. 
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Procedure 
Animals: The subjects were 38 male HsdCpb: WU (Harlan Wistar) rats (supplied by 
Harlan-Winkelmann, Borchen) with free-feeding body weights ranging 220- 250 
grams aged 10 weeks at the start of the experiment. Rats were housed in pairs in 
standard MakrolonTM Type III cages in which water was continuously available, with 
a 12: 12 hour light/ dark cycle, lights on at 07.00 am. 
Apparatus and Methods Immediately preceding the administration of the challenge 
drugs the body temperature was measured electronically (Testotherm 9019, 
Testotherm GmbH, Lenzkirch, Germany) with a rectal probe. Fifteen, 30,45,60,90, 
120,180 and 240 min after administration of the challenge doses, additional 
measurements were performed. 
Analysis: The effects of the compounds were analysed with a Treatment by Time 
ANOVA, in which the time after administration was considered a repeated measures 
factor. 
Cholinesterase Inhibitiorr. 
Methods and Analysis The inhibition of cholinesterase activity was measured and 
analysed as with the brain samples in section 9.1 
Results 
Donepezil (See figure 7, panel A) 
Averaged over the entire observation period (3 hrs) drug treatment affected body 
temperature differently (GENERAL MEAN: F3,34= 7.51, p<0.001). Post hoc analyses 
on the general mean by Fischer's LSD revealed that the groups treated with 
combination of donepezil and 100 or 150 mg/kg metrifonate produced a higher 
increase in body temperature than the control group treated with donepezil alone. 
The body temperature changed over the time of observation (TIME: F81272= 60.15, 
p<0.001) and this change in body temperature was different between treatment 
groups (TIME by TREATMENT: F24,272= 4.35, p<0.001). All groups returned to pre- 




Administration of donepezil to the group treated with 100 mg/kg metrifonate 
produced the highest increase of body temperature 45 min post administration 
(37.98 °C ± SEM). 
Nicotine (see figure 7, Panel B) 
One animal was removed from analysis 
Nicotine appeared to affect the body temperature of control (nicotine 0.7 mg/kg + 
vehicle) and metrifonate treated (nicotine + 50,100 or 150 mg/kg metrifonate) rats 
differently when averaged over the entire observation period (180 mins). However, 
this impression was not confirmed statistically (GENERAL MEAN: F3,33= 1.52, n. s). 
The body temperature changed over the time of observation (TIME: F8,272= 57.39, 
p<0.001), however this change in body temperature was not different between 
treatment groups (TIME by TREATMENT: F24,272= 0.96, n. s). All groups returned to 
pre-treatment body temperatures after 3 hours (ANOVA on last time point: F3,33= 
1.54, n. s). 
Oxotremorine (See figure 7, Panel C) 
Averaged over the duration of the observation period (180 mins) oxotremorine did 
not differentially affect the body temperature of control (oxotremorine 0.3 mg/kg + 
vehicle) and metrifonate treated (oxotremorine + 50,100 or 150 mg/kg 
metrifonate) rats (GENERAL MEAN: F3,34= 0.09, n. s). The body temperature 
changed over the time 
of observation (TIME: F81272= 20.39, p<0.001), however this change in body 
temperature was different between treatment groups (TIME by TREATMENT: 
F24,272= 2.66, p<0.001). All groups returned to pre-treatment body temperatures 
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Figure 7 Panel A: Effects of 3 mg/kg Donepezil on body temperature in Wistar rats pre-treated with 
metrifonate 50,100 and 150 mg/kg daily for 12 weeks. Panel B Effects of 0.7 mg/kg Nicotine on body 
temperature in Wistar rats pre-treated with metrifonate 50,100 and 150 mg/kg daily for 12 weeks. Panel 
C. Effects of 0.3 mg/kg Oxotremorine on body temperature in Wistar rats pre-treated with metrifonate 50, 




Averaged over all groups the brain cholinesterase activity after 12 weeks was 
reduced by metrifonate treatment (F3,35 = 5.95, p<0.05). Post hoc comparisons 
revealed that both the groups treated with 100 and 150 mg/kg metrifonate differed 
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Figure 8: Effects of sub-chronic Metrifonate on cholinesterase activity in the brain. Data is measured as 
a percentage of control animals, ± SEM. 
Discussion 
The aim of the present study was to assess whether long-term inhibition of 
cholinesterase activity by metrifonate created adaptive changes in the development 
of tolerance. In addition, the question was addressed whether the adaptive changes 
were a central or peripheral phenomenon. To do this the cholinesterase activity 
after sub chronic metrifonate treatment was measured in tissues which produce the 
cholinergic side effects of salivation, tremor diahorrea etc. Changes to the adverse 
event profile and frequency with peripherally and centrally acting nicotinic, 
muscarinic and cholinesterase stimulation and the effects on body temperature after 





In experiment 9.1, Cholinesterase inhibition occurred in a dose dependent manner. 
Metrifonate treatment caused a 30 % reduction in brain cholinesterase activity by 
the highest dose tested (50 mg/kg). Erythrocyte cholinesterase inhibition after 12 
weeks of treatment as compared to the shorter treatment period of 6 weeks 
mediated the same level of inhibition (i. e. 60% inhibition). The concomitant 
inhibition of erythrocyte and brain cholinesterase activity up to three months of 
treatment confirms the findings of Moriearty et a/ (1991) that metrifonate does not 
induce any alterations in normal blood cell differentiation. Peripheral inhibition of 
cholinesterase activity such as on erythrocytes is thought by some to be unwanted 
and may constitute a safety risk, and that brain selective cholinesterase inhibitors 
would be more preferable. However, as shown in this study, pharmacologically 
active doses of metrifonate after long term administration, inhibition of 
cholinesterase activity in brain and blood was well tolerated by rats. Further findings 
of this study are that no significant inhibition in other peripheral tissues such as 
salivary glands, skeletal and smooth muscle were observed. It appears that 
inhibition of peripheral cholinesterase in the blood does not necessarily lead to 
peripheral side effects. 
Adverse event profile and body temperature 
Repeated administration of cholinesterase inhibitors is thought to induce 
behavioural tolerance to the transient, but supposedly limiting cholinergic side 
effects. Compared to an acute administration of metrifonate to drug naive animals, 
the same challenge dose of metrifonate given to subchronically pre-treated rats 
results in a lower incidence of adverse effect (Blokland et a/, 1995). The 50mg/kg 
dose was chosen because it is effective in patients (Cummings et al, 1998) and 
behavioural tasks in animals (Schmidt et al, 1997) The 150mg/kg dose of 
metrifonate was chosen as an outer limit to the development of tolerance over time, 
higher concentrations would cause irreversible damage or even death. 
Behavioural tolerance is supposedly due to the activation of secondary processes 
which compensate for the increase in acetylcholine resulting from cholinesterase 
inhibition In view of this, challenge doses of either centrally or peripherally acting 
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muscarinic, nicotinic and cholinesterase inhibitors were administered to rats 
subchronically treated with metrifonate. 
No distinct changes were observed with the peripherally acting compounds 
bethanechol (muscarinc agonist) or neostigmine (cholinesterase inhibitor). In 
response to oxotremorine treatment, a centrally acting muscarinic agonist, there 
was a subsensitivity to muscarinic receptor-mediated changes in only one of the 
observed side effects i. e. clonic seizures whereas nicotine, caused no changes in 
sensitivity an rats pre-treated with metrifonate. These two compounds also 
produced no changes in sensitivity in body temperature, which is regulated by 
muscarinic receptors in the hypothalamus (Ghanta et al, 1996). Donepezil, a 
centrally acting cholinesterase inhibitor produced a supersensitivity, in both adverse 
effects and body temperature. Lack of effects with muscarinic and nicotinic agents 
and a supersensitivity to cholinesterase inhibitors suggests possible changes to the 
cholinesterase enzyme itself rather than changes in acetylcholine receptors. 
Previous studies have shown tolerance development with the repeated 
administration of cholinesterase inhibitors (Chippendale eta/, 1972; Overstreet etal, 
1974; Costa eta/, 1982; Russel eta/, 1986). This effect was interpreted as resulting 
from a down regulation of muscarinic receptors in the brain and other tissues 
(Churchill, et a/ 1984; Costa et a/, 1982; Bushnell et a/, 1991). Pharmacological 
evidence for tolerance to chloropyrifos was observed as a reduction in sensitivity to 
the hypothermic response of oxotremorine providing a functional index to 
muscarinic receptor down regulation (Bushnell et a/, 1994). Development of 
tolerance has also been observed during repeated exposure to di- 
isopropylfluorophosphate (DFP) (Overstreet et a/, 1974; Bushnell et at, 1991) and 
disulfoton (Costa et al, 1982). However, in the case of metrifonate no changes in 
either muscarinic or nicotinic receptor binding or affinity are observed after 
subchronic treatment (Hinz et al, 1998). This study has shown no changes to the 
hyperthermic response and side effects. Consequently another mechanism must be 
responsible for the changes in tolerance to metrifonate treatment. 
One such mechanism could be changes in the second messenger systems within the 
cell. Past studies have looked at the effects of cholinesterase inhibitors on 
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muscarinic second messenger systems. An important receptor linked signal 
transduction system for the muscarinic receptors involves the hydrolysis of 
membrane phosphoinositides (PI) to diacylglycerol and inositol triphosphate, both of 
which may act as second messengers (for review see Ehlert etal, 1980) 
Experiments concerning repeated cholinesterase inhibition on muscarinic receptor 
coupled PI hydrolysis have been inconsistent (Costa et a/, 1986) found that 
disufoton (an OP compound) decreased carbachol-stimulated PI hydrolysis in rat 
brain cortical slices. This was also observed after administration of DFP (Pintor etal 
1992). However, Abdallah and El-Fakahany (1991) reported no changes in 
hydrolysis in the rat cortex, hippocampus or striatum after repeated DFP 
administration. Further, Keifer-Day and El-Fakahany (1992) reported no change in 
muscarinic receptor agonist stimulated PI hydrolysis in brain cells from mice treated 
with tacrine (a cholinesterase inhibitor). It would be important to determine whether 
metrifonate is affecting this second messenger system rather than producing 
changes in receptor density and affinity. 
The cholinesterase (ChE) enzyme can be subdivided into heteromeric and 
homomeric families as well as into globular and asymmetric forms (See Chapter 1, 
pg 3-4). This diversity is produced by alternative mRNA splicing. DFP has been 
shown to have more affinity for the intracellular membrane bound G1 form of AChE 
and metrifonate has been shown to have similar affinity for both the G1 and 
extracellular membrane bound G4 form (Ogane et al, 1992). These differences 
might be related to an effect on the allosteric binding site or on a non-catalytic 
binding site, which is known to have a regulatory effect on enzyme activity 
(Gentinetta, et al, 1976; Skau, 1986). This may explain that metrifonate and DFP 
may have differences in their eventual effects on muscarinic receptor binding and 
affinity. 
Cholinesterase can be found as one of two forms, acetylcholinesterase (AChE) or 
butyrylcholinesterase (BuChE). A possible explanation for the effects of the 
increased sensitivity to donepezil could be the affinity for the compounds for either 
AChE or BuChE. According to published data donepezil is more selective for AChE 
(Rogers et al, 1991) and metrifonate has more affinity for BuChE than for AChE. 
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(Pacheco eta/, 1995). The potency and respective selectivity index for AChE versus 
BuChE are not related to their tolerability and as such more selective BuChE 
compounds such as metrifonate do not cause more symptoms than inhibitors that 
are selective for AChE, i. e. donepezil (Schmidt & van der Staay, 1998) when 
administered alone. However, the combination of the two compounds may cause an 
additive effect, thus increasing the sensitivity to side effects and body temperature. 
This needs to be studied further with other combinations of AChE and BuChE 
selective compounds to see if this is a general effect or if this effect is specific for 
metrifonate alone. Further studies on the distribution of the compounds within 
different regions of the brain, with also studies in abundance and distribution of 
AChE and BuChE may further explain this effect. 
Finally, the administration of metrifonate may counter regulate changes in the 
expression of the genes coding for AChE and BuChE in the brain (See chapter 10). 
In conclusion from this study it is thought that the development of tolerance is a 
centrally acting phenomenon that is mediated by either changes of the 
cholinesterase enzyme within the brain or of the gene expression of AChE and 
BuChE. 
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Changes in Gene Expression of Acetyl and 
Butyrylcholinesterase in Brain after Sub-chronic Metrifonate 
Treatment 
Abstract 
A modified polymerase chain reaction (PCR) assay was used to analyse acetyl and 
butyrylcholinesterase gene expression in the rat brain after sub-chronic treatment 
with metrifonate (10,30,50 and 100 mg/kg). The method describes the use of the 
housekeeping enzyme hypoxanthine phosphoribosyltransferase (HPRT) as an 
internal standard, since its range of detectable expression is similar to that of the 
enzymes under test. 
Results show that sub chronic treatment with metrifonate produced about a 2-fold 
increase in both AChE and BuChE mRNA expression. 
This up regulation of ChE expression could be responsible for the decrease in 
adverse side effects observed over time (see chapter 9) and would generally 
indicate a decrease in the therapeutic efficacy of AChE inhibitors in Alzheimer 
therapy. However, there are no changes in the cognitive benefit of metrifonate in 
patients (Dubois et al., 1999) or in experimental animals (Schmidt et al., 1997). At 
this time it is unknown as to the reason of these effects though it is thought that 
possibly another mechanism within the brain maintains the cognitive improvement. 
Introduction 
Metrifonate is a dual inhibitor of acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE) developed for the cholinergic therapy of Alzheimer's 
disease (Schmidt and Heinig, 1998; Jann, 1998). Its long-term efficacy has been 
demonstrated in double-blind, placebo-controlled clinical trials (Becker et al., 1996; 
Morris et al., 1998; Dubois et al., 1999). The compound also improves the cognitive 
behavior of animals (Schmidt et al., 1997) whereby the best results are usually 




Cholinesterase inhibitor treatment produces an accumulation of acetylcholine at the 
muscarinic and nicotinic cholinergic receptors; this produces classical cholinergic 
side effects such as salivation, diarrhoea, tremor etc. Multiple doses of some 
cholinesterase inhibitors induce the development of tolerance, which is shown by a 
marked recovery from the signs of toxicity associated with cholinergic 
overstimulation (Chippendale eta/, 1972; Overstreet eta/, 1974; Bigami eta/, 1975; 
Costa, eta/, 1982; Russel eta/, 1986). 
The resulting subsensitivity is not restricted to the occurrence of cholinergic side 
effects, but may also affect the functionality of central cholinergic pathways 
including those involved in attentional or cognitive processes (e. g. Bushnall et a/, 
1991; McDonald eta/., 1988; Stamper eta/., 1988; Wolthuis eta/, 1990). However, 
in the case of metrifonate one behavioural aspect of cholinergic activation, i. e. 
adverse reaction to cholinergic overstimulation becomes hyposensitive, the other, 
cognitive improvement is spared. 
As AChE is a vital enzyme, a long-term inhibition might result in a counterregulatory 
upregulation of the expression of the gene coding for this enzyme to restore normal 
levels of activity. This would, however, decrease the therapeutic efficacy of AChE 
inhibitors in Alzheimer therapy and necessitate an increase in dosage over time. In 
order to assess whether there are changes in gene expression, we treated rats for 
three months with metrifonate (0,10,30,50 or 100mg/kg orally twice daily) and 
measured the levels of AChE and BuChE expression in whole forebrain samples. 
Procedure 
Anima/s" Male HsdCpb: Wu Wistar rats, weighing about 220 to 250 grams, were 
obtained from Harlan-Winkelmann, Borchen, Germany. They were allowed to adapt 
to our animal facilities for one week before start of the pretreatment. The rats were 
housed in groups of two in standard MakrolonTm Type III cages. Food and water 




Drug Administration: Rats (N= 7-8) were pre-treated orally twice daily with 10,30, 
50 or 100 mg/kg Metrifonate, in an application volume of 5 ml/kg for 12 weeks in 
order to induce steady state cholinesterase inhibition. Controls received the vehicle 
(Sodium citrate buffer, pH 5.5) under identical conditions. 
Analysis: Gene expression of AchE and BuChE across the selected dose range was 
analysed by Kruskal-Wallis, with the factor Dose, complemented by post-hoc Fischer 
LSD comparisons. 
Determination of A ChE and BuChE gene expression in brain 
RNA preparation (the method of Chromczynski and Sacchi (1987) was used) 
18 hours after the final application the animals treated with metrifonate or vehicle 
were killed by decapitation. Whole brains were dissected over ice and homogenised 
for 30-60s in 5 ml of lyses buffer. Aliquots of 1 ml were then prepared. To this, 50 pl 
2M NaAc pH 4,0; 500 pl Phenol and 100 pl Chloroform/Isoamylalcohol 24: 1 was 
added, and then centrifuged for 20 min at 4°C and 14000 rpm. The top layer was 
removed. 8-15 pl RNA-Matrix was then added and vortexed for 30s, followed by 5 
min agitated incubation at 55°C (Thermomixer, Eppendorf). Following 30s 
centrifugation at 14000 rpm, 250 pl RNA-Wash solution was added and then re- 
centrifuged for an additional 30s 
The top layer was removed and the pellet allowed to dry, preferably overnight. 20- 
30µ1 DEPC- H2O were added and agitated for 5 min at 55 °C. Following 
centrifugation for 30 s at 14000 rpm the top layer was removed and re-centrifuged 
twice to make sure the entire matrix was removed. The RNA was stored at -70°C. 
Reverse transcription 
RNA was reverse transcribed into cDNA as described by Murphy et al. (1993). A 
40pl reaction mixture contained about 200 ng -2 pg of total RNA. 
A Mastermix was first prepared without RNAsin (RNAase inhibitor, Gibco) and RT 
(Reverse Transcriptase, Gibco), over ice (See table 1). Once these were added the 
mix was incubated for 10 min (annealing) and then for 1h at 37°C (synthese). 
Denaturing the enzymes then followed for 3 min at 96°C. The samples were then 




5x buffer 8 pI 
dNTP (25 mM) 4 pl 
Oligo dTPrimer (500 pg/mI) 1 NI 
DTT (0,1 M) 1 pi 
DEPC-H20,3-15 pl 
RNAsin (10000 U/mI) 1 PI 
RT (Superscript, 200 U/pI) 2 pl 
RNA 8-20 pI 
Table 1: Mastermix for the reverse transcription of RNA to cDNA. 
Primers and control figment (see table 2) 
Primer pairs for the 5' and 3' region were selected. The annealing temperature was 
optimised empirically for each primer pair. Primer pairs were designed such that 
they do not exhibit 3'-complementarity and span one or more intones to distinguish 
amp icons of cDNA from those of genomic DNA. As control fragment for 
hypoxanthine phosphoribosyltransferase (HPRT) a synthetic gene containing 5' and 
3' primers were constructed using complementary 40mer oligonucleotides chosen 
with the GENMON-program (design and use of primers and probes is reviewed in 
O'Garra and Vieira, 1992) by TIB Molbiol, GmbH iG, Berlin. The gene was cloned in 
pBluescript II KS+ (Stratagene, La Jolla, CA) and controlled for the correct 
sequence. It was obtained as fragment from the plasmid by restriction with Pst 
I/Kpn I. The specificity of the PCR products was verified by restriction analysis, 
using two restriction enzymes indicative of the expected amplified sequence. 
Table 2: Rat gene primer sequences 
Gene Primers Gene Sequence 
HPRT sense 5'-GTA ATG ATC AGT CAA CGG GGG AC-3' 
antisense: 5'- CCA GCA AGC TTG CAA TAA CCA-3' 
probe 5'- GCT TTC CCT GGT TAA GCA AGT CAG CCC C-3' 
AChE sense: 5'-CAG GCC TAC TTC TCC CAC AC -3' 
antisense: 5'- GAG TCA CTG ACA TCG GGT CT -3' 
BuChE sense: 5'- AGT GGA TGG CGA TTT TCT CAC-3' 
antisense: 5'- CCA GTG CAG GGC AGA TGA T-3' 
Competitive RT-PCR 
The competitive PCR has been introduced (Gilliland 1990) in which a competitor 
control fragment is amplified together with sample cDNA in the PCR reaction 
51 
CHAPTER 3 
mixture with the same primers. Variations in efficiency of amplification between 
reactions can be estimated using the control fragment as internal control. The 
control and sample PCR products are distinguished by differences in length. With 
the known input concentration of the control fragment and amplification of both 
PCR products occurring proportionally, the sample cDNA can be quantified. This 
method was used to quantify HPRT (housekeeping gene content of cDNAs). 
HPRT cDNA quantification was performed as described by Siegling et al. (1994). A 
cDNA equivalent of about 5 ng total RNA was amplified in a 25 pl reaction volume 
containing 250 pM of each dNTP, 100 pM of the appropriate primer pair, 2.5 pl 
10-fold PCR buffer (Perkin Elmer/Cetus, Emeryville, CA) and 0.5 pl Taq DNA 
polymerase ("Ampli"-Taq, Perkin Elmer/Cetus). After an initial denaturation step, 
cDNA samples were subjected to rounds of denaturation (94° C for 15 sec), 
annealing ( 68° C [beta-actin] and 60° C [AChE, BuChE] for 15 sec) and extension 
(72°C for 15 sec) using the thermal cycler 9600 (Perkin-Elmer/Cetus). According to 
the varying contents of specific cDNA and varying amplification efficiencies, the 
samples were subjected to 30 cycles: Control PCRs without cDNA were performed in 
all experiments to exclude contamination. To correct for variations across different 
preparations, the cDNA samples were adjusted to equal input concentrations based 
on their HPRT content before determining cytokine cDNA concentrations. PCR 
products were subjected to agarose (1%) gel electrophoresis, stained with 
SybrGreen® (Biozym) and the intensity of the beta-actin bands was measured using 
a video imaging system (Herolab) with the appropriate software. 
TagMan-Polymerase chain reaction (PCR) 
cDNA quantification was performed as described in the user manual. A HPRT-cDNA 
amount of about 10-20 pg was amplified in a 25 pl reaction volume of the TaqMan 
PCR CORE Reagent Kit N808-0228 (Perkin Elmer/Cetus, Emeryville, CA) and a cDNA 
amount of about and 30-300 fg (AChE), 3-30 fg (BuChE) was amplified in a 25 pl 
reaction volume of the SYBR Green PCR Core Reagent Kit 4304886 (Perkin Elmer/ 
Cetus, Emeryville, CA) using the sequence detection system 1.6.3 (PE Applied 
Biosystems). To correct for variations across different preparations, the HPRT 
content of the specific cDNA samples was determined. 
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According to the varying input concentrations of cDNAs AChE/BuChE amounts were 
quantified relative to their HPRT content. Control PCRs without cDNA were 
performed in all experiments to exclude contamination. To avoid unspecific products 
AChE/BuChE-PCR products were subjected to agarose (1%) gel electrophoresis, 
stained with SybrGreen® (Biozym). 
Results 
Treatment effects on A CNE and BuChE gene expression in brain 
Adjustment of HPRT content of cDNAs. - 
Figure 1: Initial analysis of HPRT expression in forebrain samples of rats treated sub-chronically with 
metrifonate (10,30,50 and 100 mg/kg). Arbitrary units for HPRT levels in the samples were obtained 
from a standard curve (not shown). 
ACNE and BuChE Standards: 
Figure 2: Initial analysis of ACNE and BuChE in forebrain samples of rats treated sub-chronically with 
metrifonate (10,30,50 and 100 mg/kg) for quantification of AChE and BuChE gene expression. 
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Quantification ofAChE- and BuChE-gene expression using TaqMan-PCR technique: 
Sub-chronic treatment of metrifonate produced an increase in AChE mRNA 
expression (Kruskal-Wallis: 8.847, p<0.05). Further post hoc analysis revealed that 
the dose of 50 mg/kg metrifonate produced a 2-fold increase compared to vehicle 
treated animals. 
BuChE mRNA expression was also shown to increased after sub- chronic metrifonate 
treatment (Kruskal-Wallis: 11.48, p<0.05). Post hoc analysis revealed that both the 
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Figure 3: mRNA expression of AChE (Left Pane/) and BuChE (Right Pane, ) in brain following chronic 
Metrifonate (10,30,50 and 100 mg/kg administration, twice daily p. o., for 12 weeks to Wistar rats 
compared to controls (Sodium Citrate buffer, pH 5.5). Data is presented as the mean of arbitrary units 




Summary of results 
Inhibitors of cholinesterases are being explored for the treatment of 
Alzheimer's disease. The aim is to rapidly enhance the levels of synaptic 
acetylcholine through inhibition of the hydrolytic capacities of cholinesterase's. 
Multiple doses of some cholinesterase inhibitors induce the development of 
tolerance, which is shown by a marked recovery from the signs of toxicity 
associated with cholinergic overstimulation (Chippendale eta/, 1972; Overstreet 
et a/, 1974; Bigami et a/, 1975; Costa, et a/, 1982; Russel et a/, 1986) 
supposedly due to the activation of secondary processes which compensate for 
the increase in ACh resulting from cholinesterase inhibition. One possible 
reason for these counterregulatory processes is the up regulation of expression 
of the cholinesterase genes. 
In the present study, sub chronic metrifonate treatment produced about a 2- 
fold increase in both AChE (50 mg/kg) and BuChE (30 and 50 mg/kg) mRNA 
expression. Metrifonate (Pacheco et al, 1995) is thought to have more affinity 
for BuChE, which might explain that the lower dose of 30 mg/kg had an effect 
on BuChE whereas it had no effect on AChE mRNA expression. Past studies 
also show an increase in cholinesterase gene expression with treatment with 
DFP, and physostigmine (Kaufer et al, 1999), 
A putative chain of events following cholinergic hyperactivation: AChE inhibition 
leads to increased levels of ACh, which then activates pre and post-synaptic 
muscarinic ACh receptors in a larger number of neurones than those activated 
under normal conditions. This increase in number of neurons firing action 
potentials leads to increased population spike amplitudes in response to 
constant electrical stimulation. The consequent depolarisation and Ca 2+ influxes 
eventually cause, via Ca 2+ responsive elements (CRE) in the c-fos promoter, 
eleyated c-fos mRNA levels (Ghosh et al, 1994). This in turn modulates the 
transcription of down stream genes encoding for AChE, ChAT and the vasicular 
ACh transporter (Kaufer et al, 1999). The results then suggest a feedback 
mechanism by which the AChE gene is activated by cholinergic transmission 
leading to increased AChE protein and 
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accelerated degredation of acetylcholine at cholinergic synapses (Nitsch et al, 
1998). 
Significance for AD therapy 
Counterregulation of acetylcholine release and/or synthesis, cholinesterase 
desensitisation or adaptive changes in muscarinic, nicotinic or cholinesterase genes 
is thought to be deleterious for the concept of cholinergic replacement therapy in a 
chronic disorder such as Alzheimer's disease. 
In this study ChE gene expression is upregulated with sub chronic metrifonate. One 
behavioural aspect of cholinergic activation, i. e. adverse reaction to cholinergic 
overstimulation becomes hyposensitive. However, the other, cognitive improvement 
is generally spared. It is not known as to why this is the case, however the increase 
in gene expression is only two fold and it is possible that other mechanisms within 
the brain are responsible for maintaining this cognitive improvement. 
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Effects of Metrifonate in the Passive Avoidance Task in Rats. 
Abstract 
The aim of the experiments described was to assess the effects of acute and sub- 
chronic cholinesterase inhibition on scopolamine induced amnesia. Acute 
metrifonate had no effect on the performance deficits during the retention session. 
When given sub-chronically before testing metrifonate effectively inhibited the 
scopolamine-induced deficit. 
Although this cholinesterase inhibitor was able to antagonise scopolamine- induced 
deficits in the passive avoidance task it is necessary to confirm the effects of 
compounds in other tasks such as the Morris water escape task. The passive 
avoidance task is a fast way to assess the effects of putative cognition enhancers. 
However it is relatively complex and poorly understood and therefore can be taken 
as a first indication only that a compound might possess cognition enhancing 
properties. 
Introduction 
The passive or inhibitory avoidance test is considered to be a useful early screening 
test to identify putative cognition enhancing compounds in rodents. Animals with 
impaired performance are needed to test putative cognition enhancers. 
Administration of scopolamine (Imanishi eta/, 1997) is a common method to induce 
amnesia of the aversive event, i. e. the footshock in the passive avoidance task. 
Compounds are usually tested in scopolamine-treated rats. 
The scopolamine model of ageing and dementia assumes that the resulting 
behavioural impairments reflect the cholinergic dysfunction seen in AD (Wesnes et 
al, 1991). This study investigated the effects of metrifonate presently being studied 
or used for AD treatment. Metrifonate has also been shown to alleviate 
scopolamine-induced deficits in rats (Itoh, etat,, 1997: Riekkinen etal, 1996). 
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Previous studies of ChEI's in the passive avoidance task report on the acute effects 
of metrifonate (Itoh, et al, 1997; Riekkinen et al, 1996). However, putative 
therapeutic agents for chronic ailments are likely needed to be administered over a 
prolonged period. Therefore the second aim of the study was to determine the 
effects of a sub-chronically administered ChEI on the passive avoidance task using 
metrifonate and to compare this with the acute effects of these compounds 
4.1: Effects of acute metrifonate in the passive avoidance task 
Animals: A group of 40 male HsdCpd: Wu (Harlan Wistar) rats (supplied by Harlan- 
Winkelmann, Borchen) were used. They were approximately 10 weeks old at the 
beginning of the experiment. Their weights ranged from 220-240 grams. The rats 
were housed in pairs in standard MackrolonTm type III cages in which food and 
water was continuously available, with a 12: 12 hour light/ dark cycle, lights on at 
07.00 am. 
Drug Administration: Rats (N = 8) were treated with 30, or 60 100 mg/kg 
Metrifonate. The compound was administered per os (p. o. ) 30 minutes prior to the 
start of the shock trial in an application volume of 5 ml/kg. Controls received the 
vehicle (Sodium citrate buffer, pH 5.5). Scopolamine (1 mg/kg was administered 30 
minutes prior to the shock session, interperitoneally (i. p. ) in an application volume 
of 2 ml/kg, i. e. scopolamine was administered in conjunction with metrifonate 
before the start of the experiment. Control groups are vehicle alone and 
scopolamine with vehicle. 
Apparatus: The inhibitory apparatus consisted of a two-compartment box with a 
light compartment and a dark compartment, each measuring 36 (height) * 27 
(depth) * 37 (width) cm. The apparatus was made of black plastic, except for the 
sidewalls of the light compartment, which were white. The floor consisted of a metal 
grid connected to a shock scrambler. 
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A guillotine door that could be raised 9 cm separated the two compartments. A 
threshold of 2 cm separated the two compartments when the guillotine was raised. 
When the door was open, the illumination in the dark compartment was about 2 
lux. The light intensity was about 500 lux at the centre of the light compartment. 
The equipment was placed in a noise box, situated in a room illuminated by red 
fluorescent strip lights. 
Method: Two habituation sessions, one shock session and a retention session were 
given, separated by an inter-session interval of 24 hours (see figure 1). In the 
habituation sessions and the retention session the rat was allowed to explore the 
apparatus for 300 seconds. The rat was placed in the light compartment, facing the 
wall opposite to the guillotine door. After an accommodation period of 15 seconds, 
the guillotine door was opened so that all parts of the apparatus could be visited 
freely. In the shock session the guillotine door between compartments was lowered 
as soon as the rat had entered the compartment with its four paws, and then a1 
mA shock for 2 sec was administered. The rat was removed from the apparatus 10 
seconds after shock termination and put back in its home cage. The procedure 
during the retention session was identical to that of the habituation sessions. 
Analysis- Two variables were selected for further analyses: 
1. The stepthrough latency, that is the first latency of entering the dark 
compartment, and 
2. The time spent in the light compartment. 
Whenever a rat did not enter the dark compartment, variables 1 and 2 (above) were 
ascribed a value of 300 seconds. Differences between groups on these variables 
were analysed for each session by analysis of variance (ANOVA), complemented 
with Fisher's LSD post hoc comparisons. 
In this chapter 'antagonism' refers to a full reversal of the scopolamine effect and 
that there is no significant difference between the vehicle and dose group. 'Partial 
antagonism' refers to a reversal of the scopolamine effect but there is still some 





First habituation session 
24-hour inter-session interval 
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Figure 1: Schematical diagram of the procedure of the passive avoidance task. Each of the four 
sessions was separated by a 24hr inter-session interval. 
Results 
Acute metrifonate, (see figure 2) 
The five treatment groups had small differences in the latency to enter the dark 
compartment during the first (F4,36 = 3.18, p< 0.05) habituation session. No 
differences were observed for the latency to enter the dark compartment in the 
second habituation session (F4,36 = 1.49, n. s) and the shock session (F4,36 = 1.96, 
n. s), see figure 2, let panel). The treatments affected the latencies in the retention 
session (F4,36 = 17.85 p< 0.001). Fisher's LSD post hoc analysis with a Bonferroni 
correction revealed that performance during the retention session was affected by 
scopolamine treatment (Vehicle vs Scopolamine: 273.75 ± 29.16). Metrifonate was 
not able to antagonise the scopolamine -induced deficit. 
60 
CHAPTER 4 
The total time spent in the light during the retention session differed between 
the groups (174,36-: 9.19, p< 0.001, see figure 2 right panel). Fisher's LSD post 
hoc analysis with a Bonferroni correction revealed that the performance during 
the retention session was affected by scopolamine treatment (Vehicle vs 
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Figure 2: Effects of acute metrifonate during scopolamine induced amnesia on the performance 
of rats in the passive avoidance task. Data is depicted as means (N=8) and standard errors of 
the means (SEM) to enter the dark compartment during the first and second habituation session, 
the shock session and the retention session (left panel) and the total time spent in the light 
compartment during the retention session (right Panel). 
4.2: Effects of sub-chronic metrifonate in the passive avoidance task 
Anima/s: One group of male HsdCpb: WU (Harlan Wistar) rats (supplied by 
Harlan- Winkelmann, Borchen) were used. They were approximately 4 months 
old at the beginning of the experiment. Their weights ranged from 380-420 
grams. The rats were housed in groups of two in standard MakrolonTM type III 
cages in which food and water was continuously available, with a 12: 12 hour 
light/ dark cycle, lights on at 07.00 am. 
Drug Administration: Rats (N= 8) were pre-treated once daily with 10,30,60 
or 100 mg/kg Metrifonate in a volume of 5 ml/kg for 10 weeks in order to 
induce steady state cholinesterase inhibition. Controls received the vehicle 
(sodium citrate buffer, pH 5.5) under identical conditions. During training this 
treatment schedule was continued. Animals were 
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applicated per os (p. o. ) 30 minutes prior to the start of the trials in an application 
volume of 5 ml/kg. Scopolamine (1 mg/kg) was administered 30 minutes prior to 
the shock session, interperitoneal (i. p. ) in an application volume of 2 ml/kg. 
Scopolamine was administered in conjunction with metrifonate before the start of 
the experiment. 
Apparatus and Methods: The apparatus described in section 2.1 was used. 
Behavioural testing was as described in section 2.1 
Analysis- The analysis of data was as in the previous section 
Results 
Sub-chronic metrifonate (See figure 5) 
The six groups had similar latencies to enter the dark compartment during the first 
(F5,42 = 1.28, n. s) and second (F5,34 = 1.25, n. s) habituation session. They differed in 
their latencies to enter the dark compartment in the shock (F5,42 = 6.63, p< 0.001) 
and retention (F5142 = 12.53, p< 0.001) sessions. Fisher's LSD post hoc analysis with 
a Bonferroni correction revealed that performance during the retention session was 
impaired by scopolamine treatment (Vehicle vs Scopolamine: 294.5 ± 53.601). This 
effect was partially antagonised by 60mg/kg metrifonate (Scopolamine vs 60 mg/kg 
metrifonate: 150.75 ± 46.42). 
The total time spent in the light (F5134 = 13.81, p< 0.001, see figure 5 right panel) 
during the retention session differed between the groups. Post hoc analysis with a 
Bonferroni correction revealed that, the total time spent in the light was decreased 
by scopolamine treatment (Vehicle vs Scopolamine: 230.0 ± 45.3) and this decrease 
was partially antagonised by 10 mg/kg (144.13 ± 39.43) and 60 mg/kg metrifonate 
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Figure 5: Effects of sub chronic metrifonate on scopolamine induced amnesia in rats in the passive 
avoidance task. Data is depicted as means (N=8) and standard errors of the means (SEM) to enter the 
dark compartment during the first and second habituation session, the shock session and the retention 
session. (left panel) and the total time spent in the light compartment during the retention session 
(right Panei). 
Discussion 
Summary of results 
Scopolamine interferes with learning and memory in humans (Beatty et al., 1986) 
and experimental animals (Stevens, 1981; Sutherland, 1982) by blocking muscarinic 
receptors in the basal forebrain area. The present study compared the effects of 
acute and sub-chronic administration of the cholinesterase inhibitors metrifonate, 
donepezil and rivastigmine against scopolamine induced memory impairments in the 
passive avoidance task. 
Acute metrifonate studies in rats, using the passive avoidance paradigm, revealed 
that this compound alleviated scopolamine-induced deficits (Riekkinen et a/ 1996; 
Itoh, eta/, 1997). 
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Metrifonate also facilitated passive avoidance retention in 23-month-old and 
27-month-old rats (Riekkinen et a/, 1996). Previous studies with metrifonate 
have shown that the beneficial dose of metrifonate for improving cognition is 
between 10-30 mg/kg (Schmidt, 1997). Acute metrifonate was unable to 
alleviate scopolamine-induced deficits in the present study if the latency to 
enter the dark compartment in the retention session was considered. This could 
be due to a lack of sensitivity to metrifonate of the strain of rats used in the 
present study. However, the time spent in the light compartment might be 
considered as an additional index of retention. For example, the animals might 
have entered the dark compartment fast due to increased arousal (the 
apparatus has been associated with the aversive event of a foot shock). Then, 
however, the animal immediately escaped from the dark to stay mostly in the 
light. I. e. there might have been recognition of the dark compartment, followed 
by escape, and avoidance of the compartment. 
In the second experiment the effects of a sub-chronically administered ChEI on 
the passive avoidance task using metrifonate treatment was determined. The 
compound was well tolerated, in that no adverse side effects were observed by 
the animals. Sub-chronic metrifonate (60 mg/kg) ameliorated the scopolamine- 
induced amnesia during the retention session. 
Repeated administration of metrifonate to rats or rabbits resulted in 
accumulation of the drug resulting in plasma steady state levels, decreasing the 
peaks and troughs of inhibition observed after a single dose. Continuous peak 
inhibition was achieved after 15-20 single doses (Kronforst et al, 1997). 
Compared with acute administration adverse events are lower with repeated 
administration without affecting the cognition enhancing potency of the 
compound (Blockland et al, 1995). This present study revealed that metrifonate 
alleviated the scopolamine- induced deficit in animals that had received a once 
daily dose for 12 weeks, whereas an acute single dose of metrifonate was 
ineffective. Therefore it is a pos$ibility that the long lasting inhibition of 
cholinesterase induced by metrifonate may contribute to its ameliorating effects 
on the impairment of learning and memory in the passive avoidance task. 
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The inability of the higher dose of subchronic metrifonate (100 mg/kg) to 
antagonise memory deficits induced by scopolamine may be related to 
excessive cholinergic stimulation in the central nervous system. 
Problems with the P. A. task 
Scopolamine, a muscarinic antagonist has been shown to impair behaviour in a 
variety of tasks (Buresova et al, 1986; Rush, 1988) and scopolamine treated 
animals have been used as a model of ageing and dementia since they show 
some of the cognitive impairments seen in AD (Wesnes et al, 1991). In the 
passive avoidance paradigm scopolamine induced decreases in retention 
latency (latency to re-enter, step through or step down) are considered to 
represent a measure of amnesia. However, although the effects of scopolamine 
on a variety of tasks are robust and reproducible there are differences between 
the scopolamine model and the symptoms of Alzheimer's disease. The 
impairments are induced by post-synaptic blockade rather than by pre-synaptic 
destruction of cholinergic neurons, whereas in the case of AD this is largely a 
pre-synaptic degenerative phenomenon. Also, with scopolamine, receptor 
blockade is widespread throughout all areas of the brain and this contrasts with 
a pattern of more specific areas that appear to be affected in brains of AD 
patients (Decker, 1995; Blokland, 1995). 
In the passive avoidance task the use of electric shocks may not only have 
affects on mnemonic processes but also produce on stress, anxiety 
emotionality, changes in motivation, and in arousal levels etc (van Dijken, 
1992). Previous studies have shown that a particular dose of scopolamine 
interacts with different levels of shock, producing decreases in retest response 
latencies only at the lowest footshock intensities tested (3 and 4 mA) but not at 
higher intensities (4.1- 5 mA; Cruz- Morales et al, 1990). It has also been 
shown that stress attenuates the effects of 
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scopolamine in a passive avoidance task. One theory suggests that scopolamine 
spares the memory for the shock punishment and alters re-entry latencies by 
alternative mechanisms (Calhoun et al, 1968). The possible impact of shock 
motivated tasks on other aspects of behavioural, such as stress should be kept in 
mind. 
There is growing agreement that the validity of the passive avoidance task is low 
and that this test yields a high number of false positive hits. A number of 
compounds that have been listed active in the passive avoidance task and have 
been tested clinically For example; Haloperidol (Devanand et al, 1989), choline 
(Becker and Giacobini, 1988), pyridostigmine (Becker and Giacobini, 1988), 4- 
aminopyridine (Davidson et al, 1988) and nicotine (Newhouse et al, 1988) have 
failed to produce any significant therapeutic effect. 
Conclusions 
Different ChE inhibitors are able to antagonise, at least partially, scopolamine 
induced performance deficits in the retention session of the PA task. This holds true 
after acute and chronic treatment with the ChE inhibitors. Though simple and fast, 
the passive avoidance task is complex and poorly understood. A positive effect in 
this task does not necessarily indicate that a substance is a cognitive enhancer. 
Instead, the conclusion should be that the drug affects behaviour in one way or 
another, possibly by modulation of CNS processes (van der Staay, 1998). A single 
test procedure based on a particular set of stimulus responses cannot be sufficient 
for determining a drug's effect on cognitive processes. Along with the limitations of 
the passive avoidance task, further verification, using more sophisticated tasks such 
as the Morris water escape task (Chapters 4-6) or timing behaviour (Chapter 8) is 
required before final conclusions can be drawn about the potential of drugs to 
improve cognitive performance. 
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Effects of Metrifonate in the Morris Water Maze Escape Task in 
Normal Rats and Mice 
Abstract 
The experiments described in this chapter were designed to assessed the effects of 
subchronic metrifonate, a second generation ChEI currently available. The effects of 
this compound were assessed in neurologically normal rats in the standard Morris 
maze water escape task. Also studied were the effects of acute and sub-chronic 
administration of metrifonate in the wild type C57/BL mouse. 
Metrifonate did not to improve spatial learning at any dose tested, in neurologically 
normal rats. 
C57/BL mice performed well in the Morris water maze while the administration of 
metrifonate did not improve the spatial reference memory performance of these 
neurologically normal mice. Sub-chronic administration of 30 mg/kg metrifonate had 
beneficial effects in mice. They escaped to the platform faster than the vehicle 
treated control group. 
Introduction 
Alzheimer's disease (AD), the most common dementia in the elderly causes severe 
cognitive dysfunction. One of the deficits observed in patients suffering from AD is 
an impairment in visuospatial discrimination (Adams et al, 1997). Spatial deficits are 
not exclusively restricted to humans: aged rats often show an impaired performance 
in spatial learning tasks (Barnes, 1988). One such task used to measure spatial 
discrimination in rodents is the Morris maze water escape task (MWM; see chapter 
1). 
The strength of the MWM is the availability of procedures for evaluating the strategy 
being used by the animal to locate the platform, and for dissociating 
pharmacological impairments of memory processes from non-mnemonic deficits. 
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An animal can use three different strategies to reach the platform during a 
swimming trial (Brandeis, 1989). It can use a learned sequence of movements, 
which brings it to the platform (praxis strategy); it can approach the platform using 
proximal cues (taxis strategy); or it can navigate to the platform using information 
about the platform's location within spatial configuration of distal cues (mapping or 
spatial strategy). An animal may conceivably use both praxis and mapping 
strategies to locate the hidden platform when random starting positions are applied 
(Dalm, 2000). 
Standard performance measures during the acquisition phase of the MWM task 
usually include escape latency (time required to reach the platform and length of 
the swimming path (distance travelled). Lindner (1997) has suggested that path 
length might be the most appropriate index of cognitive performance in the MWM. 
Learning and cognitive performance can be assessed simultaneously and the swim 
speed can be used to assess motoric and motivational deficits within each learning 
trial. After a series of acquisition trial blocks, a probe trial is usually performed in 
which the rat is permitted to swim freely about the pool without any platform 
present. The idea is that if the rat spends more time in the quadrant that previously 
contained the platform or crosses over the old platform position a small region 
around the previous platform position (annulus) more often than in equivalent areas 
in the other three quadrants. In this study a time of 30 seconds was used, as this 
was the time the animal was required to stay on the platform during the acquisition 
trials. These measures quantify the strength and accuracy of the original learning 
(Brandeis et al, 1989). Other advantages of this task are: no extensive pre- training 
is required, and normal animals learn where the platform is located very quickly, so 
testing can be carried out over a short period of time, usually within one week. 
ChE inhibitors have been shown to be effective in ameliorating learning and memory 
in animals with experimentally induced cognitive impairments (e. g. medial septal 
lesions; Riekkinen et al, 1990; basal forebrain lesions; Niigawa et al, 1995; Rogers 
eta/, 1991). However, the validity of these animals as models for AD or for specific 
symptoms of the disease has been questioned (Fibiger, 1991; Dunnett et al, 1991). 
The aim of the present study was to assess the effects of metrifonate used in the 
treatment of AD in normal animals, which are young animals with no 
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pharmacologically or mechanically induced impairments. Secondly, previous studies 
with metrifonate (van der Staay et a/, 1996b) investigated the effects of acute 
administration of metrifonate (12.5mg/kg, p. o. ), administered before each of the 
daily acquisition sessions. The compound facilitated the acquisition of the Morris 
water escape task; metrifonate-treated rats swam a shorter distance to reach the 
escape platform than did the vehicle-treated rats. Here, we extended previous work 
to study the effects of a sub-chronically administered metrifonate in the MWM 
paradigm in the rat. 
Finally, a commonly used species for Alzheimer's transgenic manipulations is the 
C57BL mouse. However few studies have assesses the effects of ChEI's of the wild 
type of this mouse strain on learning and memory. Therefore, we studied the effect 
of acute and sub-chronic metrifonate in neurologically intact C57 BL mice to 
determine as to the innate sensitivity to the cognition-enhancing properties of 
metrifonate. 
5.1: Effects of Sub-Chronic Metrifonate in the Morris Maze Water Escape 
in Normal Harlan Wistar Rats 
Procedure 
Animals: One group of 40 male HsdCpb: WU (Harlan Wistar) rats (supplied by 
Harlan-Winkelmann, Borchen, Germany) were used. They were approximately 10 
weeks old at the beginning of the experiment. Their weights ranged from 220 to 
250 grams. The rats were housed in groups of two in standard MakrolonTm type III 
cages in which food and water was continuously available, with a 12: 12 hour light/ 
dark cycle, lights on at 07.00 am. 
Drug Administration: Rats (N= 8-10) were pre-treated orally once daily with 10,30, 
60 or 100 mg/kg Metrifonate (see experimental protocol 1, Appendix 1), in an 
application volume of 5 ml/kg for 3-5 weeks in order to induce steady state 
cholinesterase inhibition. Controls received the vehicle (Sodium citrate buffer, pH 
5.5) under identical conditions. During training this treatment schedule was 
continued. Vehicle or test compounds were administered 30 minutes prior to the 
start of the training sessions. 
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Apparatus and Methods: Morris water escape performance was assessed in a water 
tank which consisted of a circular grey tub with a slightly sloping wall (Material: 
polyethylene; inner dimensions: diameter at top 153 cm, diameter at bottom 143 
cm, depth 63 cm), filled with 43.5 cm of clear tap water at a temperature of 
approximately 22°C. The escape platform consisted of a grey polyethylene cylinder 
(diameter 10.8 cm), submerged 1.5 cm below the surface of the water. In this 
version of the test the water was not made opaque because the grey escape 
platform was virtually invisible in the grey tank. The water tank was situated in a 
room illuminated by white fluorescent tubes. Abundant extra-maze cues were 
provided by the furniture in the room, including desks, computer equipment, the 
presence of the experimenter, and by a radio on a shelf that was playing softly (See 
Figure 1). All testing was done between 9: 00 and 15: 00. A video camera, mounted 
in the centre above the circular pool, provided a picture of the pool on a TV- 
monitor. 
The movements of the rat were registered automatically by a video-tracking system 
(EthoVision®, Noldus Information Technology, 
Wageningen, The Netherlands) and stored in an MS-DOS compatible 
microcomputer. 
Figure 1: Experimental Room Layout 
The rats were tested in the Morris water escape task with four trials per session on 
five successive days (Morris, 1984) The test compound or vehicle was injected 
intraperiteoneally, 30 minutes before each daily training session. A trial was started 
by placing a rat into the pool, facing the wall of the tank. Each of the four starting 
positions (arbitrarily assigned north, south, east, west) was used in a series of four 
trials; their order was randomised. The escape platform was always in the same 
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fixed position in the west quadrant. A trial was terminated as soon as the rat had 
climbed onto the escape platform or when 90 seconds had elapsed, whichever 
event occurred first (see figure. 2). Each rat was allowed to stay on the platform for 
30 seconds. Then it was taken from the platform and the next trial started 
immediately. Rats that did not find the platform within the 90 seconds were put on 
the platform by the experimenter and were allowed to stay there for 30 seconds. 
After the fourth trial on the fifth session, an additional trial was given as a probe 
trial: the platform was removed, and the time spent in the four quadrants was 
measured for 30 seconds. The area was around the platform is defined as the 
annulus region. On the probe trial, all rats started from the same position, opposite 
to the quadrant where the escape platform had been positioned during acquisition. 
40 Platform position during acquisition 
Figure 2. The Standard Morris Maze. The invisible submerged platform was always in the same 
quadrant. A trial was terminated as soon as the rat had swum and climbed on to the platform, as 
depicted on the illustration. 
Analysis: EthoVision-"' analysed the distance travelled, the distance to point 
(Platform), the time spent in zone and the velocity of the animal. The mean per 
animal, per trial was then calculated 
This data was then analysed per animal per session by the SAS GLM-procedure. The 
following three parameters for acquisition of the water escape task were analysed 
statistically: the escape latency (in s); the distance travelled (in cm); and the 
swimming speed (in cm*s 1). They were assessed with a TREATMENT*SESSION 
analysis of variance (ANOVA) with repeated measures over SESSIONS. Analysis was 
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supplemented by T- test post hoc comparisons. A difference between groups was 
considered significant if the p value was below 0.05. Treatment effects on the time 
spent in the annulus during the probe trial was assessed by ANOVA. Drug effects on 
the time and distance travelled in the quadrant was assessed with a repeated 
measures ANOVA over QUADRANTS. In addition, treatment effects were further 
evaluated by T test post hoc comparisons (p< 0.05). 
Results 
Metrifonate 
The data obtained during the acquisition of the experiment is summarised in fig. 3. 
The performance during the probe trial is depicted in fig. 4 
Acquisition Trials 
Escape latency. All rats started from the same level of performance (First session: 
F4136 = 0.28, n. s, see figure 3, upper left panel). Averaged over all sessions, 
Metrifonate had no influence on the escape latency (GENERAL MEAN: F4135 = 0.55, 
n. s). The escape latencies of the groups decreased in the course of training 
(SESSIONS: F4,140 = 48.43, p<0.01), however this rate of learning was not affected 
by metrifonate treatment (SESSIONS by TREATMENT: F161140 = 0.71, n. s). 
Quadrant Entries, The rats all started from the same level of quadrant entries (First 
Session: F4135 = 0.20, n. s see figure 2, upper right panel). Overall, the treatment of 
metrifonate did not influence the mean number of quadrants entered during 
swimming (GENERAL MEAN: F4135 = 0.62, n. s. ). During training the rats reduced 
their quadrant entries (SESSIONS: F41140= 31.75, p<0.01). The rate of improvement 
across the sessions was similar for all groups (SESSIONS by TREATMENT: F161140 = 
0.37, n. s). 
Distance Travelled The path lengths to escape onto the platform were all similar at 
the start of training (First Session: F4,35 = 0.37, n. s see figure 3, lower left panel). 
Averaged over all sessions, metrifonate did not decrease the mean distance 
travelled during training (GENERAL MEAN: F4,35= 0.44, n. s., ). All groups decreased 
the distance swum across the sessions (SESSIONS: F4,140= 32.36, p<0.01). 
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The distance travelled across the sessions was similar for all treatment groups 
(SESSIONS by TREATMENT: F1,140 = 0.60, n. s), i. e. there was no effect of treatment 
with metrifonate. 
Swimming Speed All rats started from the same level of performance (First Session: 
F4,35 = 1.10, n. s). Averaged over all sessions, Metrifonate had no influence on the 
swimming speed (GENERAL MEAN: F4,35 = 0.38, n. s., see figure 2, Lower right 
panel). The swimming speed of the rats changed in the course of training 
(SESSIONS: F4,140 = 10.63, p<0.01), this was affected by metrifonate treatment 
(SESSIONS by TREATMENT: F16,140 = 1.89, p<0.05). However further analysis by 
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Figure 3: Effect of sub-chronic metrifonate (10,30,60 and 100 mg/kg) on the performance in the 
water escape task by young male Harlan Wistar rats (N= 8 per group). Session means and standard 
errors of the means (SEM) are depicted for latencies (s) to escape onto a platform (upper left panel), 
number of quadrant entries (upper right panel), distance travelled (cm; lower left panel) and 






Time in Quadrant., The time the groups spent in the four quadrants were different 
(QUADRANTS: F3,105 = 158.19, p<0.001; see figure 4, right panel) and this 
difference was affected by metrifonate treatment (QUADRANTS by TREATMENT: F12, 
105 = 1.94, p<0.05; ). However the bias for the quadrant in which the platform had 
been positioned during training was not influenced by metrifonate treatment 
(TARGET QUADRANT: F4,35 = 1.04, n. s). 
Distance Travelled. - The distance travelled in the four quadrants was different 
(QUADRANTS: F3,105 = 156.30, p<0.001; Data not shown). This difference was not 
affected by metrifonate treatment (QUADRANTS by TREATMENT: F12,105 = 1.42, 
n. s), and the bias for the quadrant in which the platform had been positioned during 
training was not influenced by metrifonate treatment (TARGET QUADRANT: F4,35 = 
0.63, n. s). 
Time in Annu/us: Metrifonate treatment did not affect the time spent in the annulus 
region of the maze (F4,35 = 1.53, n. s; see figure 4, left pane, ) 
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Figure 4: Effects of sub-chronic metrifonate (10,30,60 and 100 mg/kg) on the performance in the 
water escape task probe trial by young male Harlan Wistar rats (N= 8). Group means and standard 
errors of the means (SEM) are depicted for Time spent in the Annulus (s) (left panel) and time spent in 
the quadrant (right panel) 
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5.2: Effects of Acute Metrifonate In Normal C57BL 6J Mice 
Animals; Male C57BL/ 61 mice, aged about 10 weeks, weighing approximately 20- 
25 grams, were supplied by Winkelmann (Borchen, Germany). The animals were 
housed in groups of ten in standard MakrolonTm type III cages. They were kept 
under an artificial 12-hour light/12 hour dark regimen (lights on from 7.00 to 19.00) 
in a temperature (ca. 21.5°C) and humidity (50%) controlled animal room. Water 
and food were available ad libitum. Before testing the animals were transferred to 
the experimental room where they were housed for the duration of the testing 
period. Housing conditions were similar to those in the animal room. 
Apparatus: The water tank used was a circular grey tank (polyethylene) with a 
slightly sloping wall (inner dimensions: diameter at top 74cm, diameter at bottom 
66 cm, depth 54 cm. ) The tank was filled with clear tap water at a temperature of 
approximately 22°C. The escape platform was a grey polyethylene cylinder (7.3 cm 
width) submerged 0.6 cm below the surface of the water. 
The tank was situated in a room illuminated by white fluorescent tubes, (the lights 
directly above the maze were turned off to prevent reflection). Blinds were closed to 
prevent the entrance of natural light. Extra maze cues were provided by the 
furniture in the room, including desks, computer equipment, the presence of the 
experimenter and by a radio on a shelf that was playing softly. All testing was done 
between 9.00 and 14.00 
Methods: The same procedure as described in section 2.1 was followed. 
Drug administration: Mice (N= 8 per group) were treated each day of training with 
3,10 or 30mg/kg Metrifonate. Controls, which received the vehicle (Sodium citrate 
buffer, pH 5.5). Drug and vehicle was applicated per os (p. o. ) 30 minutes prior to 
the start of the daily training sessions in an application volume of 20 ml/kg. 
Analysis: The data analysed were as explained in section 2.1. Two animals were 




Acquisition Trials (see figure 5) 
Escape latency. All groups of mice started from the same level of performance 
(First session: F3126 = 0.76, n. s). Averaged over all sessions, Metrifonate had no 
influence on the escape latency (F3,26 = 0.99, n. s). The escape latencies of the 
mice decreased in the course of training (F41104 = 36.07, p<0.01), however the 
rate of learning was not affected by metrifonate treatment (F12,104 = 0.60, n. s). 
Quadrant Entries: The treatment groups started from the same level of 
quadrant entries (First Session: F3126 = 0.92, n. s). The treatment with 
metrifonate did not influence the mean number of quadrants entered during 
swimming (GENERAL MEAN: F3,26 = 2.83, n. s., see figure 6, upper right panel). 
During training the mice reduced their quadrant entries (SESSIONS: F4,104= 
29.61, p<0.01) but the rate of improvement across the sessions, however, was 
similar for all groups (SESSIONS by TREATMENT: F12,104 = 0.63, n. s). 
Distance Travelled The path lengths to escape onto the platform were all 
similar at the start of training (First session: F3126 = 2.04, n. s). Averaged over all 
sessions, all groups of animals travelled a similar distance (GENERAL MEAN: 
F3126 = 1.23, n. s., see figure 6, lower left panel). All mice decreased the 
distance swum during the sessions (SESSIONS: F4,104= 32.35, p<0.01). The 
distance travelled across the sessions was similar for all groups (SESSIONS by 
TREATMENT: F12,104 = 1.87, n. s). 
Swimming Speed`. All mice started from the same level of performance (First 
session: F3126 = 2.5, n. s). Averaged over all sessions, metrifonate had no 
influence on the swimming speed (GENERAL MEAN: F3126 = 0.30, n. s., see 
figure 6, lower right panel). The swimming speed of the mice changed in the 
course of training (SESSIONS: F4,104= 6.92, p<0.01), this was affected by 
metrifonate treatment (SESSIONS by TREATMENT: F12,104 = 2.44, p<0.05). Post 
hoc analysis did not clarify the nature of this interaction, except that post hoc 
comparisons per session revealed during session 3 the swimming speed was 
reduced by 3,10 and 30 mg/kg metrifonate compared to the speed of the 











































Figure 6: Effect of acute metrifonate (3,10 and 30 mg/kg) on the performance in the water 
escape task by young male C57/BL mice (N= 8 per group). Session means and standard errors of 
the means (SEM) are depicted for latencies (s) to escape onto a platform (upper left panel), 
number of quadrant entries (upper right pane, distance travelled (cm; lower left pane/) and 
swimming speed (cm/s; lower right panel). 
Probe Trial (See figure 7). 
Time in Quadrant. - The time the groups spent in the four quadrants was 
different (QUADRANTS: F3,75 = 8.18, p<0.001; see figure 7, right paneO. This 
difference was not affected by metrifonate treatment (QUADRANTS by 
TREATMENT: F9,75 =1.39, n. s. ), and the bias for the quadrant in which the 
platform had been positioned during training was not influenced by metrifonate 
treatment (TARGET QUADRANT: F3,26 = 0.94, n. s). 
-0- 3 mg/kg Metrifonate 
-0- 10 mg/kg Metrifonate 




















Distance Travelled. - The distance travelled in the four quadrants was different 
(QUADRANTS: F3,75 = 8.24, p<0.001; data not shown) and this difference was 
affected by metrifonate treatment (QUADRANTS by TREATMENT: F9775 =2.63, 
p<0.05). However the bias for the quadrant in which the platform had been 
positioned during training was not influenced by metrifonate treatment (TARGET 
QUADRANT: F3,26 = 1.24, n. s). 
Time in Annu/us: Metrifonate treatment did not affect the time spent in the annulus 
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Figure 6: Effects of acute metrifonate (3,10 and 30 mg/kg) on the performance in the water escape 
task probe trial by young male C57/BL Mice (N= 8 per group). Session means and standard errors of 
the means (SEM) are depicted for Time spent in the annulus (s) (left panel) and time spent in the 
quadrants (right panel). 
5.3: Sub chronic Metrifonate in Normal C57BL 63 Mice in the Morris Maze 
Anima/s: 40 Male C57/BL/6J mice, aged about 10 weeks, weighing approximately 
18-25 grams, were supplied by Winkelmann (Borchen, Germany). The animals were 
housed in groups of ten in standard Makrolon'm type III cages. They were kept 
under an artificial 12 
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hour light/12 hour dark regimen (lights on from 7.00 to 19.00) in a temperature 
(ca. 21.5°C) and humidity (50%) controlled animal room. Water and food were 
available ad libitum. Before testing the animals were transferred to the experimental 
room where the were housed for the duration of the testing period. Housing 
conditions were similar to those in the animal room. 
Drug Administration: Mice (N= 10 per group) were pre-treated orally once daily with 
10,30,60 mg/kg Metrifonate in an application volume of 20 ml/kg for 3 weeks in 
order to induce steady state cholinesterase inhibition. Controls received the vehicle 
(sodium citrate buffer, pH 5.5) under identical conditions. During training this 
treatment schedule was continued. Drug or vehicle was administered 30 minutes 
prior to the start of the training sessions. 
Apparatus and Methods: The same procedure as described in section 5.2 was 
followed 
Analysis: The same analysis as explained in section 5.1 was performed. 
RESULTS 
Acquisition Trials 
Escape latency. All mice started from the same level of performance (First session: 
F3136 = 0.33, n. s). Averaged over all sessions, Metrifonate affected the escape 
latency (GENERAL MEAN: F3,36 = 6.91, p<0.01, see figure 7 upper left pane/). The 
escape latencies of the mice decreased in the course of training (SESSIONS: F4,144 = 
28.93, p<0.01). However this rate of learning was not affected by metrifonate 
treatment (F121144 = 1.09, n. s). Post hoc analysis by Duncans Multiple range test on 
the general mean revealed that 30 mg/kg metrifonate, on average had a shorter 
escape latency than the vehicle control group and 60 mg/kg metrifonate on average 
had a longer escape latency compared to the vehicle treated controls. 
Quadrant Entries- On day one of training there was no difference in the number of 
quadrant entries (First Session: F3,36 = 0.32, n. s). Metrifonate treatment did 
influence the mean number of quadrants entered (GENERAL MEAN: F3,36 = 4.41, 
p<0.01., see figure 7, upper right panel). During training the mice reduced their 
quadrant entries (SESSIONS: F4,144= 45.52, p<0.01). The rate of reduction of the 
number of quadrant entries across the sessions was not different between groups 
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(SESSIONS by TREATMENT: F12,144 = 1.04, n. s). Post hoc analysis by Duncans 
Multiple range test on the general mean revealed that the 10 and 30 mg/kg dose 
had a lower number of quadrant entries than the vehicle control group. 
Distance Travelled The path lengths to escape onto the platform showed no 
difference at the start of training (First session: F3,36 = 0.03, n. s). Averaged over all 
sessions, the groups had a different distance travelled during training (GENERAL 
MEAN: F3,36 = 4.13, p<0.01., see figure 7, lower left panel). Post hoc analysis 
revealed that compared to vehicle, 10 and 30 mg/kg treated groups had a 
decreased path length. All groups of mice decreased the distance swum across the 
sessions (SESSIONS: F4,144= 44.98, p<0.01). The decrease in distance travelled 
across the sessions was different for groups (SESSIONS by TREATMENT: F12,144 _ 
6.80, <0.01). With the groups treated with 10 and 30 mg/kg having steeper 
learning curves. 
Swimming Speed`. On day one of training there was no difference in the swimming 
speed (F3,36 = 1.28, n. s). Averaged over all sessions, Metrifonate showed no 
influence on the swimming speed (GENERAL MEAN: F3,36 = 1.77, n. s., see figure 7, 
lower right panel). The swimming speed of the mice changed in the course of 
training (SESSIONS: F4,144 = 2.63, p<0.05), this was not affected by metrifonate 
treatment (SESSIONS by TREATMENT: F12,144 = 1.17, n. s). 
Probe Trial. 
Time in Quadrants. The time the groups spent in the four quadrants were different 
(QUADRANTS: F3,105 = 15.66, p<0.001; see figure 8, right panel. However, this 
difference was not affected by metrifonate treatment (QUADRANTS by 
TREATMENT: F91105 =0.47, n. s. ). The bias for the quadrant in which the platform 
had been positioned during training was not influenced by metrifonate treatment 
(TARGET QUADRANT: F3,36 = 0.37, n. s). 
Distance Travelled: The distance travelled in the four quadrants was different 
(QUADRANTS: F3,105 = 3.95, p<0.01; data not shown) and this difference was not 
affected by metrifonate treatment (QUADRANTS by TREATMENT: F9,105 =1.35, n. s. ). 
The bias for the quadrant in which the platform had been positioned during training 
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Figure 7: Effect of Sub-chronic metrifonate (10,30 and 60 mg/kg) on the performance in the water 
escape task in young male C57BL Mice (N= 10 per group). Session means and standard errors of the 
means (SEM) are depicted for latencies (s) to escape onto a platform (upper left pane/, number of 
quadrant entries (upper right pane, distance travelled (cm; lower left panel) and swimming speed 
(cm*s 1; lower right panel) 
Time in Annulus: Metrifonate treatment did not affect the time spent in the annulus 
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Figure 8: Effects of sub-chronic metrifonate (10,30 and 60 mg/kg) on the performance in the water 
escape task probe trial young male C57BL Mice (N= 10 per group). Session means and standard errors 
of the means (SEM) are depicted for time spent in the Annulus (s) (left panei) and time spent in the 
quadrant (right panel) 
Discussion 
Effects of metrifonate inhibitors in the rat 
In this study metrifonate, at all doses tested, failed to induce significant 
improvement in spatial reference memory in neurologically normal rats (section 5.1) 
The lack of improvement in learning in the Morris water maze escape task by 
metrifonate could be explained by the fact that intact young rats do not suffer from 
memory impairments or cholinergic hypofunction. Multiple doses of metrifonate 
increase and prolong the effect on ACh levels in the brain (Hallak and Giacobini, 
1989) and this increased ACh concentration in the synaptic cleft will induce agonistic 
effects postsynaptically. However, presynaptic action may also occur, blocking the 
mechanism for choline uptake and thus slowing down the rate of synthesis and 
release of ACh. In the intact rat with no existing cholinergic deficit chronic doses 
may mask the beneficial effects of cholinesterase inhibition by presynaptical 
blockade (Nordgren, 1992). 
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However previous studies have shown that cognitive improvement in various animal 
models (Blokland et al, 1995; van der Staay et al, 1996a, b; Kronforst et al 1995) 
was not diminished after subchronic administration. One possible explanation for 
the lack of effect of metrifonate on behaviour in the Morris water escape task is the 
high performance level of the young rats in this study may have imposed a ceiling 
effect (i. e. the rats performed at a that masked) any performance improving effect 
of metrifonate. 
Possible biological variability or differences in sensitivity of the rats to the treatment 
with the compound may also have obscured the efficacy of the continuous 
metrifonate regimen compared to previously reported results (van der Staay et al, 
1996a, b). Although the two groups of rats were tested under highly standardised 
conditions, there were extremely different performances in the probe trials. The 
Wistar strain used was an outbred strain in which the genome is not fixed, as is in 
the case of inbred strains and their F1 crosses. The changes in performance 
between the two experiments could be due to genetic drift between the two 
different shipments of animals (van der Staay, 2000). 
Metrifonate in the mouse 
The behaviour of mice in tasks of learning and memory is less documented than in 
rats. In view of the development of transgenic mouse models with predefined 
deficiencies as new tools to identify putative cognition enhancers, it is important to 
conduct preliminary tests on parental strains that are used to produce these 
transgenic animals, in order to calibrate the behavioural paradigm before beginning 
testing of the transgenic or knockout mice. As the acute and of sub- chronic 
experiment using rats as subjects, this study looked at the effects of acute and sub- 
chronic metrifonate on performance in the Morris water escape task using the wild 
type C57BL 6J mouse strain. This mouse strain has previously been shown to readily 
learn the platform escape response in the Morris water tank (Paylor et al, 1990; 
Finkelstein et al 1994) 
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The cognitive testing performed in this present study confirmed that the wild type of 
C57BL mice performs well in the Morris water maze. The administration of 
metrifonate, however, induced no improvements in spatial reference memory in 
these neurologically normal mice. This confirms previously reported results (Ikonen 
et al, 1999) of a lack of effect of metrifonate treatment in intact mice. 
With a pre-treatment regimen of three weeks before the testing began metrifonate 
showed beneficial effects at the dose of 30 mg/kg with the mice escaped to the 
platform faster than the control group. However an impairment was observed in 
learning performance with the higher dose of metrifonate (60 mg/kg) this was most 
probably due to first cholinergic side effects, which, however, were not overt during 
the behavioural testing. 
As discussed in chapter 4 repeated administration of metrifonate to rats or rabbits 
accumulates this long lasting cholinesterase inhibitor resulting in a stable level, 
thereby decreasing the fluctuations between peak and trough ChE inhibition seen 
after each single dose. Therefore it is a possibility that the long lasting inhibition of 
cholinesterase induced by metrifonate may contribute to the improvement in the 
mouse Morris water escape task compared to that of the acute study in the mouse. 
Normal Animal Model 
The use of normal animals makes the assumption in that the subjects perform 
suboptimally and that there is room for improvement. Moreover, it makes the 
implicit assumption that if a compound that is active in normal subjects then it 
would also be useful for the treatment of patients (Gamzu, 1985). A problem of 
assessing cognitive enhancing potential in normal animals is that improved 
performance in normal animals may not necessarily predict efficacy of the drug in 
AD patients. Moreover, no effects are observed in normal animals, the compound 
might still ameliorate cognitive impairments in patients (Decker, 1995). 
The most important point is that compounds that improve cognitive function in 
normal animals may be classed as cognitive enhancers. However, because there is 
no clinical symptom of AD in these animals, the potential of a compound as disease 




Based on literature results, there is a strong correlation between the cholinergic 
system and cognitive performance. Cognitive impairment as seen in AD is related to 
cholinergic hypofunction (Bartus et al, 1982; Bierer et al, 1995). To further assess 
the effects of cholinesterase inhibitors designed for the treatment of AD it is 
necessary to use animals with naturally occuring or experimentally induced 
cholinergic hypofunction. For example, the use of pharmacological agents such as 
scopolamine or lesions of cholinergic structures that could induce cognitive 
impairments in the rodent is indicated. The effects of the cholinesterase inhibitors 






Acute Metrifonate in the Morris Maze with Scopolamine 
Induced Amnesia. 
Abstract 
We investigated the effects of acute pre-training treatment of the cholinesterase 
inhibitors metrifonate on water maze spatial navigation in mice with 
scopolamine-induced amnesia. 
Scopolamine (1 mg/kg) impaired acquisition of the Morris water escape task: it 
induced an increase in escape latency. Retention was also impaired: as the 
scopolamine treated mice spent less time in the annulus region of the maze. 
Metrifonate (10 and 30 mg/kg) had no ameliorating effects on the scopolamine- 
induced amnesia. 
Introduction 
The Morris Maze task (Morris, 1984) is one of the most frequently used 
experimental paradigms designed to assess cognitive performance. Most studies 
have used rats as subjects, whereas mice have been less frequently used 
(Paylor, et al 1993; Sweeney, et al, 1988 and van der Staay, 2000). Mice have 
been shown to produce a normal learning curve (van der Staay et al, 2000; 
Klapdor, & van der Staay, 1996). 
The behaviour of mice in tasks of learning and memory is less characterised 
than in rats and in view of the development of transgenic mouse models with 
predefined deficiencies as new tools to identify putative cognition enhancers, it 
is important to conduct preliminary tests on wild type strains that are used to 
produce these transgenic animals, to calibrate the behavioural paradigm before 
beginning testing of the transgenic or or knockout mice. 
Scopolamine, a muscarinic antagonist that has been shown to impair behaviour 
in a variety of tasks (Buresova et al, 1986; Rush, 1988) and has been used as a 
model of ageing and dementia producing some of the cognitive impairments 
seen in AD 
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(Wesnes et al, 1991). Once having confirmed that scopolamine treatment causes 
deficits in the Morris maze task, future study would involve testing cognitive 
enhancers in this model to try to ameliorate this scopolamine induced deficit. 
The aim of this study is determine the effects of metrifonate on scopolamine- 
induced amnesia in the mouse 
Procedure 
Animals; male C57BI/6J mice, aged about 10 weeks, weighing approximately 20-25 
grams, were supplied by Winkelmann (Borchen, Germany). The animals were 
housed in groups of eight in standard MakrolonTh type III cages. They were kept 
under and artificial 12-hour light/12 hour dark regimen (lights on from 7.00 to 
19.00) in a temperature (ca. 21.5°C) and humidity (50%) controlled animal room. 
Water and food were available ad libitum. Before testing the animals were 
transferred to the experimental room where they were housed for the duration of 
the testing period. Housing conditions were similar to those in the animal room. 
Apparatus and Methods: The water tank used was a circular grey tank 
(polyethylene) with a slightly sloping wall (inner dimensions: diameter at top 74cm, 
diameter at bottom 66 cm, depth 54 cm. ) The tank was filled with clear tap water at 
a temperature of approximately 22°C. The escape platform was a grey polyethylene 
cylinder (7.3 cm width) submerged 0.6cm below the surface of the water. 
The tank was situated in a room illuminated by white fluorescent tubes. The lights 
directly above the maze were turned off to prevent reflection. Blinds were closed to 
prevent the entrance of natural light. Extra maze cues were provided by the 
furniture in the room, including desks, computer equipment, the presence of the 
experimenter and by a radio on a shelf that was playing softly. All testing was done 
between 9.00 and 14.00 
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The video camera, mounted in the centre above the circular pool, provided a picture 
of the pool on a TV monitor. The movements of the mice were registered using the 
automatic video tracking system EthoVision-r". 
The animals received four trials daily, on five successive days (Morris, 1984). A trial 
was started by placing a mouse into the pool, facing the wall of the tank. Each of 
the four starting positions (arbitrarily assigned north, south, east, west) was used in 
a series of four trials; their order was randomised. The escape platform was always 
in the same fixed position in the west quadrant. A trial was terminated as soon as 
the mouse had climbed onto the escape platform or when 90 seconds had elapsed, 
whichever event occurred first. Each mouse was allowed to stay on the platform for 
30 seconds. Then it was taken from the platform and the next trial started 
immediately. Mice that did not find the platform within the 90 seconds were put on 
the platform by the experimenter and were allowed to stay there for 30 seconds. 
After the fourth trial on the fifth session, an additional trial was given as a probe 
trial: the platform was removed, and the time spent in the four quadrants was 
measured for 30 seconds. The area around the platform was defined as the annulus 
region. On the probe trial, all mice started from the same position, opposite to the 
quadrant where the escape platform had been positioned during acquisition. 
Drug Administration: Metrifonate was solved in Sodium citrate buffer, pH 5.5 and 
applicated daily per os (p. o) 30 minutes prior to the start of the trials in an 
application volume of 20ml/kg. Scopolamine was solved in 0.9% NaCl solution and 
was applicated interperitoneally (i. p. ) in an application volume of 10 ml/kg. 
Scopolamine was administered in conjunction Metrifonate, 30 mins prior to training. 
For the doses and number of animals per group/ per compound see table 1. 
Table 1: Number of animals per group and treatment combinations (doses in mg/kg) in three 
experiments designed to study the effects of the ChEI's metrifonate, rivastigmine and donepezil on 




N=10 N=10 N=8 N=10 
Metrifonate 0 (Vehicle) 0 (Vehicle) 10 30 
Scopolamine 0 (Vehicle) 111 
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Analysis: EthoVisionT'' analysed the distance travelled, the distance to point 
(platform), the time spent in zone and the velocity of the animal. The mean per 
mouse, per trial was then calculated. This data was then analysed per mouse per 
session by the SAS GLM-procedure. The following four parameters for acquisition of 
the water escape task were analysed 
Statistically: the escape latency (in s); number of quadrant entries; the distance 
travelled (in cm); and the swimming speed (in cm/s). They were assessed with a 
TREATMENT*SESSIONS analysis of variance (ANOVA) with repeated measures over 
SESSIONS. Analysis was supplemented by T test post hoc comparisons. A difference 
between groups was considered significant if the p value was below 0.05. Group 
differences in the time spent in the annulus during the probe trial was assessed by 
ANOVA. Drug effects on the time and distance travelled in the quadrant was 
assessed with a repeated measures ANOVA over QUADRANTS. Group differences 
were further evaluated by T test post hoc comparisons (p< 0.05). The scopolamine 




Escape latency. All mice started from the same level of performance (First SESSION: 
F1114 = 1.83, n. s). Averaged over all sessions, scopolamine had an influence on the 
escape latency (GENERAL MEAN: F1,14 = 87.56 p<0.01 see figure 1, Upper left 
panel). The escape latencies of the mice decreased in the course of training 
(SESSIONS: F4,72= 36.07, p<0.01), and this rate of learning was affected by 
scopolamine treatment (F4,72 = 2.81, p<0.05). 
Quadrant Entries: The mice alI started from the same level of quadrant entries (First 
Session: F1114 = 0.45, n. s). Scopolamine influenced the mean number of quadrants 
entered during swimming, averaged over al sessions (GENERAL MEAN: F1114 = 
44.28, p<0.01, see figure 1, Upper right panel). During training the mice reduced 
their quadrant entries (SESSIONS: F4,72 = 12.97, p<0.01) and though the rate of 
improvement during the sessions appeared to be similar for both groups (SESSIONS 
by TREATMENT: F4172 = 1.75, n. s). 
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Distance Travelled The path lengths to escape onto the platform were all similar at 
the start of training (F1114= 0.64, n. s). Averaged over all sessions, scopolamine 
treated swam a longer distance (GENERAL MEAN: F1,14 = 48.67, p<0.01; see figure 
1, Lower left panei). All mice reduced the distance swum over the sessions 
(SESSIONS: F4,72 = 6.00, p<0.01). The reduction in the distance travelled during the 
sessions appeared to be similar for both groups (SESSIONS by TREATMENT: F4172 = 






















































Figure 1: Effect of acute scopolamine (1 mg/kg) on the performance in the water escape task by in 
treated young male C57/BL Mice (N= 8). Session means and standard errors of the means (SEM) are 
depicted for latencies (s) to escape onto a platform (upper left pane/), number of quadrant entries 
(upper right panel), distance travelled (cm; lower left panel) and swimming speed (cm*-'; lower right 
pane/ 
Swimming Speed Averaged over all sessions, scopolamine had no influence on the 
swimming speed (GENERAL MEAN: F1114 = 0.32, n. s., see figure 1, Lower tight 
panel). The swimming speed of the mice changed in the course of training 
(SESSIONS: F4,72= 8.52, p<0.01), this was affected by scopolamine treatment 









revealed that during session 2 the swimming speed was increased by scopolamine 
compared to the speed of the vehicle treated mice. 
Probe Trial. 
Time in Quadrant. - There was a slight difference in the time the groups spent in the 
four quadrants (QUADRANTS: F3,54 = 2.37, p<0.06; data not shown). The bias for 
the quadrant in which the platform had been positioned during training was 
influenced by scopolamine treatment (TARGET QUADRANT: F1,18= 4.22, p<0.05); 
i. e. the scopolamine treated mice spent less time in the target quadrant than vehicle 
treated mice. 
Distance Travelled. - The distance travelled in the four quadrants was different 
(QUADRANTS: F3,54 = 4.41, p<0.05) and tended to be affected by the scopolamine 
treatment (QUADRANTS by TREATMENT: F3,54 = 2.40, p<0.07). The bias for the 
quadrant in which the platform had been positioned during training was not 
influenced by scopolamine treatment (TARGET QUADRANT: F1,18= 2.63, n. s). The 
scopolamine treated mice tended to travel a longer distance in the target quadrant 
than vehicle treated mice. 
Time in Annu/us: Scopolamine treatment did affect the time spent in the annulus 
region of the maze (F1,18= 9.09, p<0.01; see figure 2), Scopolamine treated mice 


















Figure 2: Effects of acute Scopolamine (1 
mg/kg) on the performance in the water 
escape task probe trial with young male 






Effects of metrifonate in scopolamine induced amnesia in the mouse 
Acquisition Trials 
Escape latency. Mice started from a slightly different level of performance (F3,34 = 
2.95, p<0.05, See figure 3 upper left panel). Averaged over all sessions, treatment 
with metrifonate and or scopolamine had an influence on the escape latency 
(GENERAL MEAN: F3,34 = 60.52, p<0.01). Post hoc analysis revealed that the 
scopolamine treated group and the metrifonate/scopolamine treated groups had a 
longer escape latency compared to that of the vehicle treated group. The 
metrifonate treated groups also had a longer escape latency compared to the 
scopolamine treated group. The escape latencies of the mice decreased in the 
course of training (SESSIONS: F4,136 = 18.01, p<0.01), and this rate of learning was 
affected by metrifonate and or scopolamine treatment (SESSIONS by TREATMENT: 
F12,136 = 3.56, p<0.01). 
Quadrant Entries- The mice all started from the same level of quadrant entries (F3,34 
= 2.42, n. s). Over all sessions the treatment of metrifonate and/ or scopolamine 
influenced the mean number of quadrants entered during swimming (GENERAL 
MEAN: F3,34 = 31.58, p< 0.001; see figure 3, Upper rightpanei). During training the 
mice reduced their quadrant entries (SESSIONS: F4,136= 17.91, p<0.01). The rate of 
improvement during the sessions was similar for all groups (SESSIONS by 
TREATMENT: F12,136 = 1.35, n. s. ). 
Distance Travelled` The path lengths to escape onto the platform were all different 
at the start of training (F3136 = 8.32, p<0.01). Averaged over all sessions, animals 
exposed to metrifonate and or scopolamine had a longer mean distance travelled 
during training (GENERAL MEAN: F3134 = 32.08, p<0.01., see figure 3, Lower left 
panel). All mice reduced the distance swum over the sessions (SESSIONS: F4,136= 
8.52, p<0.01) however, the rate of reduction over the sessions was similar for all 
groups (SESSIONS by TREATMENT: F121136 = 1.27, n. s). 
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Swimming Speed The swimming speed of the mice differed at the start of training 
(F3,34 = 5.49, p<0.01). Averaged over all sessions, Metrifonate and or scopolamine 
treatment had an influence on the swimming speed (GENERAL MEAN: F3,34 = 3.72, 
p<0.05., see figure 3, Lower right panel). The swimming speed of the mice changed 
in the course of training (SESSIONS: F4,136= 9.34, p<0.01), this was not affected by 
metrifonate or scopolamine treatment (SESSIONS by TREATMENT: F121136= 1.74, 
n. s. ). However further post hoc analysis revealed that 30 mg/kg metrifonate treated 
group slightly increased the swimming speed compared to vehicle and scopolamine 
treated groups over sessions. 
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Scopolamine 1 mg/kg 
Metrifonate 10 mg/kg + Scopolamine 1 mg/kg 
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Figure 3: Effect of acute metrifonate (10 [N = 8] and 30 mg/kg [N = 10]) on the performance in the 
water escape task in scopolamine (1 mg/kg [N= 10]) treated young male C57/BL Mice. Session means 
and standard errors of the means (SEM) are depicted for latencies (s) to escape onto a platform 
(upper left pane, number of quadrant entries (upper right panel), distance travelled (cm; lower left 









Time in Quadrant. - The time spent in the four quadrants was not different 
(QUADRANTS: F3,102 = 1.12, n. s.; see figure 4, Right pane, ), However, the bias for 
the quadrant in which the platform had been positioned during training was 
influenced by drug treatment (TARGET QUADRANT: F3,34 = 3.88, p<0.05). Post hoc 
analysis revealed that the 10 and 30 mg/kg treated groups spent less time in the 
training quadrant than the vehicle treated group. 
Distance Travelled. The distance travelled in the four quadrants was different 
(QUADRANTS: F3,102 = 7.69, p<0.001; data not shown) and this difference tended 
to be affected by drug treatment (QUADRANTS by TREATMENT: F91102 =1.92, 
p<0.07). The bias for the quadrant in which the platform had been positioned 
during training tended to be influenced by drug treatment (TARGET QUADRANT: 
F3,34 = 2.72, p<0.06). Post hoc analysis revealed that the 10 and 30 mg/kg treated 
groups swam a shorter distance in the target quadrant than did the vehicle treated 
group. 
Time in Annu/us: The time spent in the annulus region of the maze was affected by 
drug treatment (F3,34 = 12.73, p<0.001; see figure 4, left panel). Post hoc analysis 
revealed that the 10 and 30 mg/kg metrifonate treated groups and the scopolamine 
treated group spent less time in the annulus region than the vehicle treated group. 
NB! It is noted that there is only slight or no differences of the time spent in the 
quadrants or the distance travelled in the vehicle treated group, indicating that the 
mice did not fully learn the task. However, taken together with the time spent in the 
annulus region of the maze, and the bias for the target quadrant do suggest that 






































Figure 4: Effects of acute metrifonate (10 and 30 mg/kg) on the performance in the water escape task 
probe trial by scopolamine (1 mg/kg) treated young male C57/BL Mice. Session means and standard 
errors of the means (SEM) are depicted for Time spent in the Annulus (s) (left panel) and time spent in 
the quadrant (right panel) 
Discussion 
Summary of results 
Scopolamine interferes with memory and cognitive function in humans (Beatty et al, 
1986) and animals (Stevens, 1981; Sutherland et al., 1982) by blocking muscarinic 
receptors. The present study compared the effects of the cholinesterase inhibitor 
metrifonate, on scopolamine-induced memory impairments in the Morris water 
maze. 
Scopolamine (1 mg/kg) impaired performance in the Morris water escape task by 
having an increase in escape latency during acquisition of the task. Retention was 
also impaired as seen by less time spent in the annulus region of the maze. 
Metrifonate (10 and 30 mg/kg) had no ameliorating effects on the scopolamine- 
induced amnesia. The inability of metrifonate to alleviate memory deficits induced 
by scopolamine may be related to excessive stimulation of the cholinergic system. 
Swimming behaviour 
The Morris water escape task has been designed to measure spatial learning and 
memory (Morris, 1984). Exploration is the first step in the spatial navigation of the 
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environment and in normal healthy rodents the occurrence of exploration decreases 
with the time spent in novel surroundings. 
The vehicle treated mice swam away from the wall, searched the inner areas of the 
pool, and found the hidden platform on nearly every trial. They also often swam 
directly from the start point to the hidden platform particularly during later sessions. 
The scopolamine treated mice on the other hand, displayed thigmotaxic swimming. 
They swam predominantly near the maze wall and failed to find the hidden platform 
during the trials (See figure 5). This thigmotaxic swimming pattern is a common 
behaviour in rats given NMDA or muscarinic antagonists (Paylor et al, 1990; 
Whishaw et al, 1987). The scopolamine + metrifonate treated rats showed similar 
thigmotaxic swimming. However, no metrifonate effect could be observed due to 
the excess cholinergic stimulation with the combination drug administration. In 
chapter 5, metrifonate alone caused no obvious changes in swimming behaviour 







Figure 5: An example of the swimming behaviour in scopolamine treated mice (upper panel and 
vehicle treated mice (lower panel) during four successive days of training in the standard Morris water 
escape task 
Other disturbances have previously been observed by Cain and Saucier (1996) in 
rats and in this study in mice, including deflecting off the hidden platform when it 
was contacted, followed by swimming away (deflections) and failure to climb onto 
the platform when they swam close to it (Passes). The animals also failed to remain 
on the platform when placed there. Instead they jump off and continue to swim 
thigmotaxically. 
These sensory motor disturbances are thought to be the reason for poor acquisition 
scores because if an animal spent most of its time swimming thigmotaxically, and 
97 
CHAPTER 6 
deflected of the platform and failed to remain on it when placed there, it would be 
unlikely to learn much about its spatial location. Visual ability is an important factor 
in the water maze task and NMDA and muscarinic antagonists have been reported 
to disrupt visual discrimination performance in other tasks (e. g. non spatial operant 
discrimination task; Clissold et al, 1991; cue discrimination; Rick et al, 1981). 
However, Morris (1986 and 1989) and Cain (1996) showed that NMDA and 
muscarinic antagonists did not interfere with simple discriminations or the learning 
phase of a visible discrimination task but did interfere with the performance. 
Therefore it can be said that muscarinic antagonists reduce the amount of 
information about platform location that animals acquire while in the maze. 
However, this does not indicate that sensorimotor disturbances cause low maze 
acquisition, rather that the antagonists cause sensorimotor disturbances and maze 
deficits by unrelated but parallel effects on sensorimotor and learning mechanisms. 
Pre-training the animals is one way to separate sensorimotor deficits and learning to 
search for, use and remain on the hidden platform (Morris, 1989; Whishaw et al, 
1987). In pre-trained animals, sensorimotor deficits were absent allowing the 
animals to behave effectively in the maze task. However, pre-training does not 
eliminate increased platform search time in drugged animals (Whishaw, 1989). 
Therefore, spatial deficits induced by a muscarinic antagonist are still present and 
still an effective method if one tries to demonstrate that cholinesterase inhibitors are 
able to ameliorate experimentally induced cognitive deficits. Finally, the vehicle 
treated mice did not perform well in the probe trial, showing only slightly better 
performance to that of the scopolamine treated animals. Future studies with mice 
need to ensure good behaviour from vehicle treated/normal use animals so that any 
drug effects can be studied more effectively. 
Conclusions and further study 
The use of a cholinesterase inhibitor scopolamine-induced impairment is merely a 
measure of in vivo muscarinic agonism and although scopolamine models are 
capable of indicating something about the interaction of a compound with the 
cholinergic system, the nature of the interaction and the ability of the compound to 
overcome the type of cholinergic hypofunction in AD are unclear. Another problem 
with cholinergic antagonist models that produce deficits through pharmacological 
manipulations is the possibility of pharmacokinetic interactions, and though in this 
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study with scopolamine and the cholinesterase inhibitors used it is a remote 
possibility that such interactions occur, other alternatives need to be studied. 
One such alternative is excitotoxic lesions, which can be aimed at more specific 
areas of the brain involved in learning and memory rather than the general effect of 
scopolamine, which inhibits muscarinic receptors throughout the entire brain. 
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Spatial Discrimination Deficits by Excitotoxic Lesions in the 
Morris Water Escape Task 
Abstract 
The effects of the cholinesterase inhibitor (ChEI) metrifonate was assessed on 
spatial performance of rats with bilateral lesions of the entorhinal cortex (EC). EC- 
lesioned rats model early changes in the brains of patients suffering from 
Alzheimer's disease. In the present study, we found that spatial discrimination 
deficits in rats, induced by bilateral ibotenic acid (IBO) lesions of the EC region can 
partially be antagonised by treatment with metrifonate (30 mg/kg). Performance 
was improved in the spatial discrimination task compared with that of the EC 
lesioned control group. It is concluded that the rat with bilateral EC lesions is a 
suitable deficit model for the assessment of effects of putative Alzheimer 
therapeutics. 
Introduction 
The hippocampus proper, the entorhinal cortex and the subiculum are intimately 
connected and are described as the major components of the hippocampal 
formation (Amaral et a/, 1989). The hippocampal formation is that it is involved in 
learning and memory processes (O'Keefe et a/, 1978; Rudy et a/, 1989). The 
entorhinal cortex receives information from the neocortex and sends major 
projections to the hippocampus by way of the trisynaptical or perforant pathway 
(Witter et a/, 1989). Cognitive dysfunctions observed after EC damage are mainly 
considered to be due to hippocampal deafferentiation. Post-mortem studies in the 
brains of Alzheimer's patients at a very early stage of the disease reveal that 
damage to the EC occurs and this early EC damage correlates with the memory 
deficits present during the early 'sage of Alzheimer's disease (Braak and Braak, 
1991; Hyman eta/, 1986; Miwa & Ueki, 1996). 
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An initial theory by O'Keefe and Naldel (1978) is that the hippocampal formation is 
involved in spatial memory. In rats, bilateral damage to the EC resulted in spatial 
learning impairments, similar to impairments due to disturbed hippocampal 
functioning (Rasmussen et al, 1989; Fugger et al, 1997; Eijkenboom et at, 2000). 
Electrophysiological data has demonstrated a direct influence of the EC in spatial 
learning and memory, as some cells within the EC fire when monkeys (Rolls et a/, 
1989) or rats (Barnes et al, 1990) are positioned in a specific area. 
Spatial learning deficits induced by entorhinal cortex lesions could be reversed by a 
positive modulator of the AMPA receptor, aniracetam (Zajaczkowski and Danysz, 
1997), by NMDA receptor antagonists, (+)-MK-801 and memantine (Zajaczkowski et 
a/, 1996), and by ganglioside (Ramirez eta!, 1991; Ramirez et al, 1998), suggesting 
a sensitivity of this deficit model for pharmacological interventions with putative and 
established Alzheimer therapeutics. 
A reduction in acetylcholinesterase positive fibres in the CA3 and stratum moleculare 
of the hippocampal formation has been found in the rat hippocampus after 
entorhinal cortex lesions (Miwa and Ueki, 1996). In the dentate gyrus, there was a 
45 percent decrease in acetylcholine after the EC lesion and a 41 percent decrease 
was found in the CA3. These results suggest that the EC lesion induced cognitive 
deficits are due to indirect damage to the hippocampal formation (Hunt et al, 1994; 
Skelton et at, 1992; Jarrard et a/, 1993). Therapeutics, which increase cholinergic 
activity might be able to antagonise the EC lesion induced deficits. 
It has been suggested that animals with lesions of the entorhinal area might be 
used as a deficit model for investigating cognitive deficits observed in 
neurodegenerative disorders such as Alzheimer's disease (Eijkenboom et at, 2000). 
In order to validate this model pharmacologically the effects the cognition enhancer 
Donepezil, which is used as therapeutic to treat Alzheimer's patients (Matthews et 
a/, 2000; Giacobini, 2000), and Metrifonate, a compound that has successfully 
completed phase III clinical trials (Raskind et a/, 1999; Gelina et a/, 2000) were 
tested for their effect on Morris water escape performance of EC-lesioned rats. 
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Metrifonate is a cholinesterase inhibitors designed to increase the deficient 
acetylcholine levels in the brains of Alzheimer patients. These compounds, known as 
second generation cholinesterase inhibitors are long lasting, safe and well tolerated. 
They aim to restore levels of endogenous acetylcholine in the synaptic cleft by 
preventing its enzymatic breakdown by acetylcholi neste rase. This study investigates 
whether these compounds are able to antagonise the EC lesion induced deficits. 
Procedure 
Material and Methods: Bilateral entorhinal cortex lesions 
Surgery. - All rats were anaesthetised with a solution (6 mg/kg) of 1.2 ml Ketavet 
(100 mg/ml-1 ketamin), 0.8 ml Rompun (2% xylacin) and 8.0 ml 0.9% NaCl and 
placed in a Sembach stereotaxic apparatus (Sembach Laborgeräte, Ratingen 
Rheinland, Germany). The dorsal skull was exposed and two holes were drilled 
above the target positions. With help of a stainless steel needle (Hamilton p/n: 
80427/00 type 2; inner diameter 0.13 mm; outer diameter 0.47 mm) 10 mg/ml-1 
ibotenic acid (molecular weight: 158.1; 95% purity; Sigma) solved in 0.9% NaCl 
(application volume: 0.5 pl) was injected bilaterally into each of three sites of the EC 
(injection speed 0.5 pl/min-1; see also Eijkenboom etat, 2000). The co-ordinates are 
summarised in Table 1. The injection needle was left in place for 2 min after 
injection. The same procedure was followed for the sham control group, which 
received injections of the solvent (0.9% NaCl) only. The animals recovered well 
after surgery. No differences in gross behaviour were observed. The animals were 
tested in the Morris water escape task after a recovery period of one week. 
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Co-ordinates of lesion sites 
First set Second set Third set 
Anterior-posterior + 1.0 mm + 1.2 mm + 1.5 mm 
Lateral J 6.8 mm ± 5.8 mm ± 6.6 mm 
Dorso-ventral + 3.1 mm + 2.7 mm + 2.4 mm 
Table 1: Stereotaxic co-ordinates used (according to Paxinos and Watson, 1986) to induce entorhinal 
cortex lesions by injections of ibotenic acid. The co-ordinates are with respect to the intra-aural line, 
the incisor bar was set at 3.3 mm above intra-aural line, and the injection needle was lowered at an 
angle of 15° in a mediolateral orientation 
Morris water escape task 
Apparatus. Morris water escape performance was assessed in a water tank which 
consisted of a circular grey tub with a slightly sloping wall (Material: polyethylene; 
inner dimensions: diameter at top 153 cm, diameter at bottom 143 cm, depth 63 
cm), filled with 43.5 cm of clear tap water at a temperature of approximately 22°C. 
The escape platform consisted of a grey polyethylene cylinder (diameter 10.8 cm), 
submerged 1.5 cm below the surface of the water. In this version of the test the 
water was not made opaque because the grey escape platform was virtually 
invisible in the grey tank. The water tank was situated in a room illuminated by 
white fluorescent tubes. Abundant extra-maze cues were provided by the furniture 
in the room, including desks, computer equipment, a second water tank, the 
presence of the experimenter, and by a radio on a shelf that was playing softly. All 
testing was done between 9: 00 and 15: 00. A video camera, mounted in the centre 
above the circular pool, provided a picture of the pool on a TV-monitor. The 
movements of the rat were registered automatically by a video-tracking system 
(EthoVision®, Noldus Information Technology, Wageningen, The Netherlands) and 
stored in an MS-DOS compatible microcomputer. 
One week after surgery the rats were tested in the Morris water escape task with 
four trials per session on five successive days. The test compound or vehicle was 
injected intraperiteoneally, 30 minutes before each daily training session. 
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A trial was started by placing a rat into the pool, facing the wall of the tank. Each of 
four starting positions (north, east, south, and west) was used once in a series of 
four trials; their order was randomised. The escape platform was always in the 
same quadrant. A trial was terminated as soon as the rat had climbed onto the 
escape platform or when 90 seconds had elapsed, whichever event occurred first. A 
rat was allowed to stay on the platform for 30 seconds. Then it was taken from the 
platform and the next trial was started. If a rat did not find the platform within 90 
seconds it was put on the platform by the experimenter and was allowed to stay 
there for 30 seconds. After completion of the fourth trial (on the fifth day after 
completion of the probe trial, see below), the rat was gently dried with crepe paper 
and returned to its home cage. The animal was kept warm under an infrared bulb 
(Original Hanau Solilux, 150 W) fixed about 60 cm above the floor of the cage. 
Pfote trial. - After the fourth trial of the fifth daily session, an additional trial was 
given as a probe trial: the platform was removed, and the time the rat spent in the 
four quadrants was measured for 30 seconds. In the probe trial, all rats started 
from the same start position, opposite to the quadrant where the escape platform 
had been positioned during acquisition. All data were collected by the automatic 
video tracking system EthoVision® (Noldus Information Technology, Wageningen, 
NL). 
Statistical analyses 
Acquisition: Four different measures were taken to evaluate the performance of the 
rats during acquisition training: escape latency, travelled distance, swimming speed, 
and distance to platform. 
Escape latency is the time (s) taken to find and escape onto the submerged 
platform (Morris, 1984). Travelled distance (cm) is the total distance swum to find 
and escape onto the submerged platform (Morris, 1984). Swimming speed was 
calculated as travelled distance (cm) divided by escape latency (s). Distance to 
platform (cm) (Gallagher, Burwell & Burchinal, 1993) was calculated as the mean 
distance to the platform across all samples drawn by the video-tracking system 
between the start of a trial and the moment the rat climbed onto the platform. 
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The measures were averaged per rat within each session. Treatment effects on the 
acquisition of the water escape task were assessed with an analysis of variance 
(ANOVA; Cotton, 1998; Winer, 1971) with repeated measures over sessions. In 
addition, treatment effects in particular sessions were analysed by ANOVA, 
complemented by post hoc comparisons where appropriate. 
Probe trial., Treatment effects of the time (s) in quadrants during the probe trial 
were assessed with a repeated measures ANOVA over quadrants (time in the 
quadrant north, east, south, and west are considered as levels of the repeated 
measures factor), complemented by ANOVAs on the swimming times perquadrant. 
Experiment 1: The effects Metrifonate on spatial discrimination performance of 
entorhinal cortex lesioned rats 
Animals: 47 male HsdWin: Wu rats, weighing between 266 and 357 grams were 
supplied by Harlan Winkelmann, Borchen, Germany. They were allowed to adapt to 
our animal facilities for one to two weeks before surgery. The animals were 
assigned randomly to their respective treatment conditions in two parallel 
experiments, in each of these two experiments; half of the animals per treatment 
condition were tested. 
Drug Administration: Metrifonate was administered p. o., solved in Na-citrate buffer, 
pH 5.5, at an application volume of 2 ml/kg-1 body weight at concentrations 10 or, 
30mg/kg, 30 min before each of the five training sessions. 
Results 
Acquisition 
Escape latency (see Fig. 2, upper left panel): Averaged over the five successive 
acquisition sessions, the time to escape onto the submerged platform was affected 
by the treatments (General mean: F3,43 = 19.37, p<0.01). Post hoc comparisons 
revealed the following: The EC-lesioned control group needed, on average, more 
time to locate the platform than the sham-lesioned control group. Treatment with 
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30 mg/kg-1 was able to improve the EC lesion induced deficit; this group of rats 
needed more time than the sham-lesioned control group, but less time than the EC- 
lesioned control group to find the submerged platform. The performance of the 
group treated with 10 mg/kg-1 Metrifonate did not differ from the EC-lesioned 
control group and the group treated with 30 mg/kg-1 Metrifonate. All groups 
reduced the time to escape onto the platform in the course of training (Sessions: 
F41172 = 45.11, p<0.01) to a similar degree (Sessions by Treatment interaction: 
F12,172 = 1.18, n. s. ). 
Distance travelled (see Fig. 2, upper centre panel): The average distance travelled 
was affected by the treatments (General mean: F3143 = 14.55, p<0.01). Post-hoc 
comparisons confirmed that the EC lesion affected the performance; this deficit was 
not ameliorated by treatment with Metrifonate. In the course of training, all groups 
reduced the swim path (Sessions: F4,172 = 40.02, p<0.01). The speed of learning 
was not affected by Metrifonate treatment (Sessions by Treatment interaction: 
F121172 = 1.44, n. s. ). 
Swimming speed (see Fig. 2, upper right panel): The average swimming speed was 
not affected by the treatments (General mean: F3,43 = 0.33, n. s. ). The swimming 
speeds slightly changed across sessions (Sessions: F41172 = 4.18, p<0.01), but 
these changes were similar for the groups (Sessions by Treatment interaction: F121172 
= 0.78, n. s. ). 
Distance to platform (see Fig. 2, lower left panel): Treatments affected the average 
distance to platform (General mean: F3143 = 14.65, p<0.01). Post hoc comparisons 
confirmed that the sham-lesioned control group swam, on average, at a shorter 
distance from the platform that did the EC-lesioned control group. The mean 
distance to platform of the EC-lesioned group of rats treated with 30 mg/kg-1 
Metrifonate was shorter than that of the EC-lesioned control group, but longer than 
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that of the sham-lesioned control group, indicating that the drug-treatment partially 
antagonised the EC-lesion induced deficit. The group treated with 10 mg/kg-1 
Metrifonate did not differ from the EC-lesioned controls. Distance to platform 
decreased across training sessions (Sessions: F4,172 = 49.45, p<0.01), and the 
decrease was different for the groups of rats (Sessions by Treatment interaction: 
F12,172 = 1,98, p<0.05). The variation in the decrease of the distance to platform 
across sessions was nearly exclusively covered by the linear trend component 
(97%). As confirmed by post-hoc comparisons, the group treated with 30 mg/kg-1 
Metrifonate showed a steeper decrease of the distance swum in the course of 
training than the sham-lesioned and the EC-lesioned control groups, indicating that 
they learned faster than the other groups of rats. However, the shape of their 
learning curve did not differ from that of the group treated with 10 mg/kg-1 
Metrifonate which might indicate that this dose also tended to improve speed of 
learning. 
Probe trial 
Time spent in quadrants (see Fig. 2, lower right panel): The time spent in the four 
quadrants was different during the probe trial (Quadrants: F3,129 = 8.45, p<0.01). 
The treatments affected the bias for particular quadrants (Quadrants by Treatment 
interaction: F9,129 = 2.37, p<0.05). Time spent in quadrant West, i. e. the quadrant 
where the platform had been positioned during training, was affected by the 
treatments (F3,43 = 5.37, p<0.01). Post hoc comparisons revealed that the sham- 
lesioned groups spent more time in this quadrant than any of the other groups, 
which did not differ from one another. The EC-lesion apparently disrupted the bias 






























































Legend acquisition sessions: 
ý- sham-lesioned control (n = 12) 
-U- EC-lesioned control (n = 12) 
-¢- EC-lesioned, 10 mg/kg MTF (n = 11) 
EC-lesioned, 30 mg/kg MTF (n = 12) 
Legend probe trial: 
quadrant south (anticlockwise) 
quadrant west (training) 
® quadrant north (clockwise) 
C quadrant east (opposite) 
Figure 1: Effects of 10 and 30 mg/kg Metrifonate (MTF), administered p. o., on the spatial 
discrimination performance of male Wistar rats with bilateral lesions of the entorhinal cortex (EC) 
region. The escape latency (upper left), distance travelled (upper centre), swimming speed (upper 
right), and distance to platform (lower left) during acquisition are depicted. In addition, the time (lower 
right) spent in the four quadrants of the pool during the probe trial is shown. All data are presented as 
means and standard errors of the means (SEMS). 
Discussion 
Paradigms employing brain lesions, typically in rats, have been used to study the 
neural basis of cognitive dysfunctions to evaluate potential therapeutic approaches. 
In the present study, ibotenic acid lesioned rats were used to assess the effects of 
metrifonate, a ChE-inhibitor. Ibotenic acid destroys cell bodies without concurrent 
damage to fibres of passage, which can occur by mechanical lesions. 
Early lesion models of AD focused primarily on the nucleus basalis of Meynert and 
the medial septum. Deficits were reported in passive avoidance retention, spatial 
swim maze learning and other reference memory tasks, as well as various working 




discussed the initial stages of AD are characterised by a neuropathological changes 
in the entorhinal cortex (Braak and Braak, 1991; Hyman et al, 1986; Miwa & Ueki, 
1996). Rats with excitotoxic lesion of the EC have previously been shown to impair 
acquisition of both passive and active avoidance learning and positive reinforcement 
operant learning with no increase in locomotor activity and sensitivity (Miwa et al, 
1996; Ueki et al, 1996) as well as spatial ability in the water maze task (Schenk and 
Morris, 1985). 
In this study, spatial discrimination deficits, induced by bilateral lesions aimed at the 
entorhinal cortex region, could, at least partially, be antagonised by treatment with 
cholinesterase inhibitors (ChE-I). In the present study, Metrifonate was tested. The 
compound improved the level of performance compared with that of the EC- 
lesioned control groups (Metrifonate at 30 mg/kg-'). No changes in the swimming 
pattern were observed in animals with EC lesions (i. e. they did not exhibit wall 
hugging or thigmotaxic behaviour, see chapter 6) and with no overall changes in the 
swimming speed suggested that the EC lesioned animals swam further around the 
maze indicating an increase in exploratory activity to escape to the platform. 
Conclusions 
These data support the notion that the deficiency model of the bilaterally EC- 
lesioned rat is sensitive to the effects of putative cognition enhancing compounds, 
and are in line with reports that compounds modulating the AMPA receptor 
(Aniracetam; Zajaczkowski and Danysz, 1997) or the NMDA receptor (memantine; 
Zajaczkowski et al, 1996), or administration of the neuroprotective compound 
ganglioside (Ramirez et al, 1991; Ramirez et al, 1998) improve cognitive functions 
in EC-lesioned rats. Bilateral EC-lesioned rats model some of the pathological and 
behavioural changes observed in Alzheimer patients, such as degenerations in the 
EC, which occur very early during the development of the Alzheimer pathology, 
concomitant dysfunctions of hippocampal circuits, and spatial discrimination deficits. 
The present experiments indicate that under conditions of pathological impairment 
of brain structures such as entorhinal cortex lesion, ChE-Is might produce beneficial 
effects on learning and memory. 
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Effects of Metrifonate on the Timing Behaviour in the Rat. 
Abstract 
The peak interval (PI) procedure is an operant conditioning schedule that has been 
suggested as a useful paradigm for assessing and characterising putative cognition 
enhancers. These compounds aim to reduce cognitive dysfunction prominent in 
conditions such as Alzheimer's disease. 
There is ample evidence that cholinergic deficits have a role in cognitive impairments. 
We tested metrifonate in a PI 20s task. This compound is a cholinesterase inhibitor 
that has been shown to enhance cognition in various animal models. Results obtained 
with this temporal procedure are interpreted according to the Scalar Expectancy theory 
(SET). 
Cognition enhancers are expected to shift the peak time to the left, reflecting a change 
in time estimation, perhaps caused by an increase in the speed of information 
processing. In the PI procedure a single administration of metrifonate shifted the peak 
time to the right, whereas sub-chronic administration of metrifonate had no effect on 
time estimation. Scopolamine produced a reduction in the spread possibly indicating a 
more accurate perception of the time of reinforcement and an increase in the run rate 
indicating an increased motivation to the task, however no other timing effects were 
observed. Therefore we are not able to conclude as to the sensitivity of this paradigm 




Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterised by a 
progressive decline in cognitive function, including loss of memory and cognitive 
function and behaviour. The causes of the disease are as yet unknown, however 
central cholinergic hypofunction is thought to be a component of the disease. Several 
lines of evidence support this notion that a loss of cholinergic function contributes the 
cognitive deficits seen in AD (Bierer, et a/, 1995). Acetylcholine (ACh) synthesis in 
nerve terminals is decreased due to a reduction in choline acetyltransferase (ChAT) 
activity. The brains of AD patients characteristically show a dramatic loss of neurones 
and synapses in many areas, particularly in the basal forebrain, amygdala, 
hippocampus and cerebral cortex (Bartus, Dean, Pontecorvo, and Flicker, 1985). 
Initial approaches to AD were to enhance cholinergic function. Cholinomimetic agents 
can augment cholinergic transmission either directly or indirectly. The most successful 
of these strategies at this time is to increase the amount of Ach by reducing its 
degradation by cholinesterase inhibitors (ChEI's). Metrifonate donepezil and 
rivastigmine are three such ChEI's currently available. 
In rats, lesions of the nucleus basalis magnocellularis (nbm) - an area of the basal 
forebrain that has significant projections to the frontal cortex, and where substantial 
degeneration is found in patients with Alzheimer's disease - produce an over estimation 
in the remembered time of reinforcement. From this, it can be suggested that AD 
patients could have a defective accuracy in time estimation (Nichelli, Venneri, Molinari, 
Tavani, & Grafman 1993). This observation leads us to think that cholinesterase 
inhibitors for the treatment in AD could be assessed using a timing behaviour model. 
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Timing behaviour is thought to be a cognitive function of the brain in terms of a 
subjects' ability to control the way in which stimulus information is integrated over 
time. In the present study the discrete trial peak interval procedure was used. This 
operant conditioning schedule is an extension of the fixed interval (FI) procedure in 
which a lever is presented and the animal is free to respond at any time, but only the 
first response after a fixed duration (e. g. 20 seconds) is reinforced. In the peak interval 
(PI) procedure some trials are identical to the FI procedure where others consist of the 
lever presented for a time that goes beyond the fixed duration (e. g. 50 seconds in our 
experiments, and typically at least twice plus a random duration of the fixed interval) 
and no reinforcement is given. 
Data is derived from the non-reinforced trials, or PI trials. When averaging across trials 
and subjects the response distribution appears to be a Gaussian like function with a 
slight positive skew (Catania, 1970; Roberts, 1981; Church, Miller, Meck & Gibbon, 
1991). The peak of the distribution occurs near the time that food is maximally 
expected (and usually granted) and is called the peak time (PT). The response rate at 
the PT is the peak rate (PR; see figure 1, left panel). PT and PR are independent 
values (Roberts, 1981), so that timing can be compared under conditions in which the 
absolute rate of responses varies. 
Response distribution on individual trials is rather different and can be characterised by 
a three- phase process called a low-high-low or break-run-break pattern of responding 
(to follow the terminology suggested by Schneider, 1969). The animal often responds 
at a low rate at the beginning of the trial, then begins responding at fast and steady 
rate and finally returns to a low rate. Performance on each of these individual trials can 
be further investigated by measuring the time at the beginning of high responding 
(Si), the time on stopping of high responding (S2), the middle of this high responding 
rate (M, middle = (S1+S2)/2) and the duration of responding (D, spread = S2-S1; see 






















































Figure 1: Group trial data: (left panel). The response distribution obtained is Gaussian with a slight positive 
skew Two major read outs are considered: 1: the peak time (PT), time at which the food is maximally 
expected and 2: the peak rate (PR), the maximum response rate at this time. Individual trial data: (Right 
panel) The response distribution obtained follows a low-high pattern of responding. Four read outs are 
considered: Si: the start time, time at which the animal begins to respond at a high rate, S2: the stop 
time, time at which the animal stops to respond at a high rate, the spread: time during which the animal 
responds at a high rate, the middle: time halfway through the spread 
Performance on each of these individual trials can be further investigated by measuring 
the time at the beginning of high responding (Si), the time on stopping of high 
responding (S2), the middle of this high responding rate (M, middle = (S1+S2)/2) and 
the duration of responding (D, spread = S2-S1; see figure 1, right panel 
Today, the most challenging theoretical framework explaining timing behaviours is the 
Scalar Expectancy Theory (SET, Gibbon et al, 1984) that involves an internal clock as 
well as memory and decision processes. According to SET, on presentation of a signal, 
the internal clock emits pulses that are switched into an accumulator. The accumulated 
pulses (n) are then compared to a representation of expected time of reinforcement 
sampled from the reference memory (n*). The representation of actual time and the 
representation of the usually reinforced time are compared at the decision level. When 
the two representations are close enough, that is when the discrepancy between them 
lies below a certain threshold, a response is made (more precisely, the probability to 
respond fall over from low to high). If a response is reinforced, the value (n) 
accumulated in the accumulator is transferred to the distribution of values kept in the 
reference memory (Gibbon etal, 1984). 
The 'internal' clock is used for measuring the speed in which information is integrated 
and this appears to be linked to dopamine function in the basal ganglia and the 
memory storage process used for the representation of the duration's of prior events 
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appears to be linked to acetylcholine function in the frontal cortex. These two systems 
appear to be linked by frontal striatal loops (Meck, 1996). 
The first aim of the present study was to determine the effects of chronic metrifonate 
on the peak interval procedure. The hypothesis is that this cholinesterase inhibitor 
administration schedule facilitates the acquisition of time estimation using the P120s 
procedure. The second aim of our study was to determine the effect of a single 
administration of the ChEI, metrifonate on the peak time and peak rate on the 20s 
peak interval procedure in well trained rats. The effects of scopolamine was also 
assessed to observe the effects of an anti cholinergic compound on the peak interval 
procedure. The usability of these methods to assess putative cognition enhancers is 
discussed. 
Procedure 
Apparatus: The rats were trained in 10 similar standard lever boxes (manufactured by 
Electronic and Computer Engineering Dept. & Mechanical Engineering Dept., University 
of Nijmegen, The Netherlands; inner dimensions: 525 mm wide, 270 mm deep, 280 
mm high) The front wall contained a food tray (34 mm deep) through which pellets 
(BioServ, USA. 45 mg) could be delivered and two retractable stainless steel levers (40 
mm wide, projecting 20 mm into the Skinnerbox), were located at a distance of 48 mm 
from both sides of the food tray. The chamber was fitted with white and red house 
lights on the roof, and was enclosed in a sound-attenuating chest. Each chamber was 
equipped with a fan for ventilation (See figure 2) An Apple Power Macintosh controlled 
the experiments and collected the data. 
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The rats were deprived to 85-90% of their free feeding weight and after each 
experimental session an adjusted ration of food (Ssniff Food pellets) was given to 
maintain this deprivation level. 
Pre-Training: The rats were magazine trained in the Skinner box for 30 minutes until 
they had consumed at least twenty pellets for two consecutive days. The pellets were 
randomly supplied at inter-trial interval (ITI) ranging from 20 to 100 seconds. During 
this phase the levers were retracted. During the continuous reinforcement training two 
levers (left and right) were presented alternatively. After pressing the lever, the lever 
was retracted and a 45 mg food pellet was delivered. An ITI interval of 10 seconds 
spaced the visit of the food tray and the presentation of the next trial. The start of 
each trial was signalled by the onset of the white house lights. The training ended after 
reaching a criterion of 50 lever presses in 30 minutes in two consecutive days. This 
was followed by FI training that consisted of a lever being presented and only the first 
lever press following a fixed amount of time is reinforced with a pellet. The FI training 
started with fixed interval schedule of 5 seconds (FI 5) where an m of 20 seconds was 
inserted between successive trials. The lever, left or right, was counterbalanced over 
the rats and remained the same during the experiment. When the rats obtained 85% 
or more of the maximum number of pellets in a session the fixed interval increased to 
10 seconds (FI 10) and then onto 20 seconds (FI 20). 
Peak interval (PI) Training. Once a steady rate of responding had established PIs were 
introduced. On random half of the trials, the rats were given fixed intervals. On the 
remaining trials, food was not primed at 20 seconds after trial onset. After 50 seconds 
the trial ended without deliverance of a pellet, the lever was retracted, and the ITI 
started. 
Drug testing 
Experiment 1: Sub-chronic metrifonate treatment 
The subjects were 30 male HsdCpd: Wu (Harlan Wistar) rats (supplied by Harlan- 
Winkelmann, Borchen, FRG) with free-feeding body weights ranging from 220 to 250 
grams. The animals were approximately 10 weeks old at the start of the experiment. 
Rats were housed in groups of two in standard type III MakrolonTM cages, water was 
continuously available, with a 12: 12 hour light/ dark cycle, lights on at 07.00 am. 
115 
CHAPTER 8 
After 2-3 weeks of pre-training, drug administration began on day one of P120" training 
and continued daily, 5 days per week for approximately 36 days. Metrifonate, 10 
mg/kg (n=7), 30 mg/kg (n=8), 50 mg/kg (n=8) or vehicle [sodium citrate buffer, pH. 
5.5. (N=7)] was administered orally through a syringe (p. o) 30 minutes before the 
start of the peak-interval session that lasted 30 minutes. The administration volume 
was 5ml/kg 
Experiment 2: Acute metrifonate or scopolamine treatment in rats trained to a stable 
performance. 
The subjects were 45 male Hsdcpd: Wu (Harlan Wistar) rats (supplied by Harlan- 
Winklemann, Borchen) with free-feeding body weights ranging 220- 250 grams from 
10 weeks old at the start of the experiment. Housing conditions and food deprivation 
were the same as for Experiment 1. After 2-3 weeks of pre-training, PI training 
continued for 40 sessions, once daily for five days per week before any drug 
administration. See Table 1 for drug administration protocol. 
Table 1: Drug administration protocol for metrifonate, rivastigmine, donepezil and scopolamine in well 
trained rats in the P120s procedure. 
Metrifonate Scopolamine 
Session 40 Session 70 
3 mg/kg, 10 mg/kg 30 0.1 mg/kg, 0.3 mg/kg, 
mg/kg 60 mg/kg or vehicle 1mg/kg, 3 mg/kg (n=9) or 
(sodium citrate buffer, pH, vehicle [sodium Chloride 
_5.5) 
0.9%) 
All groups are N=9 (except 60 mg/kg metrifonate where N 
8). All compounds with the exception of scopolamine were 
administered orally 30 minutes prior to the peak interval 
sessions. Scopolamine was administered inter eritoneallyýi L 
Data Analysis: In all drug sessions, results were only taken from the peak trials. The 
peak time was determined as follows. The number of responses in each 4-second 
interval (1-4,2-5,3-6 etc. ) was counted and the maximum number of responses was 
identified. The median time for each of these intervals was found. If there was only 
one such interval, its median was defined as the 
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peak time. If there were several such intervals the median of their medians was 
defined as the peak time (Meck, Komeily-Zadah & Church, 1984). 
For each peak trial there was a measure of the time that the rat started to respond at 
a high rate (Si) and the time at which it stopped at the high rate (S2), These times 
were determined by an exhaustive search of all the possible locations to maximise the 
difference between the high rate and the low rates, weighted the relative time in the 
high and low states. On each trial the index that was maximised was t1*(r-rl)+t2*(r2- 
r)+t3*(r-r3), where t1, t2 and t3 were the times until S1, the time between S1 and S2 
and the time from S2 until the end of the trial. r1, r2 and r3 were the mean response 
rates corresponding to these times and r is the overall mean response rate. The values 
reported were for all peak trials on which S1 was less or equal to the time of 
reinforcement (T*), which indicates good starts and S2 was greater than T* indicating 
good stops. Determined from Si and S2 was the middle of this time interval 
(M=(S1+S2)/2) and the spread of this time interval (D=S2-S1) The run rate is the 
mean response rate during the spread of the high responding period (Church, Meck & 
Gibbon, 1994 were the first to use this formula, 
Data presented as start, stop, spread, middle [respectively S1, S2, D and M], peak time 
and run rate in this report are means ± standard errors of the means. In experiment 1, 
the effect of sub-chronic metrifonate treatment on the timing behaviour in rats was 
analysed in blocks of 4 days over the period of 36 days of treatment (Metrifonate Vs 
vehicle) and this was analysed by TREATMENT* BLOCKS ANOVA with repeated 
measures on the last factor. This was further assessed by a one factorial ANOVA on 
orthogonal trend components supplemented with Fisher's least significant difference 
(LSD) post hoc comparisons. In experiment 2, treatment effects were analysed by 
difference scores (Delta) between pre-treatment and treatment sessions (day before 
drug administration and day of drug administration) and this was supplemented with 
Fisher's least significant difference (LSD) post hoc comparisons, supplemented by 




Experiment 1: Sub-chronic metrifonate treatment (see figure 2) 
Si (See fig 2, panel A): Averaged across the nine blocks of 4 sessions (GENERAL 
MEAN: F3122 = 0.59, n. s) metrifonate treatment had no effect on S1. S1 decreased in 
the course of training (BLOCKS: F81176 = 24.19, p<0.01), however this decrease was 
similar for the treatment groups (BLOCKS by TREATMENT interaction: F241176 =0.88, 
n. s) 
S2 (See fig 2, Panel B): Metrifonate treatment had no effect on S2 when the average 
across the nine blocks of 4 sessions was considered (GENERAL MEAN: F3122 = 1.24, 
n. s). S2 was decreased in the course of training (BLOCKS: F81176 = 8.04, p<0.01), 
similarly for the treatment groups (BLOCKS by TREATMENT interaction: F241176 =0.92, 
n. s) 
Middle (See fig 2, Panel C): Metrifonate treatment had no effect on the middle, 
averaged across the nine blocks of 4 sessions (GENERAL MEAN: F3,22 = 0.87, n. s). The 
middle was decreased in the course of training (BLOCKS: F8,176 = 16.07, p<0.01), this 
decrease however was similar in all groups (BLOCKS by TREATMENT interaction: F24,176 
=0.75, n. s) 
Spread (See fig 2, Panel D): The average spread across the nine blocks of 4 sessions 
(GENERAL MEAN: F3,22 = 0.23, n. s) was not affected by metrifonate treatment. The 
spread was decreased in the course of training (BLOCKS: F8,176 = 7.52, p<0.01), at a 
similar rate in all the treatment groups (BLOCKS by TREATMENT interaction: F24,176 
=1.18, n. s) 
Run Rate (See fig 2, Panel E): Averaged across all sessions (GENERAL MEAN: F3,22 = 
11.16 p<0.01) metrifonate treatment decreased the run rate. Post hoc comparisons 
revealed that the 10,30 and 50 mg/kg differed from the vehicle treated group. There 
was an increase in the run rate during the course of training (BLOCKS: F8,176 = 59.66, 
p<0.01), and this was affected by metrifonate treatment. (BLOCKS by TREATMENT 
interaction: F24,176 = 48.47, p<0.01). Subsequent orthogonal trend components showed 
that the change in run rate can be described by a linear (F3122 = 7.27, p<0.001), 
quadratic (F3,22 = 29.86, p<0.001) and a cubic (F3,22 = 66.89, 
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p<0.001) trend, which covered 27.62%, 4.16% and 13.64% of the variance 
respectively. T- tests showed that all groups were covered by the linear trend (vehicle: 
t6 = 10.89, p< 0.001; 10 mg/kg: t6 = 2.92, p< 0.05.; 30 mg/kg: t5 = 5.62, p< 0.05.; 
50 mg/kg: t5 = 3.67, p< 0.05). For the quadratic trend only the vehicle group was 
covered (t6 = -9.19, p< 0.001). 10,30 and 50 mg/kg could not show a second order 
trend (t6 = 0.78, n. s.; t5 = 0.05, n. s.; t5 = -0.44, n. s. respectively). For the cubic trend 
only the vehicle group was covered (t6 = -12.47, p< 0.001). 10,30 and 50 mg/kg 
could not show a third order trend (t6 = 0.79, n. s.; t5 = -0.41, n. s.; t5 = -0.66, n. s. 
respectively). 
Peak time (See fig 2, Panel F): The average Peak time across the nine blocks of 4 
sessions (GENERAL MEAN: F3,22 = 1.62, n. s) was not affected by metrifonate 
treatment. The peak time was decreased in the course of training (BLOCKS: F81176 = 
9.53, p<0.01), however this decrease was similar for all groups. (BLOCKS by 
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Figure 3: Effects of sub-chronic metrifonate (10,30 and 50 mg/kg) on the peak interval procedure in 
Harlan Wistar rats over a period of 36 days. The effects on S1, (Upper left) S2, (Middle Left ), Middle 
(Lower left), Spread (Upper Right) PR (Middle right) and PT (Lower right) were observed All results are t 
SEM and N=7-8. 
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Experiment 2: Acute metrifonate treatment on well trained rats (Figure 4) 
Si: Treatment with metrifonate affected the difference score of S1 between the pre- 
treatment and the treatment sessions (F4,38 =7.06, p<0.05). Post-hoc analysis 
confirmed that metrifonate, 3,30 and 60 mg/kg increased S1 compared with vehicle 
treated group. This was confirmed by t-tests per treatment groups: There was no 
difference between the two sessions in the controls (t8 = 2.01, n. s. ) whereas the 
different scores differed from zero in the 3 mg/kg group (t8 = -5.17, p<0.01) and the 
60 mg/kg group (t7 = -2.96, p<0.05). The 30 mg/kg did not differ from zero (t8 =- 
1.45, n. s). 
S2: Treatment with metrifonate affected the difference score of S2 between the pre- 
treatment and the treatment sessions (F4138 = 6.88, p<0.01). Post-hoc analysis 
confirmed that metrifonate, 3 and 60 mg/kg increased S2 compared with vehicle 
treated group. This was confirmed by t-tests per treatment group: There was no 
difference between the two sessions in the controls (t8 = 1.29, n. s. ) whereas the 
difference scores differed from zero in the 60 mg/kg group (t8 = -4.55, p<0.01). 
Spread: The spread was not affected by metrifonate treatment (F4,38 =1.01, n. s). 
Middle: Treatment with metrifonate affected the difference score of the middle 
between the pre-treatment and the treatment sessions (F4,38 = 2.77, p<0.05). Post-hoc 
analysis confirmed that metrifonate, 60 mg/kg increased the middle compared with 
vehicle treated group. This was confirmed by t-tests per treatment group: There was 
no difference between the two sessions in the controls (t8 = -0.11, n. s. ) whereas the 
difference scores differed from zero in the 3 mg/kg group (t8 = -6.26, p<0.01) and the 
60 mg/kg group (t7 = -4.04, p<0.01). 
The run rate was not affected by metrifonate treatment (F4,38 =1.83, n. s). 
Peak time: Treatment with metrifonate affected the difference score of the peak time 
between the pre-treatment and the treatment sessions (F4,38 =5.90, p<0.01). Post-hoc 
analysis confirmed that metrifonate, 60 mg/kg increased the peak time compared with 
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vehicle treated group. This was confirmed by t-tests per treatment group: There was 
no difference between the two sessions in the controls (t8 = 0.29, n. s. ) whereas the 
difference scores differed from zero in the 60 mg/kg group (t7 = 3.48, p<0.05). 
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Figure 4: Differences in group trial (PT and Run Rate) and individual trial measures (S1, Middle, S2, 
Spread) between the day of treatment and the day before treatment when testing single administration of 
metrifonate in the PI procedure. Metrifonate (3,10,30 and 60 mg/kg) was injected p. o. in an application 
volume of 10 ml/kg. All results are ± SEM and N=9, except in the 60 mg/kg group, where N=8. 
Scopolamine treatment on well trained rats (Figure 5). 
Animals were removed from analysis when S1 was not less or equal to 20 seconds 
and/or S2 was not greater than 20 seconds. 
Si showed no effect of scopolamine treatment, because performance was not different 
between the pre-treatment and the treatment sessions (F4130 = 1.54, n. s. ). 
S2 showed no effect of scopolamine treatment, because performance was not different 
between the pre-treatment and the treatment sessions (F4,3o = 0.48, n. s. ) 
Treatment with scopolamine affected the difference score of the spread between the 
pre-treatment and the treatment sessions (F4,38 = 4.09, p<0.05). 
Post-hoc analysis 
confirmed that scopolamine, 1 mg/kg decreased the spread compared with 
that of the 
vehicle treated group. 
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Scopolamine treatment did not affect the middle (F4,30 = 0.14, n. s) 
The difference score on the run rate was affected with scopolamine treatment as there 
was a change from the pre-treatment to the treatment session (F4,30 = 5.26, p<0.05). 
Post hoc analysis confirmed that scopolamine 1 and 3 mg/kg increased the run rate 
compared with that of the vehicle treated group. 
The peak time was similar in the pre-treatment to treatment sessions i. e. scopolamine 
treatment did not affect this measure (F4,30 =0.25, n. s). 
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Figure 5: Differences in group trial (PT and Run rate) and individual trial measures (Si, Middle, S2, 
Spread) between the day of treatment and the day before treatment when testing single administration of 
scopolamine in the PI procedure. Scopolamine (0.1,0.3,1 and 3 mg/kg) was injected p. o. in an 
application volume of 10 ml/kg. All results are ± SEM 
Discussion 
Summary of Results 
The present results are consistent with many previous studies with the PI procedure. 
Group trial data showed a Gaussian-like distribution (data not shown: Roberts, 1981; 
Meck and Church, 1987a; Meck and Church, 1987b), and individual trial data showed a 
low-high-low distribution of responding (Cheng & Westwood, 1993; Church et a/, 
1994). 
Sub chronic metrifonate (10,30 and 50 mg/kg) was given over a period of 36 days 
during P120s training. Temporal discrimination acquisition was reflected by changes in 
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the Peak Time (PT), Spread and Middle. Metrifonate did not predominantly improve the 
acquisition of this task. 
Acute metrifonate in well trained rats increased Si, S2, middle and peak time (60 
mg/kg) and did not affect the spread and run rate. Scopolamine (1 mg/kg) produced a 
decrease in the spread and an increase in the run rate. No other effects were observed 
and especially no changes imply the middle or peak time. This point is important as it 
could be interpreted as an improvement of the performance as more lever presses are 
concentrated around the reinforced time. 
Timing behaviour and the cholinergic system 
It has previously been reported that, in the peak procedure, cholinergic compounds 
such as choline (Meck and Church, 1987a) and physostigmine (Meck and Church, 
1987b) will shift the gaussian curve to the left indicating a change of the remembered 
time of reinforcement to earlier time. In this study, acute metrifonate showed an 
increase in the peak time, suggesting a rightward shift, i. e. a change to the 
remembered time of reinforcement to a later time. This result was unexpected for a 
cholinesterase inhibitor. Metrifonate has been shown to improve cognitive performance 
in a variety of behavioural tasks (e. g. Schmidt eta/, 1997). However the rightward shift 
suggests that cognitive processes were disturbed rather than that they were enhanced 
by the compound. 
As hypothesised by Meck and Church (1984) changes in internal clock speed are 
transient whereas changes in the memory storage process are long lasting. A 
substance influencing internal clock speed should acutely shift the PT. The initial effect 
will disappear with repeated exposure as the animal learns to rescale time. On arrest of 
the drug, a rebound shift in the opposite direction should be observed. Contrarily, 
changes in the memory storage stage are only observed if the substance is chronically 
administered. The drug should permanently maintain the effects. A shift will slowly 
build up on drug administration, and slowly return to its original value when the drug is 
removed, no rebound shift will occur. 
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It has previously been suggested that cholinergic compounds affect the memory 
storage process which is thought to be linked to acetylcholine function in the frontal 
cortex. Therefore, we that a single dose of metrifonate would have no effect on the 
memory storage speed and any changes in timing would be produced by long term 
administration. Unexpectedly metrifonate affected timing behaviour in an opposite 
manner by producing an immediate shift to the right with a single administration and 
no effects with sub-chronic administration. It was suggested that effects of metrifonate 
may be observed after several days of administration but should only appear after a 
saline baseline (at least the time to build the representation of reinforced time in the 
reference memory). After a baseline has been established, several days of metrifonate 
administration should induce a modification of the temporal representation. However, 
in previous studies metrifonate has shown to produce a clear difference in behavioural 
performance in the Morris maze escape task on the first day of testing which indicates 
a fast onset of cognition enhancing effects (van der Staay, Hinz & Schmidt, 1996a). 
Scopolamine, a muscarinic antagonist has been shown to impair behaviour in a variety 
of tasks (Buresova et at, 1986; Rush, 1988). In the peak interval procedure it has 
previously been shown to have an effect consistent with an increase in the 
remembered time of reinforcement, thus shifting the peak time to the right (Meck, 
1983). In the present study, Scopolamine (1 mg/kg) produced a decrease in the 
spread which could possibly indicate a more accurate perception of the remembered 
time of reinforcement and an increase in the run rate which could suggest an increase 
in motivation for this timing task indicating a positive rather than a negative effect. 
Cholinesterase inhibition 
A possible explanation could be that the 60 mg/kg dose of metrifonate produced first 
adverse side effects which caused the rightward shift as you would expect of a 
compound to impair the behaviour of the rat in this timing task. Previous studies with 
metrifonate have shown that the beneficial dose of metrifonate for improving cognition 
is between 10-30 mg/kg (Schmidt, 1997). It has been hypothesised that metrifonate 
may possesses a second mechanism of action that is unrelated to cholinesterase 
inhibition. In fact, it has already been shown that there is a discrepancy in the effective 











Effects of Strain or Sub-Chronic Metrifonate in the Two Choice 
Water Escape Task. 
Abstract 
The aim of the present study was to assess the performance of two strains of rat on 
the matching to position (MTP) and non-matching to position (NMPT) two choice 
water escape task. Also studied were the effects of the cholinesterase inhibitor 
(ChEI) metrifonate on the MTP task in order to evaluate the task as to its usefulness 
in identifying and characterising future putative cognition enhancers. 
Both the Hooded Lister and the Harlan Wistar strain acquired the MTP task; with the 
Lister strain having a faster escape latency in the test run. However, there were no 
differences in choice accuracy. Neither strain could learn the NMTP version of the 
task. 
Sub-chronic treatment with metrifonate (60 mg/kg) during MTP training tended to 
increase the escape latency during the test run, though large variances were 
observed within groups. No differences were observed in choice accuracy. To 
attempt to increase the difficulty of the task for the animals the retention interval 
was prolonged from 5 min to 2 hours. No effects due to a longer retention interval 
were observed. However, the longer in the retention interval combined with a 
change in platform position caused a transient performance deficit, with a decrease 
in escape latency in the control group. 
No firm conclusions can be drawn from these results due the large variations within 




Animal studies that involve memory for trial dependent information to make correct 
choices are known as working memory tasks. However the subject normally uses 
both reference and working memory to solve these tasks. (Honig, 1978; Olton et al, 
1979). The subject must use reference memory to retain the reinforcement 
contingency rules and/or general task requirements (win-stay, response alternation, 
matching to object etc. ) that are in effect on all trials and use working memory to 
retain the trial dependent information (all previous choices of a given trial, the last 
response, sample stimulus etc. ) 
To determine effects on working memory rather than reference memory, one must 
train animals to a performance criterion and then test the subjects under conditions 
where the working memory requirements of the task are varied in difficulty. When a 
subject can meet performance criterion when working memory components are 
minimally difficult then the subject has acquired the reference memory components 
of the task. If the animal performs more poorly when the working memory 
components of the task are made more difficult while the reference memory 
components are held constant then the poor performance is probably due to the 
working memory components of the task (Means and Kennard, 1991). The working 
memory requirements of a task can be made more difficult by increasing the 
retention interval (Beatty et al, 1985; Ordy et al, 1988) or by increasing the amount 
of information to be retained (Aggleton et al, 1989) 
Many of these working memory paradigms in rodents such as the radial arm maze 
(Olton and Samuelson, 1976), T- maze spontaneous alternation (Dember and 
Fowler, 1958, Gerlai, 1998), operant go/no-go alternation (Means et al, 1979) or 
operant delayed matching to sample (Dunnett et al, 1988) are appetitively 
controlled. T- maze win-shift or win-stay (Means et al, 1971; Stanton et at, 1984) is 
aversively motivated. 
The water maze, a spatial reference memory task (Morris, 1981; 1984) in which rats 
tend to return on the second trial to the location in which an escape platform has 
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been found on the first trial has been adapted to test explicitly working memory 
(Buresova et al, 1985; Macutus and Murray, 1986). In this variation of the task (see 
Figure 1), the subjects are given trials that consist of two runs: an information run 
and a test run which are separated by a retention interval. The information run 
consists of a forced choice trial during which subjects are forced to the correct 
choice section by closing of the incorrect sections. The test run consists of a free 
choice trial, during which the doors to all choice sections are open. Incorrect first 
choices are punished by detaining the animal in the incorrect choice section for 20s 
or 30 s. 
The task has many advantages of the Morris water maze, in that it involves no food 
or water deprivation which could interact with pharmacological or neural 
manipulations and ultimately alter behaviour that indirectly influence cognitive 
performance scores. Moreover, it appears to be less aversive than shock motivated 
tasks. The task provides a choice measure of performance as well as a latency 
measure. Choice is a better measure of cognitive processes than is response latency 
because choice is influenced less by variables such as age, or neurophysiological 
and pharmacological manipulations that alter motor ability and activity levels 
The task has proven to be sensitive to age (Means and Kennard, 1991), oestrogen 
therapy in ovariectomised females (O'Neal et al, 1990) and gender (Means and 
Dent, 1991). There has also been observed improved performance in animals 
treated with Piracetam and BMY 21502, both putative cognition enhancers. 
The present study is an examination of two different strains of rat on the matching 
to position (MTP) and non-matching to position (NMTP) two choice water escape 
task. It also to determines the effects of sub-chronic metrifonate on the matching to 
position water escape task. Finally, using metrifonate as a reference compound, the 
aim of this study is to evaluate whether the task is useful for assessing putative 
cognition enhancers as therapeutics of AD and other dementia type diseases. 
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9.1: Comparison of the Harlan Wistar and Hooded Lister strain of rat in 
the MTP and NMTP tasks in the two choice water escape maze 
Procedure 
Animals- 10 male Hsd Ola: LH rats and 10 Hsd Cpb: Wu (supplied by Harlan- 
Winkelmann, Borchen) were used. They were approximately 3 months old at the 
beginning of the experiment. Their weights ranged from 220-250 grams. The rats 
were housed in pairs in standard MakrolonTM cages in which food and water was 
continuously available, with a 12: 12 hour light/ dark cycle, lights on at 07.00 am. 
Apparatus and Methods; Cognitive testing took place in a circular white tub 
(material: polyethylene; inner dimensions: diameter 153 cm, depth 63 cm) that was 
filled with clear tap water at a temperature of approximately 22°C. A white 
polyethylene cylinder (diameter 17 cm), placed in the correct choice section, 
submerged 1.5 cm below the surface of the water served as an escape platform. 
Each strain was divided into two groups of five animals of which one group received 
MTP training and the other group received NMTP training. After 22 sessions with the 
NMTP schedule, training in all animals was continued with the MTP schedule. All 
animals received approximately 47 training sessions. 
All subjects were trained in one session per day. Each session consisted of two trials 
during which the escape platform was in the same choice section for MTP task. For 
the NMTP the escape platform was changed to the alternate choice section for the 
second run. Animals began all runs in the same start position that was located at 
the perimeter of the tank directly across from the centre of the top of the ,T divider 
(see figure 1). The first trial was labelled the Information run and the second, the 
Test run. For each run, an animal was released into the water facing the pool wall. 
Choices were forced during the information run i. e., the section not housing the 
escape platform was closed by a sliding panel. After climbing onto the escape 
platform and after staying there for a duration of 10 seconds, the animal was placed 
in a transfer cage during the retention interval, the time between the information 
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and the beginning of the test run. Choices were free for all subjects during Test 
runs; i. e., the sliding panel was positioned so that the subjects could enter either 
the left or right section. If a subject entered an incorrect choice section, the panel 
was closed and the animal was detained for 30 seconds before the panel was 
opened allowing it to swim to the correct choice section. Thus the rats were trained 
with a correction procedure in which incorrect choices were punished by 30 seconds 
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Figure 1. The two choice water escape task. 
An animal was never retained in the incorrect choice section more than once in any 
given trial. A rat was removed from the water after 30 s to avoid reinforcing 
the 
incorrect choice. If an animal failed to reach the platform within 120 seconds, it was 
placed on the platform for 10 seconds by the experimentor. Throughout acquisition 
the retention interval was approximately 5 minutes. 
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Escape latencies (the time of release until the animals reached the platform) were 
recorded and first choice (whole body excluding tail in choice section) was recorded 
on both the information and test run. 
Analysis: The latency to escape to the platform in all animals was assessed with a 
STRAIN*SESSION analysis of variance (ANOVA) with repeated measures over the 
first 10 Daily SESSIONS, supplemented by Duncan's multiple range test post hoc 
comparisons. A difference between groups was considered significant if the p value 
was below 0.05. In addition, the number of trials required to reach criterion (9 out 
of 10 sessions in succession without errors), the number of errors to criterion and 
the number of errors in the first 18 trials was analysed by ANOVA, with factor 
Strain, complemented by Duncan's multiple range post hoc comparisons. Also the 
correct choice escape latencies in the information run and test run of the animals 
that reached criterion was analysed by ANOVA with factor Strain, complemented by 
Duncan's multiple range post hoc comparisons. 
Results 
Experiment 1: Comparison of the MTP and NMPT of the Hooded Lister and Harlan 
Wistar strain of rat in the two choice water escape maze. 
Matching to position: acquisition over the first 10 sessions 
Escape Latency (see figure 2) 
Information run: At the start of training the rats showed a similar level of 
performance (FIRST SESSION: F118 = 0.15, n. s). The average escape latencies of 
the two strains were similar across the training sessions (GENERAL MEAN: F118 = 
1.16, n. s). Over the 10 sessions, both strains decreased their escape latency 
(SESSIONS: F9172 = 7.88, p<0.001). The learning curves were not influenced by 
strain (SESSIONS by STRAIN: F9,72 = 1.02, n. s) 
Test Run: The time to escape onto the platform were all similar at the start of 
training (FIRST SESSION: F1,8 = 0.11, n. s). The two strains of rat had a different 
mean escape latency during the first 10 training sessions (GENERAL MEAN: 
F1,8 = 
6.85. p<0.05), the hooded Lister rats being faster than the Harlan Wistar rats. 
The 




p<0.05). However the speed of learning was not different for the strain (SESSIONS 
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Figure 2: A comparison of Hooded Lister rats (N =5) and Harlan Wistar rats (N =5) on their 
performance in the two choice water escape task during the first 10 sessions of training on the MTP 
schedule. Session means and standard errors of the means (SEM) are depicted for latencies (s) to 
escape onto a platform in the information run (left pane, ) and in the test run (right panel). 
Escape latencies for the correct choice trials (Figure 3): Averaged over the nine 
correct choice trials the escape latency in the information run was lower for the 
Harlan Wistar's than the Hooded Listers (t-test: t8 =23.76, p<0.001). However, in 
the test run there was no difference in escape latency between the two strains (t8 
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Figure 3: A comparison of Hooded Lister rats (N=5) and Harlan Wistar rats 
(N=5) on the performance 
in the two choice water escape task. The mean escape latencies for the nine correct choice 
trials + 




Trials and Errors to Criterion: See figure 4. The two strains required almost identical 
number of trials needed to acquire the criterion of nine correct choices out of ten 
trials (F1,8 = 0.00, n. s). The number of errors to criterion (F119 = 0.02, n. s) and the 
number of errors in the first 18 trials (F1,8 = 0.06, n. s) was also very similar 
























Figure 4: A comparison of Hooded Lister rats (N =5) and Harlan Wistar rats (N =5) on the 
performance in the two choice water escape task. The mean number of trials required + SEM (left 
pane. The mean number of errors to reach criterion +SEM and the number of errors in the first 18 
trials (right pane/). 
Non Matching to , position 
Escape Latency (see figure 5) 
Information run: At the start of training the rats showed a similar level of 
performance (FIRST SESSION: F118 = 1.36, n. s). The escape latencies of the two 
strains were, on average similar during the course of training (GENERAL MEAN: F118 
= 1.71, n. s). In the course of training, both strains reduce their escape latencies 
(SESSIONS: F9,72 = 13.43, p<0.001). This was not influenced by strain (SESSIONS 
by STRAIN: F9,72 = 1.78, n. s) 
Test Run: The time to escape onto the platform were all similar at the start of 
training (FIRST SESSION: F1,8 = 0.11, n. s). The escape latencies of the two strains 
were, on average similar during the course of training (GENERAL MEAN: F1,8= 
6.85, p<0.05). 
A: - Number of Errors To Criterion 
B: - Number of errors in the tust 18 trials 
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Over 10 sessions the escape latency during the test run did decrease only slightly 
(SESSIONS: F9172= 1.76, p<0.05) and this decrease was similar for both strains 















Figure 5: A comparison of Hooded Lister rats (N =5) and Harlan Wistar rats (N =5) on the 
performance in the two choice water escape task during the first 10 sessions of training of NMTP. 
Session means and standard errors of the means (SEM) are depicted for latencies (s) to escape onto a 
platform in the information run (left pane, ) and in the test run (right panel). 
Trias and Errors to Criterion: Neither the Hooded Lister nor the Harlan Wistar 
strains reached a criterion of nine correct choices out of ten sessions in the non- 
matching to position two choice water escape task within 21 training sessions (Data 
not shown). This was the reason for discontinuing training on the NMTP schedule. 
9.2: The effects of Sub- Chronic metrifonate treatment in the hooded 
Lister rat in MTP in the two choice water escape task 
Animals: 35 male HsdOla: LH rats (supplied by Harlan- Winkelmann, Borchen) were 
used. They were approximately 10 weeks old at the beginning of the experiment. 
Their weights ranged from 220-250 grams. The rats were housed in groups of two 
in standard MakrolonTM cages in which food and water was continuously available, 




Drug Administration: Rats were treated orally once daily with 30 (N=9), 60 (N=7) or 
100 (N=9) mg/kg Metrifonate in an application volume of 5 ml/kg from day one of 
training. Controls (N= 10) received the vehicle Sodium citrate buffer, pH 5.5 under 
identical conditions. Metrifonate was administered 30 minutes prior to the start of 
the session. 
Apparatus: Apparatus and methods are as described in experiment 1 with the 
exception than only MTP was studied and that the retention interval was prolonged 
from 5 minutes to 2 hours after the animals had reached criterion 
Analysis: The latency to escape to the platform latencies in the information run and 
test run was assessed with a TREATMENT*SESSION analysis of variance (ANOVA) 
with repeated measures over 5 Daily SESSIONS, supplemented by Fischer's Least 
Significant Difference (LSD) post hoc comparisons. A difference between groups 
was considered significant if the p value was below 0.05. The number of trials 
required to reach criterion (7 out of 8 training sessions without errors) and the 
number of errors to criterion was analysed by ANOVA, with factor treatment 
complemented by Fischer's LSD post hoc comparisons. The correct choice escape 
latencies in the information run and test run of the animals that reached criterion 
was analysed by ANOVA, with factor treatment complemented by Fischer's LSD post 
hoc comparisons. Also to determine the effects of prolonging the retention interval, 
the escape latencies of the test run was analysed by ANOVA with factor treatment 
with repeated measures over sessions. Session 1 was the final day with a5 min 
retention interval. In session 2 is the day at which the retention interval was 
prolonged to 2 hours. In session three, the retention interval remains at 2 hours and 
the platform position is changed from left to right and session 4 and 5 is with a2 
hour retention interval and the platform position on the right side of the maze. 
Results 
Escape Latency 
Information run: At the start of training the groups of rats showed a different level 
of performance (F3131 = 10.46, p<0.05). Averaged over the first 5 sessions, 
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metrifonate influenced on the escape latency (GENERAL MEAN: F3331 = 2.62, 
p<0.05). Post hoc analysis by Fischer's LSD revealed that 60 mg/kg Metrifonate 
had, on average, a shorter platform escape latency than the vehicle treated group. 
The escape latencies of metrifonate treated groups generally decreased during the 
course of training (SESSIONS: F4,124 = 11.31, p<0.001) and this decrease was 
influenced by metrifonate treatment (SESSIONS by TREATMENT: F12,124 = 4.16, 
p<0.001). 
Test Run: The time to escape onto the platform were slightly different at the start 
of training (First Session: F3,31 = 3.66, p<0.05). The average escape latencies were 
not affected by metrifonate treatment (GENERAL MEAN: F3,31 = 0.30, n. s). Post hoc 
analysis by Fischer's LSD revealed that 60 mg/kg Metrifonate had a shorter platform 
escape latency than compared to the vehicle treated animals. Across the 5 sessions 
the escape latencies became shorter (SESSIONS: F4,124= 7.65, p<0.001). The 
decrease of escape latencies was affected by metrifonate treatment (SESSIONS by 
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Figure 6: The effects of metrifonate (30,60 and 100 mg/kg) in Hooded Lister rats on the performance 
in the two choice water escape task during the first 5 sessions of training of MTP. Session means and 
standard errors of the means (SEM) are depicted for latencies (s) to escape onto a platform 
in the 





Escape latencies for the correct choice trials: (See figure 7). 
Averaged over the seven correct choice trials of animals that had reached criterion, 
the escape latency in the information run was not affected by metrifonate (F3,31 
=0.62, n. s). However, in the test run there were differences in escape latency 
between the metrifonate treated groups (F3131= 3.53, p<0.05). Post hoc analysis by 
Fischer's LSD revealed that the 30 and 60 mg/kg treated group had a longer escape 
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Figure 7: The effects of Metrifonate (30,60 and 100 mg/kg) on the performance in the two choice 
water escape task. The mean escape latencies for the correct choice trials ± SEM in both the 
information and test runs. 
Trials and Errors to Criterion: All groups required almost identical number of trials 
needed to acquire the criterion of seven correct choices out of eight trials (F3,31 = 
0.40, n. s). The number of errors to the criterion (F3,31= 0.27, n. s) was also very 
similar between metrifonate treated groups (Data not shown). 
Retention interval 
Test Run. (See figure 8). On the final day of training with a retention interval of 5 
min (Session 1) there was a similar escape latency in the test run 
between all 
groups (F3,31 =1.11, n. s) and this was also observed on the 
first day (Session 2) of a 
retention interval of 2 hours. (F3,31 =1.11, n. s). However 
the escape latencies 
developed differently between groups (SESSIONS: (F4,12 =4.97, p<0.05) and this 
was affected by metrifonate treatment (SESSION 
by TREATMENT (F4,112 =2.83, 
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p<0.05). Changing the platform position from left to right in the third session, in 
addition to prolonging the retention interval, affected the performance (F3331 
=3.43, p<0.05). Post hoc analysis revealed that the vehicle control group had a 
longer escape latency than the three metrifonate treated groups, which did not 
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Figure 8: Effects of metrifonate (30,60 and 100 mg/kg) on the test run platform escape latency. 
Session 1: the final retention Interval of 5 minutes. Session 2: prolonging the retention interval to 2 
hours. Session 3: Changing the platform position from left to right with a retention interval of 2 hour. 
Sessions 4 and 5: the platform position staying in the right position with a2 hour retention interval. 
Results are ± SEM, N= 7-10. 
Discussion 
The aim of the present study was to compare the efficiency of two strains of rat in 
acquiring either the matching to position (MTP) and non matching to position 
(NMTP) two-choice water escape task and to determine the effects of metrifonate, a 
cholinesterase inhibitor in one of these strains on the matching to position water 
escape task. 
Strain Comparison 
The results show that both the hooded Lister's and the Harlan Wistar strain of rat 
acquired the working memory matching to position (MTP), and that the hooded 
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Listers had a faster escape latency in the test run. They did not; however make 
fewer mistakes to the choice section compared to the Harlan Wistar's suggesting 
that both strains had a similar ability to retain the correct escape choice over the 5 
min retention interval. 
Neither strain could acquire the non matching to position (NMPT) task and it was 
observed that both strains were faster to the platform in the test run and 
information run in MTP compared to NMTP (data not shown). It was also observed 
that when the animals changed over to the MTP from NMTP task after 21 sessions 
there was no further improvement in learning the MTP task and that they performed 
worse than animals that had been trained on the MTP directly (Data not shown). 
Sub chronic metrifonate administration. 
In this study the group of rats treated sub-chronically with metrifonate (60 mg/kg) 
had a shorter escape latency than the vehicle treated group in the information run. 
However, no effects of metrifonate were observed in the test run. Also, as with the 
strain comparison, there was no difference for the number of trials or the number of 
errors to criterion. 
All animals performed with 80-100 percent accuracy during criterion trials that 
involved a 5-minute retention interval (RI). This accuracy remained with the 
introduction of a retention interval of 2 hours (Data not shown). There were also no 
changes in escape latencies between treatment groups. However when the platform 
position was changed from left to right before the information run of a session, the 
percent accuracy of the vehicle treated animals was reduced to 30%. In conjunction 
to this there was a large increase in the escape latency. The metrifonate treated 
groups showed no changes in either the percent accuracy or escape latency. This 
suggests a transient impairment in the vehicle group when two parameters are 
changed: RI and platform position. When only one of these two procedural changes 
was introduced, no impairments were observed. 
A final observation in both experiments was that though the Hooded Listers were 
faster to escape onto the platform in all test trials, the escape latency was lower 
for 
the Harlan Wistar's when only the correct choice trials was considered. This was 
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also observed with the groups treated with 30 and 60 mg/kg metrifonate. Perhaps 
the animals take more time to make the correct choice. 
Discussion of task 
Collectively, both experiments showed that the most natural response of the rats 
given pairs of trials is to follow the same path for every trial. The animals appear to 
be using a strategy in which the immediately preceding trial is used to the extent 
that it influences the collective memory of all proceeding trials. They also adopt a 
course that takes them to the escape platform in a relatively short time. The first 
experiment showed that the animals could not learn a non-matching position 
strategy in the water maze. 
The delayed matching procedures have several advantages over other paradigms 
frequently used to study mnenomic processes in animals, such as shock motivated 
avoidance procedures. They can allow selection of a clearly defined element of 
behaviour that can be studied by specific task variables. In this two choice water 
escape task three different aspects of behaviour can be studied. 
Escape latency can be used to determine changes in reference memory. The subject 
must use reference memory to retain the reinforcement contingency rule (win-stay, 
response alternation, matching to sample etc. ) that is in effect on all trials. Another 
dependent variable of interest is response accuracy. Changes in response accuracy 
are thought to reflect changes in non-mnenomic processes such as motivation, 
attention and /or motor processes (van Hess, et al, 1996) 
Finally, to determine effects on working memory rather than reference memory, one 
must train animals to a performance criterion and then test the subjects under 
conditions where the working memory requirements of the task are varied in 
difficulty. The working memory requirements of a task can be made more difficult 
by increasing the retention interval (Beatty et al, 1985; Ordy et al, 1988). 
These variables can allow dissociation between mnemonic effects and other factors 
that may alter performance. However, in this study changes were only observed in 
142 
CHAPTER 9 
reference memory (escape latency) with no changes in choice accuracy (attention) 
and only a transient change in working memory in the vehicle treated group when 2 
parameters are changed together i. e. RI and platform position. Also the task has 
some disadvantages in that training the animals to stable baseline performance is 
time consuming and ceiling effects are critical for interpretation of data, particularly 
where the animals escape latency is already fast and accuracy is at a high level. The 
effects of metrifonate did not show any cognition enhancing properties, which have 
been observed in previous behavioural experiments (van der Staay et al, 1996). 
From this study we are unable to evaluate the effectiveness of this task for 
assessing future cognition enhancers. Further study is required, for example by 
introducing changing RI earlier during training or possible by inducing 






SUMMARY AND CONCLUSIONS 
Introduction 
Animal tests of cognitive function have the potential to assist in drug discovery both 
directly as screening procedures, and indirectly through their fundamental role in 
the investigation of the neurochemical basis of cognition. 
The cholinergic system is thought to be the primary system involved in learning and 
memory. Alzheimer's disease (AD) is a chronic neurodegenerative disorder 
characterised by a progressive decline in cognitive function, including loss of 
memory and changes in behaviour. The causes of the disease are as yet unknown. 
However, central cholinergic hypofunction is thought to be a major component of 
the disease (Bartus eta/, 1982). Several lines of evidence support this notion that a 
loss of cholinergic function contributes to the cognitive deficits seen in AD (Bierer, et 
a/, 1995). The most successful of these strategies at this time is to increase the 
amount of acetylcholine by reducing its degradation by cholinesterase inhibitors 
(ChEI's). 
Metrifonate is a second generation of cholinesterase inhibitors currently available 
(See chapter 1). Firstly, we looked at further biochemistry of metrifonate to 
determine how the compound develops tolerance and whether this is a central or 
peripheral phenomenon. The aim of this study to confirm the behavioural effects of 
metrifonate, serving as a reference cognition enhancer in known behavioural models 
in the rat and second to determine these effects in another species i. e. the mouse. 
The third aim was the assessment of new methods which allow to test and 
characterise future cognition enhancers using the reference compounds. 
Summary of Results 
In chapters 2 and 3 the biochemical activity of metrifonate was further 
characterised, specifically in relation to the development of tolerance after repeated 
exposure to the compound. With administration of central or peripherally acting 
cholinergic compounds to animals pre-treated with metrifonate it was found that the 
development of tolerance is a centrally acting phenomenon and specifically related 
to the cholinesterase molecule. Further study on the gene expression of 
acetylcholinesterase and butyrylcholinesterase showed that there is a two fold up 
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regulation of the gene increasing the amount the these two proteins. However, 
there is reported to be no changes in acquisition in retention of behavioural tasks. 
A second mechanism of action for metrifonate was suggested and recent reports 
have revealed a high selectivity of metrifonate for the substance acylpeptide 
hydrolase (ACPH, Richards etal, 2000; Richards eta/, 1999). The in vitro sensitivity 
of DDVP (Metrifonate active metabolite) for ACPH is about 7 times greater than for 
AChE, a higher sensitivity has also been confirmed in vivo. When 47% inhibition of 
AChE is obtained by DDVP treatment, ACPH is nearly totally inhibited i. e. to 93% 
(Richards et a/, 2000). ACPH is a peptidase and not an esterase like AChE, which 
broaden the range of mechanism of organophosphorous ChEI. 
The enzyme catalyses the hydrolysis of N-acetylated amino acids from short 
peptides to form an acylamino acid and a peptide with a free NH2-terminus. 
Preference for N-acetyl-methionyl-, alanyl-, glycyl-, and seryl-containing peptides 
(common N-terminal residues for cystosolic proteins) has led to the suggestion that 
the enzyme is important in protein catabolism or removal of N-acylated amino acids 
from nascent polypeptide chain emerging from the ribosome (Raphel etal, 1999). 
The role of ACPH in neuropeptide turnover had been put forward as a new and 
plausible mechanism for the cognitive-enhancing effects of certain 
organophosphorous compounds (Ray etal, 1998). However, further research in this 
direction was inconclusive (unpublished results). 
In chapter 4, the effects of the cholinesterase inhibitor metrifonate was observed 
after either chronic or acute administration in the passive avoidance task which is 
commonly used as a fast screening tool. Acute metrifonate had no effect on the 
performance deficits in the retention session. The chronic study (experiment 4.2. ) 
demonstrated that the reference compound effectively inhibited the scopolamine- 
induced deficit. Although the cholinesterase inhibitor was effective in antagonising 
the scopolamine induced deficits, it was concluded that a single test cannot be 
sufficient to determine the full cognitive enhancing properties of the reference 




Chapter 5 studied the effects of sub-chronic metrifonate in neurologically normal 
rats in the standard Morris water escape task. The compound improved spatial 
memory. Previous studies with metrifonate have shown cognitive improvement in 
various animal models (Blokiand eta/, 1995; van der Staay etal, 1996; Kronforst et 
a/ 1997) after subchronic administration. One explanation for the negative findings 
was that the performance of the rats in this study may have imposed a ceiling effect 
(i. e. the rats had reached maximum performance levels) any and therefore changes 
in behaviour was masked. Administration of acute metrifonate in neurologically 
normal mice also did not improve spatial reference memory, however sub chronic 
administration (30 mg/kg) showed beneficial effects: metrifonate treated mice 
escaped to the platform faster than the vehicle treated control group. 
An important point of this chapter is that compounds that improve memory may not 
necessarily improve performance in neurologically normal animals and therefore to 
further assess the effects of cholinesterase inhibitors was considered necessary to 
use animals that have a cholinergic hypofunction. 
In chapter 6, we investigated the effects of acute treatment of metrifonate on water 
maze navigation in mice with scopolamine-induced amnesia. Metrifonate had no 
ameliorating effects on the deficit induced by scopolamine. The unsuccessful use of 
metrifonate in ameliorating a scopolamine induced deficit possibily indicated that 
pharmacokinetic interactions between scopolamine and future, unknown cognition 
enhancers may interfere with behavioural observations. It was suggested that the 
alternative is excitotoxic lesions, which can be aimed to more specific regions of the 
brain involved in learning and memory rather than the general effect of scopolamine 
In chapter 7 metrifonate was assessed on spatial performance of rats with bilateral 
lesions of the entorhinal cortex (EC). Treatment with metrifonate (30 mg/kg) in rats 
with bilateral EC lesions improved performance in the spatial discrimination task 
compared with that of the sham lesioned control group. The present experiments 
indicate that under conditions of pathological impairment of brain structures such as 




In chapter 8, the Peak interval procedure was used to assess the effects of the 
ChEI's on time estimation. A single administration Metrifonate (60 mg/kg), shifted 
the peak time to the right, indicating an impairment in time estimation. This could 
have been due to unobservable adverse side effects. Sub-chronic administration of 
metrifonate had no effect on time estimation. 
In chapter 9, we investigated the differences between two strains of rat and the 
effects of sub chronic metrifonate treatment in the two choice water escape task. 
Both the Hooded Lister and the Harlan Wistar rats acquired the matching to position 
task, with the Lister strain being faster in escaping onto the platform. However 
there was no difference in choice accuracy and neither strain could learn the non- 
matching to position version of the task. Sub chronic metrifonate treatment (60 
mg/kg) increased the escape latency to reach the platform. However there was no 
difference in choice accuracy. Extending the retention interval from 5 min to 2 hours 
had no effects. No specific conclusion could be drawn as to the effectiveness of this 
task in assessing future cognition enhancers. Further study is required with the 
inclusion of deficits earlier in the training and/or the inducement of scopolamine or 
lesion deficits. 
Evaluation of the tasks used 
When using animals to model the behavioural impairments of humans, the choice of 
task and manipulation are of considerable importance. The tasks discussed below 
cover relevant aspects of information processing. Their value for characterising 
cognitive impairments and evaluating putative cognition enhancers is discussed 
below. 
Passive A voidance task 
The passive avoidance task is considered to be a fast screening tool (Iversen, 
1997). However, as discussed in chapter 2, the validity of this task is extremely low. 
Though mnemonic processes are affected in this task, there are also effects on 
stress, anxiety, emotionality, changes in motivation, and in arousal 
levels etc (van 
Dijken, 1992). Compounds, which give positive results in this task, do not 
necessarily improve cognition in other, more complex tasks. 
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With the passive avoidance task, changes in the latency to enter the dark 
compartment in the retention session are considered to be a measure of retention 
performance. Long latencies are interpreted as reflecting good retention 
performance and short latencies are indicative of poor retention or possibly 
amnesia. However, in experiment 2.1 in chapter 2, metrifonate had no effect on the 
latency to enter the dark compartment, though it did increase the amount of time 
spent in the light compartment. As previous studies have shown positive effects 
with metrifonate (Riekkinen et a/ 1996; Itoh, eta/, 1997), it might be useful to look 
at the time spent in the light compartment during the retention session as an 
additional index of retention. For example, the animals might have entered the dark 
compartment fast due to increased arousal (the apparatus has been associated with 
the aversive event of a foot shock). Then, however, the animal immediately escaped 
from the dark to stay mostly in the light. I. e. there might have been recognition of 
the dark compartment, followed by escape, and avoidance of the compartment. 
Morris water escape task 
Spatial discrimination tasks in mazes, most commonly the Morris water maze are 
among the most frequently used tests to detect potential cognition enhancers and 
to assess their potency (Merlini et a/, 1989; Andrews, 1996). An advantage of the 
Morris water escape task is that no food deprivation is necessary for motivating the 
animals to solve the task. However, other aspects of the task have received 
criticism. One of the main disadvantages of the test (Block, 1999; Stewart and 
Morris, 1993 and Wenk, 1998), is that it requires the tested animals to flight from 
an aversive environment seemingly devoid of escape routes. The immersion of the 
animals into the water and the initial sensation of being trapped in it may cause 
considerable stress during the first stages of the test. Although Stewart and Morris 
(1993) have argued that stress would be minimal at reasonable water temperatures. 
To reduce this kind of interference, the use of a short adaptation procedure to 
accustom the animals to immersion in water has been recommended. 
The escape latency is the most used parameter for assessing water maze behaviour. 
However, this measure is dependent on the speed in which the animal negotiates 
the maze. Other aspects need to be measured to determine the affects of possible 




experimental manipulation, the distance swum before escaping onto the platform is 
a more useful measure of spatial navigation performance. Looking at search 
patterns/strategies of the animals would provide additional relevant information 
about the effects of compounds on spatial navigation performance (Whishaw, 1985; 
Lipp and Wolfer, 2000). 
This was observed in chapter 6 where scopolamine induced deficits caused 
thigmotaxis, or wall hugging behaviour. The chance of finding the platform in the 
water tank decreases with increasing thigmotaxic behaviour, because the animal 
does not negotiate the maze (Paylor et al, 1990; Whishaw et al, 1987; Cain and 
Saucier , 1996). 
The MWM test is one of the most frequently used research tools The test has a 
number of advantages, and has been used in such an impressive variety of 
applications that it might also rank as one of the best assays for spatial learning and 
memory in laboratory rodents. its disadvantages and limitations, however should be 
recognized as well, and researchers should continue to look for new and better 
alternatives 
Timing behaviour 
The timing discrimination performance in the Skinnerbox was suggested to be a tool 
to test cognition enhancing properties of new therapeutics. The timing behaviour 
can be assessed by a peak interval procedure (see chapter 8). Rats are trained to 
respond to a discrete fixed interval (FI) procedure in which a lever is presented and 
the animal is free to respond at any time, but only the first response after a fixed 
duration (e. g. 20 seconds) is reinforced. In the peak interval (PI) procedure some 
trials are identical to the FI procedure where others consist of the lever presented 
for a ti me that goes beyond the fixed duration (e. g. 50 seconds in our experiments, 
and typically at least twice plus a random duration of the fixed interval) and no 
reinforcement is given (Catania, 1970; Roberts, 1981; Church, etal, 1991). 
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The maximal response rate can shift to a longer or shorter interval as a 
consequence of experimental manipulations (e. g. choline, Meck and Church, 1987a; 
physostigmine, Meck and Church, 1987b; Scopolamine, Meck, 1983). Cognition 
enhancers are expected to shift the peak time to the left, reflecting a change in time 
estimation. However, our study could not conclude as to the effectiveness of this 
paradigm. Training is lengthy, thus as a screening tool, the throughput of testing 
compounds on the acquisition of the timing task is low. Also, data analysis is 
relatively complex and results are difficult to interpret. 
The timing task could be used to further evaluate compounds rather than as an 
initial screening paradigm, it could be used in conjunction with other behavioural 
paradigms. It might help to further characterise compounds, which are supposed to 
improve cognition. 
Two choice water escape task 
The Two choice water escape task is an extension of the standard Morris water 
escape task in which the animals have to choose as to which section of the maze to 
enter in order to reach a platform (see chapter 9). The task itself has great potential 
in that it can measure three different aspects of performance. Reference memory 
can be measured by the escape latency that is in effect on all trials as this reflects 
that the animal has learned that it can swim to a platform to escape from the water. 
Changes in response accuracy are thought to reflect changes in non-mnemonic 
processes such as motivation, attention and /or motor processes but also in 
reference memory (van Hest, et a/, 1996). Finally, the effects on working memory, 
by introducing increasing difficulties in the task, i. e. by increasing the retention 
interval. 
However, performing this task I found that training the animals to stable baseline 
performance is time consuming. Only changes in reference memory were observed. 
This does not preclude that the task is not effective in assessing future cognitive 
enhancers; it does suggest further work is required. For example, the use of 
reference compounds other than metrifonate is required and the effects of 
introducing deficits by scopolamine or by selective brain lesions need also to be 
studied. Previous studies with bilateral lesions of the hippocampal formation 
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produced deficits, with the rats, taking longer and swimming farther to find the 
platform on the test swims (Glen and Mumby, 1998), i. e. the task appears to 
depend on normal hippocampal functioning, 
Evaluation of the animal mode/5 used 
Animal models remain the main tool to characterise compounds that can be used as 
therapeutics in the treatment of behavioural deficits caused by disease (Sarter eta/, 
1992; Allain, 1997). The focus of animal models of AD has been on identifying the 
areas of the brain and neurotransmitter systems thought to be involved with 
memory. The cholinergic system has received the most attention, because of 
studies showing degradation of the basal forebrain cholinergic system in AD (see 
chapter 1). 
Normal animals as models of cognitive deficits and/or AD 
Normal animals present no observable behavioural deficits, and cognitive effects of 
a compound may be masked due to the restricted range of potential of 
performance. i. e. a ceiling or floor effect in the test used. If no effects are observed 
in normal animals, the compound might still ameliorate cognitive impairments in 
patients (Decker, 1995). However, it is important to determine as to whether that 
particular strain or species has underlying, undetectable deficiencies. The most 
important point is that compounds which improve cognitive function in normal 
animals may be classed as cognitive enhancers. However, because there are no 
clinical symptoms of AD in these animals, the potential of a compound as disease 
modifiers remains unknown. 
Animals with Scopolamine-induced performance deficits as a model for AD 
The most widely used model of the memory impairment of AD is the administration 
of the muscarinic antagonist, scopolamine, which has been shown to interfere with 
learning and memory in humans (Beatty et at., 1986) and experimental animals 
(Stevens, 1981; Sutherland, 1982). In this study, scopolamine was shown to induce 
deficits in the passive avoidance task in rats (chapter 4), and the Morris water 
escape task (chapter 5) in mice. 
Although scopolamine appears to be an effective tool in producing deficits on tests 
of memory, it also acts on central and peripheral sites of autonomic and motor 
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control. In addition, the cholinergic system is probably involved in psychological 
processes other than memory that may affect performance on tasks that we infer as 
memory (Fibiger, 1991; Fibiger et al, 1991). Effects on acquisition might be 
reflection of disrupted attentional processes (Cheal, 1981) or information 
processing. The various actions of scopolamine must be considered when 
attempting to interpret its behavioural effects. 
The effects of scopolamine on a variety of tasks are robust and reproducible. 
However, there are differences between the scopolamine model and the symptoms 
of Alzheimer's disease. The impairments are induced by post-synaptic blockade 
rather than by pre-synaptic destruction of cholinergic neurons, whereas in the case 
of AD this is largely a pre-synaptic degenerative phenomenon (Decker, 1995). 
Animals with lesions as a model for AD 
Degeneration of the basal forebrain cholinergic neurons occurs early in the course 
of AD and is correlated with cognitive deficits (Coyle et al.., 1983; Winkler et al., 
1998). Cholinergic lesion paradigms have been used to study the role of the 
cholinergic system in cognitive function (Nabeshima, 1993; McDonald ant Overmier, 
1998). Many types of acute manipulations, including electrocoagulation, use of 
excitotoxins, transection of the fimbria fornix and treatment with cholinotoxin, 
AF64A have been applied to reduce cholinergic activity. 
Although none of these animal models shows the neuropathological characteristics, 
such as senile plaques and NFT (see chapter 1), found in the brains of patients with 
AD, they have been widely used for assessing the validity of therapeutic 
interventions with cholinergic drugs (Murray and Fibiger, 1986; Itoh etal., 1997). 
Early work directed at lesioning the cholinergic neurons focused 
largely on the use 
of ibotenic acid to destroy cholinergic neurons of the nucleus 
basalis magoncellularis 
(NBM). Lesions of the NBM cause deficits on a broad range of tasks including 
passive avoidance (Matsuoka et al, 1992; Yamamoto et al, 
1993; Yamamoto et al, 
1994) and object discrimination learning (Ridley eta/, 1985). 
Acquisition of a Morris 




Another area primarily focused upon lesions of the medial septal area (MS) that is 
located caudal to the NBM (McKinney et at, 1983). Like lesions of the NBM, lesions 
of the MS impair performance in some tests of memory (Decker at al, 1991; 
Miyamoto et al, 1987). The MS provides cholinergic input to the hippocampus 
(Amaral et a/, 1985). These fibres from the medial septum and also the diagonal 
band of Broca reach the hippocampus via the fimbria fornix pathway and perforant 
pathway. It is commonly believed that the hippocampus is a central component of 
the memory related neural system (O'Keefe et al, 1978; Olton et at, 1979, 
Eichenbaum, 1992). 
The hippocampal formation (which includes the hippocampus proper, the entorhinal 
cortex and the subiculum Amaral etat, 1989) is thought to be the site of initiation of 
Alzheimer's pathology. 
Like all commonly used models of AD, lesions of the hippocampus readily produce 
deficits in many tasks, such as acquisition and performance on the Morris water task 
(Maier et a/, 1990; Sutherland et a/, 1986) and retention of passive avoidance 
(Olton, 1973). Hippocampal deafferentiation by damage to the entorhinal cortex can 
also cause cognitive dysfunctions (Rasmussen et a/, 1989; Fugger et a/, 1997; 
Eijkenboom et at 2000). A role for the entorhinal cortex in modelling AD was based 
on post mortem studies, which revealed that at a very early stage of the disease the 
E. C. in the brains of Alzheimer's patients showed signs of degeneration and the 
extent of the degeneration was correlated with the memory deficits present during 
the early stage of AD (Hyman et at Braak and Braak, 1991). In rats, bilateral 
damage to the E. C. resulted in learning and memory deficits due to disturbed 
hippocampal functioning (Rasmussen et al, 1989) and previous studies have shown 
that this deficit is sensitive to pharmacological enhancement, i. e. by aniracetam, an 
AMPA receptor agonist (Zajaczkowski, 1997) and memantine, an NMDA receptor 
antagonist. This thesis has shown EC lesions produce deficits in the Morris water 
escape task and can be alleviated by treatment with ChEI's. 
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Strain and Species comparisons 
A comparative approach in which one or more species is considered is necessary for 
the decision to either reject or accept a specific model. This study looked at 2 
different species of rodent to determine the effects of the cholinesterase inhibitors. 
Some rat or mouse strains are more successful in certain tasks than others. Housing 
conditions, diet, biological rhythms, stress, route of administration, strain, age, 
handling and training parameters to name only a few can influence data 
significantly. Strain dependent effects may account for many conflicting results in 
the literature concerning cognitive performance (Andrews, 1996). Strains can differ 
in their pharmacodynamic and pharmacokinetic properties, which could possibly 
affect the outcome of the drug effects on behaviour. Therefore, well-defined, inbred 
strains can increase the reproducibility and predictability of results. Also, the 
environment in which strains are bred and kept must be highly standardised along 
with the testing area and procedure (Andrews, 1996) and the age at which the 
testing is performed (Meier, 1964). 
Different strains must first be identified to be able to evaluate their influence on 
cognitive performance and drug evaluation. Small differences between strains were 
observed in the rat in chapter 9. The Hooded lister and the Harlan Wistar were 
compared in the two choice water escape task and it was found that the Hooded 
lister had faster escape latency. Because this is a measure of reference memory it is 
important to take into account this difference when doing further studies on spatial 
reference memory. 
The reference compound 
The compound used in this study was the second generation cholinesterase 
inhibitors metrifonate (See chapter 1). Previous work with metrifonate has shown 
that the compound to be an effective cognition enhancer in various animal models 
(Schmidt et al, 1997) and in patients with mild to moderate AD (Raskind et al, 
1999; Gelina et al, 2000). During the course of this thesis, it was noticed that 
metrifonate produced very little effects in enhancing cognition in the tasks studied; 




The previously reported optimum dose range for metrifonate to produce positive 
effects on learning and memory was 10-30mg/Kg (van der Staay et al, 1996a), and 
particularly an effective dose was 12.5mg/kg (van der Staay et al, 1996b), however 
in this study, if positive results in the behavioural tasks were obtained, the optimum 
dose range was 30-60mg/kg. Another study had used a broad dose range, i. e. 10- 
100mg/kg (Riekkinen et al, 1996) and had positive effects even with the higher 
dose range of 100mg/kg, with no suggestion of cholinergic side effects. 
A previous report by van der Staay (1997) found that the performance of the Wistar 
strain of rat has shifted towards a poorer performance in the Morris water maze 
over a period of 71 weeks. This was conducted on aged (24 month old) rats, 
however it is likely that this shift in performance may also occur in young rats. In 
the van der Staay study it suggested a possible reason for the changes in 
performance between the two experiments could be due to genetic drift between 
the two different shipments of animals. Also, the possibility of biological variability 
or differences in sensitivity of the rats to the treatment with metrifonate could 
explain that a previous study found no impairments with the 100mg/kg dose 
whereas in this study it occurred regularly. This might suggest a narrowing of the 
therapeutic index of metrifonate in this strain of rat as well as a shift from the lower 
dose being optimum to a higher dose range. 
Because of the inconsistent results of metrifonate in this study and because its 
clinical development has been discontinued, it is advisable to use other reference 
compounds. The compounds that could be used for future studies include donepezil 
or rivastigmine. 
Rivastigmine (Exelon, ENA 713) is a phenyl-carbamate derivative with a centrally- 
acting and long lasting anti-acetylcholinesterase activity. In the rat, rivastigmine 
acts principally in the hippocampus and the cortex. It has been shown to improve 
the performance of scopolamine- treated and basal forebrain- lesioned rats, in the 
Morris water escape task and the step down avoidance task (Enz et a/, 1989; 
Niigawa et a/, 1995). This compound has been shown to be effective in patients 
with mild to moderate AD in a number of clinical trials (Corey-Bloom et a/, 
1998; 
Rösler etal, 1999) and is currently available in some European countries. 
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Donepezil (Aricept, E2020) is a piperidine compound that is a centrally acting 
cholinesterase inhibitor. Pharmacological studies in vivo and in vitro have shown 
that the compound acts reversibly and non-competitively (Rogers eta/, 1991) with a 
high selectivity for acetylcholinesterase (>1250) over butyryicholinesterase 
(Sherman, 1991). It produces long lasting brain acetylcholinesterase inhibition and 
increases the brain content of ACh in vivo (Yamanishi, eta/, 1988). Donepezil has a 
long half-life of 70 hours, producing a steady state of inhibition after once daily 
administration within 14-21 days in humans (Rogers et al, 1998a and 1998b). This 
compound has been shown to be effective in patients with mild to moderate AD in a 
number of clinical trials (Rogers eta/, 1998a and 1998b; Giacobini, 2000). In animal 
studies donepezil improved performance in the 8-arm radial maze in scopolamine 
treated rats and in rats with lesions of the nucleus basalis magnocellularis (nbm; 
see Rogers eta/, 1991). 
A reference compound needs to be effective across tasks, models and species. The 
cognitive enhancing properties of rivastigmine and donepezil have been observed in 
previous work (Enz et al, 1989; Niigawa et al, 1995; Rogers et a/, 1991) and it is 
recommended these compounds are assessed as metrifonate has been in this thesis 
to determine its their effectiveness as reference compounds so that they can be 
used assess future models for AD 
General considerations 
D'Mello and Stecker (1996) introduced points that are needed to be considered 
when choosing an animal model and to assist in the design of new and improved 
animal model. Some of these features are discussed in reference to the experiments 
completed in this thesis. 
" Paradigms need to be selected that are suitable for testing two or more 
species. Rodents are particularly well suited for cognition and ageing 
research, which is comparable to that of humans (Steckler & Muir, 1996). 
The comparative approach between species, for example the rat and the 
mouse help determine more about brain function and behaviour in order to 
extrapolate to the human. In this thesis the standard Morris water escape 
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task was used for the rat and the mouse (See chapter 5). The passive 
avoidance task (chapter 4) and the Two Choice water escape task (chapter 
9) can also be adapted for the two species. It is also important to determine 
the efficacy on compounds in relation to different species, in the same task. 
" Train a performance baseline that is neither too high or two low as drug or 
lesion induced changes in performance may be confounded by ceiling or 
floor effects. This was observed in normal animals in the Morris water 
escape task in chapter 5 in both experiment 1 and 2. 
Select two or more paradigms each thought to measure the same cognitive 
process. This provides and estimate of the construct validity (See chapter 1) 
of an experimental approach, for example Morris water escape task (Chapter 
3-5) and the Two Choice water Escape task (chapter 9) which both look at 
spatial navigation. However, it is important to determine as to whether the 
tasks use the same memory processes. 
" Test a number of doses that range from just no effect to reliable motor 
disruption. This helps validate data that have no observable effects on motor 
function. i. e. in chapter 3,10 30 or 60 mg/kg metrifonate were administered 
sub chronically and their effects determined in the Morris water escape task. 
30 mg/kg metrifonate improved performance in this task whereas 10 mg/kg 
metrifonate had no effects and 60 mg/kg impaired performance. 
" Where possible, measure mnemonic and non-mnemonic performance 
in the 
same animal and in the same task. i. e. in the two choice water escape task 
effects on both reference memory and attention could be observed. 
However, further study is required on this task. 
" Finally, take into account the effects of individual animal variability. 
Ideally 
use a single subject repeated measures design. i. e. each animal serves as 
its 
own control. For example in chapter 8 each animal's peak 
time was 




Taking these considerations and the additional recommendations by D'Mello and 
Steckler (1996) and of Sarter et a/, (1992), a broad characterisation of putative 
cognition enhances is recommended. As studied in this thesis, the efficacy of a test 
compound should be determined in a series of tests that cover a variety of cognitive 
processes (Maitre and Pepeu, 1989), the tests of which have previously been 
discussed. 
Conclusions and Future study 
There is no animal model available that can mimic all the cognitive, biochemical and 
histopathological abnormalities observed in patients with AD. However partial 
reproduction of AD neuropathology and cognitive deficits can be achieved. Future 
models that can be used to assess future cognition enhancers need to include the 
neuropathology of Alzheimer's disease. A growing number of studies have 
demonstrated that acute or continuous infusion of Aß (See chapter 1) into the brain 
causes brain dysfunction as evidenced by neurodegeneration and an impairment of 
learning and memory (Pepeu eta/, 1996; Yamada eta/, 1999). 
The effects of Aß fragments on learning and memory were first examined in mice 
(Flood et a/, 1991). Many subsequent studies have demonstrate that various Aß 
fragments such as Aß1-40, Aß1-42 and Aß25-35, cause learning and memory 
impairments in mice and rats (McDonald eta/, 1994; Chen eta/, 1996; Maurice et 
al, 1996,1998; Pepeu et a/, 1996; Harkany et a/, 1998; Oka et a/, 1999). This in 
vivo neurotoxicity produced by Aß is potentiated by co-injection with ibotenic acid 
(Morimoto et a/, 1998). From this it might be useful to suggest a combination of 
cholinergic lesions and Aß administration, thus producing a more complex model in 
producing behavioural dysfunction and the underlying pathology related to AD. This 
then could be used to assess compounds for the treatment of AD. 
Models employing transgenic mice might also be used to study future cognition 
enhancers. Transgenic mice overexpressing human APP751, which develop early AD 
like histopathology with diffuse deposits of Aß and aberrant tau protein 
immunoreactivity in some cases (Higgins, et al, 1994), exhibit age-dependent 
deficits in spatial learning in a water maze and in spontaneous alternation behaviour 
in a Y-maze (Moran, eta/, 1995). 
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There is no definitive behavioural model for AD. Although animal models discussed 
in this thesis, particularly EC lesions induce mnemonic deficits similar to those seen 
in AD, the relationship is less than perfect. Further testing in other spatial and non- 
spatial cognitive tasks might provide further insight into the character of the deficits. 
With greater specificity and sensitivity in the choice of task, i. e. improved validation 
of these tasks. Also, as discussed above employing animal models that integrate 
lesions, transgenic animals and/or pharmacological manipulation, could be 
important in expanding knowledge on the complex interactions that might exist 
between neuropathological changes and the functional consequences caused by 
brain damage. This combined approach needs to be studied to determine as to 
whether there is an increased validity of animal models of behavioural dysfunctions 
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ABBREVIA TIONS 
Aß B Amyloid protein 
Ach Acetylcholine 
Acetyl CoA Acetyl coenzyme A 
AChE Acetylcholinesterase 
AD Alzheimer's Disease 
ApoE Apolipoprotein E 
APP ß amyloid Precursor Protein 
BuChE Butyrylcholinesterase 
ChAT Choline acetyltranferase 
ChEI Cholinesterase Inhibitors 
CNS Central Nervous System 
E. C Entohinal Cortex 
FI Fixed Interval 
ITI Intertrial Interval 
MTP Matching To Position 
MWM Morris Water Maze 
NMTP Non Matching To Position 
PI Peak interval 
PS-1 Presenilin 1 
PS-2 Presenilin 2 
PT Peak Time 
PR Peak Rate 
SET Scalar Expectancy Theory 
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